

NOTAS

- 1 BURNE, F. M. *The concept of immunological surveillance*. Progr Experim Tumor Res, 1970. 13: 1-27.
- 2 PURTILO, D. T. *Defective immune surveillance in viral carcinogenesis*. Lab Invest, 1984. 51: 373-385.
- 3 LUTGENDORE, S. K. et al. *Social Support, Psychological Distress, and Natural Killer Cell Activity in Ovarian Cancer*. JCO, 1º out. 2005. 23 (28): 7.105-7.113.
- 4 BEN-ELIYAHU, S. *The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology*. Brain Behav Immun, 17 fev. 2003. 17: Supl 1: S27-36.
- 5 BEN-ELIYAHU, S; PAGE, G. G.; YIRMIYA, R.; SHAKHAR, G. *Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity*. Int J Cancer, 15 mar. 1999. 80(6): 880-888.
- 6 SHAKHAR, G.; BEN-ELIYAHU, S. *Potential prophylactic measures against postoperative immunosuppression: Could they reduce recurrence rates in oncological patients?* Ann Surg Oncol, out. 2003. 10 (8): 972-992.
- 7 AYHAN, A.; CELIK, H.; TASKIRAN, C.; BOZDAG, G.; AKSU, T. *Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer*. Eur J Gynaecol Oncol, 2003. 24 (3-4): 223-232.
- 8 GARZETTI, G.; CIGNITTI, M.; CIAVATTINI, A.; FABRIS, N.; ROMANINI, C. *Natural killer cell activity and progression-free survival in ovarian cancer*. Gynecol Obstet Invest, 1993. 35(2): 118-120.
- 9 HEAD, J. F.; WANG, F.; ELLIOT, R. L.; McCOY, J. L. *Assessment of immunologic competence and host reactivity against tumor antigens in breast cancer patients. Prognostic value and rationale of immunotherapy development*. Ann NY Acad Sci, 12 ago. 1993. 690: 340-342.
- 10 ANDERSEN, B. L. et al. *Psychological, behavioral, and immune changes after a psychological intervention: A clinical trial*. J Clin Oncol, 1º set. 2004. 22(17): 3.570-3.580.
- 11 LEVY, S.; HERBERMAN, R. B.; LIPPMAN, M.; D'ANGELO, T.; LEE, J. *Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer*. Behav Med, verão de 1991. 17: 67-75.
- 12 TINDLE, R. W. *Immune evasion in human papillomavirus-associated cervical cancer*. Nat Rev Cancer, jan. 2002. 2(1): 59-65.
- 13 TADA, T. et al. *Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing-state*. J Immunol, 1º fev. 1991. 146(3): 1.077-1.082.
- 14 KOEBEL, C. M. et al. *Adaptative immunity maintains occult cancer in an equilibrium state*. Nature, 6 dez. 2007. 450(7.171): 903-907.

- 15 GROOM, S. N.; JOHNS, T.; OLDFIELD, P. R. *The potency of immunomodulatory herbs may be primarily dependent upon macrophage activation.* J Med Food, mar. 2007. 10(1): 73-79.
- 16 McCLAIN, K. L. *Immunodeficiency states and related malignancies.* Cancer Treat Res, 1997. 92: 39-61.
- 17 VETVICKA, V. *Beta Glucan-immunostimulant, adjuvant, potential drug.* World J Clin Oncol, 10 fev. 2011. 2(2): 115-119.
- 18 DVORAK, H. F. *Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.* N Engl J Med, 25 dez. 1986. 315(26): 1.650-1.659.
- 19 GUPTA, R. B. et al. *Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.* Gastroenterology, out. 2007. 133(4): 1.099-1.105; quiz 1.340-1.341.
- 20 ERRENI, M.; MANTOVANI, A.; ALLAVENA, P. *Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.* Cancer Microenviron, ago. 2011. 4(2): 141-154.
- 21 ALLAVENA, P.; MANTOVANI, A. *Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.* Clin Exp Immunol, fev. 2012. 167 (2): 195-205.
- 22 ESCÁRCEGA, R. O.; FUENTES-ALEXANDRO, S.; GARCÍA-CARRASCO, M.; GATICA, A.; ZAMORA, A. *The transcription factor nuclear factor- κ B and cancer.* Clinical Oncology, 2007. 19(2): 154-161.
- 23 LUO, J. L.; MAEDA, S.; HSU, L. C.; YAGITA, H.; KARIN, M. *Inhibition of NF-kappa β in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.* Cancer Cell, set. 2004. 6(3): 297-305.
- 24 KARIN, M.; CAO, Y.; GRETEN, F. R.; LI, Z. W. *NF-kappa β in cancer: from innocent bystander to major culprit.* Nat Rev Cancer, Abr. 2002. 2(4): 301-310.
- 25 KARIN, M. *Nuclear factor-kappa β in cancer development and progression.* Nature, 25 mai. 2006. 441(7.092): 431-436.
- 26 GUPTA, S. C.; KIM, J. H.; PRASAD, S.; AGGARWAL, B. B. *Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals.* Cancer Metastasis Rev, set. 2010. 29(3): 405-434.
- 27 SINGH, M.; SINGH, R.; BHUI, K.; TYAGI, S.; MAHMOOD, Z.; SHUKLA, Y. *Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappa β and Akt activation in human cervical cancer cells.* Oncol Res, 2011. 19(6): 245-257.
- 28 BERGER, F.; BÜCHSLER, I.; MUNZ, B. *The effect of the NF-kappa β inhibitors curcumin and lactacystin on myogenic differentiation of rhabdomyosarcoma cells.* Differentiation, jun. 2012. 83(5): 271-281.
- 29 GUPTA, S. C.; KIM, J. H.; KANNAPPAN, R.; REUTER, S.; DOUGHERTY, P. M.; AGGARWAL, B. B. *Role of nuclear factor κ B-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents.* Exp Biol Med (Maywood), 1º jun. 2011. 236(6): 658-671.
- 30 DAS, K. C.; WHITE, C. W. *Activation of NF-kappa β by antineoplastic agents. Role of protein kinase C.* J Biol Chem, 1997. 272: 14.914-14.920.
- 31 BASU, S.; SODHI, A. *Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565.* Immunol Cell Biol, 1992. 70(Parte 1): 15-24.

- 32 ZAKS-ZILBERMAN, M.; ZAKS, T. Z.; VOGEL, S. N. *Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines.* Cytokine, 2001. 15: 156-165.
- 33 HUANG, M. et al. *Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.* Cancer Res, 15 mar. 1998. 58(6): 1.208-1.216.
- 34 AGUADO, L. I. *Role of the central and peripheral nervous system in the ovarian function.* Microsc Res Tech, 15 dez. 2002. 59(6): 462-473.
- 35 CHAN, A. T.; OGINO, S.; FUCHS, C. S. *Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.* N Engl J Med, 2007. 356: 2.131-2.142.
- 36 FLOSSMANN, E.; ROTHWELL, P. M. *Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.* Lancet, 2007. 369: 1.603-1.613.
- 37 REINAGEL, M. *The inflammation free diet plan.* Nova York: Ed. McGraw Hill, 2006.
- 38 MURCIA, M. A.; JIMÉNEZ, A. M.; MARTÍNEZ-TOMÉ, M. *Evaluation of the antioxidant properties of Mediterranean and tropical fruits compared with common food additives.* J Food Prot, dez. 2001. 64(12): 2.037-2.046.
- 39 MARTÍNEZ-TOMÉ, M.; JIMÉNEZ, A. M.; RUGGIERI, S. *Antioxidant properties of Mediterranean spices compared with common food additives.* J Food Prot, dez. 2001. 64(9): 1.412-1.419.
- 40 MURCIA, M. A.; EGEE, I.; ROMOJARO, F. *Antioxidant evaluation in dessert spices compared with common food additives. Influence of irradiation procedure.* J Agric Food Chem, 7 abr. 2004. 52(7): 1.872-1.881.
- 41 YIHAI, C.; LANGER, R. *A review of Judah Folkman's remarkable achievements in biomedicine.* Proc Natl Acad Sci EUA, 9 set. 2008. 105(36): 13.203-13.205.
- 42 O'REILLY, M. S.; HOLMGREN, L.; SHING, Y. *Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.* Cell, 21 out. 1994. 79(2): 315-328.
- 43 AHAMED, M. B. et al. *Cat's whiskers tea (Orthosiphonstamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation.* Nutr Cancer, 2012. 64(1): 89-99.
- 44 CHOCARRO-CALVO, A.; GARCÍA-MARTÍNEZ, J. M.; ARDILA-GONZÁLEZ, S.; DE LA VIEJA, A.; GARCÍA-JIMÉNEZ, C. *Glucose-induced β -catenin acetylation enhances wnt signaling in cancer.* Mol Cell, 7 fev. 2013. 49(3): 474-486.
- 45 JALVING, M. et al. *Metformin: taking away the candy for cancer?* Eur J Cancer, set. 2010. 46(13): 2.369-2.380.
- 46 VAZQUEZ-MARTIN, A. et al. *Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.* Curr Mol Med, out. 2010. 10(7): 674-691.
- 47 CHATSUDTHIPONG, V.; MUANPRASAT C. *Stevioside and related compounds: therapeutic benefits beyond sweetness.* Pharmacol Ther, jan. 2009. 121(1): 41-54.
- 48 YASUKAWA, K.; KITANAKA, S. *Inhibitory effect of stevioside on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.* Biol Pharm Bull, nov. 2002. 25(11): 1.488-1.490.
- 49 TAKASAKI, M. et al. *Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.* Bioorg Med Chem, 15 jan. 2009. 17(2): 600-605.

- 50 PHILLIPS, K. M.; CARLSEN, M. H.; BLOMHOFF, R. *Total antioxidant content of alternatives to refined sugar*. J Am Diet Assoc, jan. 2009. 109(1): 64-71.
- 51 VAUPEL, P. *Tumor microenvironmental physiology and its implications for radiation oncology*. Semin Radiat Oncol, 2004. 14: 198-206.
- 52 TANNOCK, I. F.; ROTIN, D. *Acid pH in Tumors and Its Potential for Therapeutic Exploitation*. Cancer Res, 1989. 49: 4.373-4.384.
- 53 SAUVANT, C. et al. *Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38*. Int J Cancer, 2008. 123: 2.532-2.542.
- 54 BRAHIMI-HORN, M. C.; POUYSSÉGUR, J. *Hypoxia in cancer cell metabolism and pH regulation*. Biochem, 2007. 43: 165-178.
- 55 CHEN, J. L. et al. *The genomic analysis of lactic acidosis and acidosis response in human cancers*. PLoS Genet, dez. 2008. 4(12): e1000293.
- 56 ROBEY, I. F.; BAGGETT B. K. et al. *Bicarbonate increases tumor pH and inhibits spontaneous metastases*. Cancer Res, 15 mar. 2009. 69(6): 2.260-2.268.
- 57 IBRAHIM HASHIM, A. et al. *Reduction of metastasis using a non-volatile buffer*. Clin Exp Metastasis, dez. 2011. 28(8): 841-849.
- 58 <http://cancer.isciii.es/ariadna.php>
- 59 <http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/epicancerjunio2009.pdf>
- 60 *El cancer en España*. SEOM. <http://www.seom.org/es/prensa/el-cancer-en-espanyacom/102744-el-cancer-en-espana-2011>.
- 61 *Globocan 2008*. IARC, 2010.
- 62 JEMAL, A. et al. *Cancer statistics, 2007*. Cancer J Clin, 2007. 57: 43-66.
- 63 BRAY, F.; JEMAL, A.; GREY, N.; FERLAY, J.; FORMAN, D. *Global cancer transitions according to the Human Development Index (2008-2030): a population-based study*. Lancet Oncol, ago. 2012. 13(8): 790-801.
- 64 OMS. *Cancer. Nota descriptiva nº 297*, fev. 2012. <http://www.who.int/mediacentre/factsheets/fs297/es/index.html>
- 65 KOLONEL, L.; ALTSHULER, D.; HENDERSON, B. *The multiethnic cohort study: exploring genes, lifestyle and cancer risk*. Nat Rev Cancer, 2004. 4: 519-527.
- 66 HAMILTON, A.; MACK, T. *Puberty and genetic susceptibility to breast cancer in a case-control study in twins*. N. Engl J Med, 2003. 348: 2313-2322.
- 67 WORLD CANCER RESEARCH FUNDS Y AMERICAN INSTITUTE FOR CANCER RESEARCH. *Alimentos, nutrição e prevenção do câncer: uma perspectiva global*. Publicação OPS, nº 7, 1997.
- 68 FANG, P. et al. *Meta-analysis of ALDH2 variants and esophageal cancer in Asians*. Asian Pac J Cancer Prev, 2011. 12(10): 2.623-2.627.
- 69 ZHAO, J. et al. *Interaction between alcohol drinking and obesity in relation to colorectal cancer risk: a case-control study in Newfoundland and Labrador, Canada*. BMC Public Health, 1º fev. 2012. 12(1): 94.
- 70 DONG, C.; YOON, Y. H.; CHEN, C. M.; YI, H. Y. *Heavy alcohol use and premature death from hepatocellular carcinoma in the United States, 1999-2006*. J Stud Alcohol Drug, nov. 2011. 72(6): 892-902.

- 71 KWAN, M. L. et al. *Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the life after cancer epidemiology study*. J Clin Oncol, 2010. 10;28(29): 4.410-4.416.
- 72 DONATO, F.; GELATTI, U.; LIMINA, M.; FATTOVICH, G. *Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence*. Oncogene, 2006. 25: 3.756-3.770.
- 73 LA VECCHIA, C.; TAVANI, A.; FRANCESCHI, S.; LEVI, F.; CORRAO, G.; NEGRI, E. *Epidemiology and prevention of oral cancer*. Oral Oncol, 1997. 33: 302-312.
- 74 TUYNS, A. *Epidemiology of alcohol and cancer*. Cancer Res, jul. 1979. 39(7 Pt 2): 2.840-2.843.
- 75 POSCHL, G.; SEITZ, H. *Alcohol and cancer*. Alcohol, 2004. 39: 155-165.
- 76 SZABO, G.; MANDREKAR, P.; OAK, S.; MAYERLE, J. *Effect of ethanol on inflammatory responses. Implications for pancreatitis*. Pancreatology, 2007. 7(2-3): 115-123.
- 77 AGGARWAL, B. B. *Nuclear factor-kappa β : the enemy within*. Cancer Cell, 2004. 6: 203-208.
- 78 KURATSUNE, M.; KOHCHI, S.; HORIE, A. *Carcinogenesis in the esophagus. Penetration of benzo(a) pyrene and other hydrocarbons into the esophageal mucosa*. Gann. 1965. 56: 177-187.
- 79 YOKOYAMA, A.; OMORI, T. *Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers*. Alcohol, 2005. 35: 175-185.
- 80 DASGUPTA, P.; KINKADE, R.; JOSHI, B.; DECOOK, C.; HAURA, E.; CHELLAPPAN, S. *Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin*. Proc Natl Acad Sci EUA, 18 abr. 2006. 103(16): 6.332-6.337.
- 81 ZIEGLER, R.; HOOVER, R. et al. *Migration patterns and breast cancer risk in Asian-American women*. J Natl Cancer Inst, 1993. 85: 1.819-1.827.
- 82 DOLL, R.; PETO, R. *The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today*. J. Natl. Cancer Inst, jun. 1981. 66(6): 1.191-1.308.
- 83 WILLETT, W. C. *Diet and cancer*. Oncologist, 2000. 5(5): 393-404.
- 84 FUHRMAN, B. J. et al. *Estrogen metabolism and risk of breast cancer in postmenopausal women*. J Natl Cancer Inst, 22 fev. 2012. 104(4): 326-339.
- 85 THOMAS, H. V.; REEVES, G. K.; KEY, T. J. *Endogenous estrogen and postmenopausal breast cancer: a quantitative review*. Cancer Causes Control, nov. 1997. 8(6): 922-928.
- 86 BOCCHINFUSO, W. P. et al. *Induction of mammary gland development in estrogen receptor-alpha knockout mice*. Endocrinology, ago. 2000. 141(8): 2.982-2.994.
- 87 ADLERCREUTZ, H. *Western diet and Western diseases: some hormonal and biochemical mechanisms and associations*. Scand J Clin Lab Invest Suppl, 1990. 201: 3-23.
- 88 NAROD, S. A. *BRCA mutations in the management of breast cancer: the state of the art*. Nat Rev Clin Oncol, dez. 2010. 7(12): 702-707.
- 89 NAROD, S. A.; SALMENA, L. *BRCA1 and BRCA2 mutations and breast cancer*. Discov Med, nov. 2011. 12(66): 445-453.
- 90 ANTONIOU, A. et al. *Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies*. Am J Hum Genet, mai. 2003. 72(5): 1.117-1.130.
- 91 TATE, P. L.; BIBB, R.; LARCOM, L. L. *Milk stimulates growth of prostate cancer cells in culture*. Nutr Cancer, nov. 2011. 63(8): 1.361-1.366.

- 92 PETTERSSON, A. et al. *Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death.* Cancer Epidemiol Biomarkers Prev, mar. 2012. 21(3): 428-436.
- 93 TATE, P. L.; BIBB, R.; LARCOM, L. L. *Milk stimulates growth of prostate cancer cells in culture.* Nutr Cancer, nov. 2011. 63(8): 1.361-1.366.
- 94 DOI, S. Q. et al. *Low-protein diet suppresses serum insulin-like growth factor-1 and decelerates the progression of growth hormone-induced glomerulosclerosis.* Am J Nephrol, jul-ago. 2001. 21(4): 331-339.
- 95 AKAZA, H. *Prostate cancer chemoprevention by soy isoflavones: Role of intestinal bacteria as the "second human genome".* Cancer Sci, jun. 2012. 103(6): 969-975.
- 96 VAN DEN BRANDT, P. A.; BOTTERWECK, A. A.; GOLDBOHN, R. A. *Salt intake, cured meat consumption, refrigerator use and stomach cancer incidence: a prospective cohort study.* Cancer Causes Control, jun. 2003. 14(5): 427-438.
- 97 WANG, X. Q.; TERRY, P. D.; YAN, H. *Review of salt consumption and stomach cancer risk: epidemiological and biological evidence.* World J Gastroenterol, 14 mai. 2009. 15(18): 2.204-2.213.
- 98 TANTAMANGO, Y. M. et al. *Association between dietary fiber and incident cases of colon polyps: the adventist health study.* Gastrointest Cancer Res, set. 2011. 4(5-6): 161-167.
- 99 MAGALHÃES, B.; PELETEIRO, B.; LUNET, N. *Dietary patterns and colorectal cancer: systematic review and meta-analysis.* Eur J Cancer Prev, jan. 2012. 21(1): 15-23.
- 100 FORTE, A.; DE SANCTIS, R.; LEONETTI, G.; MANFREDI, S.; URBANO, V.; BEZZI, M. *Dietary chemoprevention of colorectal cancer.* Ann Ital Chir, jul-ago. 2008. 79(4): 261-267.
- 101 CHAINANI-WU, N. *Diet and oral, pharyngeal, and esophageal cancer.* Nutr Cancer, 2002. 44(2): 104-126.
- 102 LUCENTEFORTE, E.; GARAVELLO, W.; BOSETTI, C.; LA VECCHIA, C. *Dietary factors and oral and pharyngeal cancer risk.* Oral Oncol, jun. 2009. 45(6): 461-467.
- 103 CALLE, E.; RODRIGUEZ, C.; WALKER-THURMOND, K.; THUN, M. J. *Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults.* N Engl J Med, 24 abr. 2003. 348(17): 1.625-1.638.
- 104 DREWNOWSKI, A.; POPKIN, B. *The nutrition transition: new trends in the global diet.* Nutr Rev, fev. 1997. 55(2): 31-43.
- 105 HURSTING, S. et al. *Energy balance and carcinogenesis: underlying pathways and targets for intervention.* Curr Cancer Drug Targets, ago. 2007. 7(5): 484-491.
- 106 TANG, C.; CHIU, Y. C.; TAN, T. W.; YANG, R. S.; FU, W. M. *Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF- κ B pathway.* J Immunol, 15 out. 2007. 179(8): 5.483-5.492.
- 107 NAREIKA, A. et al. *High glucose enhances lipopolysaccharide-stimulated CD14 expression in U937 mononuclear cells by increasing nuclear factor κ B and AP-1 activities.* J Endocrinol, jan. 2008. 196(1): 45-55.
- 108 HURSTING, S. D.; LAVIGNE, J. A.; BERRIGAN, D.; PERKINS, S. N.; BARRETT, J. C. *Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans.* Annu Rev Med, 2003. 54: 131-152.
- 109 GROSS, L.; DREYFUSS, Y. *Reduction in the incidence of radiation-induced tumors in rats after restriction of food intake.* Proc Natl Acad Sci EUA, dez. 1984. 81(23): 7.596-7.598.
- 110 ROSS, M. H.; BRAS, G. *Lasting influence of early caloric restriction on prevalence of neoplasms in the rat.* J Natl Cancer Inst, nov. 1971. 47(5): 1.095-1.113.

- 111 HURSTING, S. D.; LAVIGNE, J. A.; BERRIGAN, D.; PERKINS, S. N.; BARRETT, J. C. *Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans*. Annu Rev Med, 2003. 54: 131-152.
- 112 STAND, F. W.; CHAKRAVARTHY, M. V.; GORDON, S. E.; SPANGENBURG, E. E. *Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy*. J Appl Physiol, 2002. 93: 3-30.
- 113 WONDERS, K. Y.; REIGLE, B. S. *Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise*. Integr Cancer Ther, mar. 2009. 8(1): 17-21.
- 114 CHEN, Z. et al. *Qigong improves quality of life in women undergoing radiotherapy for breast cancer: Results of a randomized controlled trial*. Cancer, 25 jan. 2013. doi: 10.1002/cncr.27904.
- 115 PARKIN, M. *The global health burden of infection-associated cancers in the year 2002*. Int J Cancer, 2006. 118: 3.030-3.044.
- 116 BLUMBERG, B. et al. *The relation of infection with the hepatitis B agent to primary hepatic carcinoma*. Am J Pathol, dez. 1975. 81(3): 669-682.
- 117 SONG, S.; PITOT, H.; LAMBERT, P. *The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals*. J Virol, 1999. 73: 5.887-5.893.
- 118 GUAN, Y.; HE, Q.; WANG, M.; LI, P. *Nuclear factor kappa β and hepatitis viruses*. Expert Opin Ther Targets, 2008. 12: 265-280.
- 119 TAKAYAMA, S.; TAKAHASHI, H.; MATSUO, Y.; OKADA, Y.; MANABE, T. *Effects of Helicobacter pylori infection on human pancreatic cancer cell line*. Hepatogastroenterology, dez. 2007. 54(80): 2.387-2.391.
- 120 COUCEIRO, L.; DÍAZ, J.; ALBAINA, N.; BARREIRO, R.; IRABIEN, J. A.; RUIZ, J. M. *Imposex and gender-independent butyltin accumulation in the gastropod Nassarius reticulatus from the Cantabrian coast (N Atlantic Spain)*. Chemosphere, jul. 2009. 76(3): 424-427.
- 121 BELPOMME, D. et al. *The multitude and diversity of environmental carcinogens*. Environ Res, nov. 2007. 105(3): 414-429.
- 122 NATIONAL RESEARCH COUNCIL; COMMITTEE TO ASSESS HEALTH RISKS FROM EXPOSURE TO LOW LEVELS OF IONIZING RADIATION; BOARD ON RADIATION EFFECTS; RESEARCH DIVISION ON EARTH AND LIFE STUDIES. *Health risks from exposure to low levels of ionizing radiation: BEIR VII, Phase 2*. Washington: National Academies Press, 2006.
- 123 GOODHEAD, D. T. *Initial events in the cellular effects of ionizing radiations: clustered damage in DNA*. Int J Radiat Biol, 1994. 65: 7-17.
- 124 NIKIFOROV, Y. E. *Radiation-induced thyroid cancer: what we have learned from Chernobyl*. Endocr Pathol, inverno de 2006. 17(4): 307-317.
- 125 DEMIDCHIK, Y. E.; SAENKO, V. A.; YAMASHITA, S. *Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present*. Arq Bras Endocrinol Metabol, jul. 2007. 51(5): 748-762.
- 126 CARDIS, E. et al. *Cancer consequences of the Chernobyl accident: 20 years on*. J Radiol Prot, jun. 2006. 26(2): 127-140.
- 127 DARBY, S. et al. *Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies*. BMJ, 29 jan. 2005. 330(7485): 223.
- 128 NATIONAL RESEARCH COUNCIL; COMMITTEE TO ASSESS HEALTH RISKS FROM EXPOSURE TO LOW LEVELS OF IONIZING RADIATION; BOARD ON RADIATION

- EFFECTS; RESEARCH DIVISION ON EARTH AND LIFE STUDIES. *Health effects of exposure to radon: BEIR VI*. Washington: National Academies Press, 1999.
- 129 WAKEFORD, R.; LITTLE M. P. *Risk coefficients for childhood cancer after intrauterine irradiation: a review*. Int J Radiat Biol, 2003. 79: 293-309.
 - 130 BRENNER, D. J. et al. *Routine screening mammography: how important is the radiation-risk side of the benefit-risk equation?* Int J Radiat Biol, dez. 2002. 78(12): 1.065-1.067.
 - 131 RUNGER, T. M.; KAPPES, U. P. *Mechanisms of mutation formation with long-wave ultraviolet light (UVA)*. Photodermatol Photoimmunol Photomed, 2008. 24: 2-10.
 - 132 <http://www.iarc.fr/en/media-centre/iarcnews/2011/monograph102.php>
 - 133 LITTLE, M. P. et al. *Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States*. BMJ, 8 mar. 2012. 344.
 - 134 HARDELL, L.; CARLBERG, M.; HANSSON MILD, K. *Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma*. Pathophysiology, 20 dez. 2012. PII: S0928-4680(12)00110-1.
 - 135 HARDELL, L.; CARLBERG, M.; MILD, K. H.; MORGAN, L. L. *Long-term use of cellular phones and brain tumours: increased risk associated with use for > or = 10 years*. Occup Environ Med, set. 2007. 64(9): 626-632.
 - 136 CZERNINSKI, R; ZINI, A; SGAN-COHEN, H. D. *Risk of Parotid Malignant Tumors in Israel (1970-2006)*. Epidemiology, 2011. 22(1): 130-131.
 - 137 SADETZKI, S. et al. *Cellular phone use and risk of benign and malignant parotid gland tumors-a nationwide case-control study*. Am J Epidemiol, 15 fev. 2008. 167(4): 457-467.
 - 138 <http://ehtrust.org/cell-phones-and-breast-a-bad-combination-2/>
 - 139 ERKEKOGLU, P.; BAYDAR, T. *Evaluation of the protective effect of ascorbic acid on nitrite- and nitrosamine-induced cytotoxicity and genotoxicity in human hepatoma line*. Toxicol Mech Methods, fev. 2010. 20(2): 45-52.
 - 140 JAKSZYN, P. GONZÁLEZ, C. A. *Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence*. World J Gastroenterol, 21 jul. 2006. 12(27): 4.296-4.303.
 - 141 WARD, M. H. et al. *Processed meat intake, CYP2A6 activity and risk of colorectal adenoma*. Carcinogenesis, jun. 2007. 28(6): 1.210-1.216.
 - 142 BAAN, R. et al. *Carcinogenicity of some aromatic amines, organic dyes, and related exposures*. Lancet Oncol, abr. 2008. 9(4): 322-323.
 - 143 XUE, W.; WARSHAWSKY, D. *Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review*. Toxicol Appl Pharmacol, 2005. 206: 73-93.
 - 144 NEBERT, D. W.; ROE, A. L.; DIETER, M. Z.; SOLIS, W. A.; YANG, Y.; DALTON, T. P. *Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis*. Biochem Pharmacol, 1^a jan. 2000. 59(1): 65-85.
 - 145 COLBORN, T.; CLEMENT, C. *Chemically induced alteration in sexual and functional development: the wildlife/human connection. Advances in modern environmental toxicology 11*. Princeton: Princeton Scientific Publishers, 1992.
 - 146 IBARLUZEA, J. M.; FERNÁNDEZ, M. F. et al. *Breast cancer risk and the combined effect of environmental estrogens*. Cancer Causes Control, ago. 2004. 15(6): 591-600.
 - 147 PARK, S. H. et al. *Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38*. J Reprod Dev, fev. 2009. 55(1): 23-29.

- 148 FERNÁNDEZ, M. F. et al. *Human exposure to endocrine-disrupting chemicals and pre-natal risk factors for cryptorchidism and hypospadias: a nested case-control study*. Environ Health Perspect, dez. 2007. 115 Supl. 1: 8-14.
- 149 LÓPEZ-ESPINOSA, M. J.; GRANADA, A.; CARREÑO, J.; SALVATIERRA, M.; OLEA-SERRANO, F.; OLEA, N. *Organochlorine pesticides in placentas from Southern Spain and some related factors*. Placenta, jul. 2007. 28(7): 631-638.
- 150 BODYBURDEN. *The Pollution in Newborns*. Environmental Working Group. 14 jul. 2005. http://www.ewg.org/reports_content/bodyburden2/pdf/bodyburden2_final-r2.pdf
- 151 INSTITUTO SINDICAL DE TRABAJO, AMBIENTE Y SALUD DE ESPAÑA (ISTAS). *Curso de Introducción a los disruptores endocrinos*. Madri: Instituto Sindical de Trabajo Ambiente y Salud de España, 2002. 33.
- 152 OLEA, N.; FERNÁNDEZ, M. F.; ARAQUE, P.; OLEA-SERRANO, F. *Perspectives on endocrine disruption*. (Artigo em espanhol). Gac Sanit., mai.-jun. 2002. 16(3): 250-256.
- 153 QIN, X. Y. et al. *Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epithelial cells*. Cancer Biol Ther, mar. 2012. 13(5): 296-306.
- 154 HWANG, K. A.; CHOI, K. C. *191 risk assessment of bisphenol A, an endocrine disruptor, via proliferative effect on the growth of estrogen-dependent ovarian cancer in cellular and animal models*. Reprod Fertil Dev, dez. 2012. 25(1): 244-245.
- 155 LAPENSEE, E. W.; LAPENSEE, C. R.; FOX, S.; SCHWEMBERGER, S.; AFTON, S.; BEN-JONATHAN, N. *Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells*. Cancer Lett, 28 abr. 2010. 290(2): 167-173.
- 156 LAPENSEE, E. W.; TUTTLE, T.R.; FOX, S. R.; BEN-JONATHAN, N. *Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells*. Environ Health Perspect, fev. 2009. 117(2): 175-180.
- 157 KANG, N. H.; CHOI, K. C. *192 resveratrol, a natural food compound, suppressed the cell growth of bg-1 ovarian cancer cells induced by 17 β -estradiol or bisphenol a through down-regulating estrogen receptor and insulin-like growth factor-1 receptor*. Reprod Fertil Dev, dez. 2012. 25(1): 245.
- 158 STAREK, A. *Estrogens and organochlorine xenoestrogens and breast cancer risk*. Int J Occup Med Environ Health, 2003. 16(2): 113-124.
- 159 OLEA, N. "Health effects of pesticides." In: SHUMAN, J. M. (ed.). *The International Conference on Regulatory Issues in crop protection and their implications for the Food Supply*. Ed. Boston, 1997. 38-40.
- 160 JAGA, K.; DUVVI, H. *Risk reduction for DDT toxicity and carcinogenesis through dietary modification*. J R Soc Promot Health, jun. 2001. 121(2): 107-113.
- 161 DARBRE, P. D.; ALJARRAH, A.; MILLER, W. R.; COLDHAM, N. G.; SAUER, M. J.; POPE, G. S. *Concentrations of parabens in human breast tumours*. J Appl Toxicol, jan-fev. 2004. 24(1): 5-13.
- 162 DARBRE, P. D. *Environmental oestrogens, cosmetics and breast cancer*. Best Pract Res Clin Endocrinol Metab, mar. 2006. 20(1): 121-143.
- 163 BARR, L.; METAXAS, G.; HARBACH, C. A.; SAVOY, L. A.; DARBRE, P. D. *Measurement of paraben concentrations in human breast tissue at serial locations across the breast from axilla to sternum*. J Appl Toxicol, mar. 2012. 32(3): 219-232.
- 164 PUGAZHENDHI, D.; SADLER, A. J.; DARBRE, P. D. *Comparison of the global gene expression profiles produced by methylparaben, n-butylparaben and 17beta-oestradiol in MCF7 human breast cancer cells*. J Appl Toxicol, jan-fev. 2007. 27(1): 67-77.

- 165 IARC. *IARC monographs on the evaluation of carcinogenic risks to humans. Formaldehyde, 2-butoxyethanol and 1-tert-butoxypropan-2-ol*. Lyon: International Agency for Research on Cancer, 2006. 88: 39-325.
- 166 HAUPTMANN, M. et al. *Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde*. J Natl Cancer Inst, 16 dez. 2009. 101(24): 1.696-1.708.
- 167 DARBRE, P. D. *Aluminium, antiperspirants and breast cancer*. J Inorg Biochem, set. 2005. 99(9): 1.912-1.919.
- 168 IARC. *IARC monographs on the evaluation of carcinogenic risks to humans. Some drinking-water disinfectants and contaminants, including arsenic*. Lyon: International Agency for Research on Cancer, 2004. 84: 1-477.
- 169 WANG, X. et al. *Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/ β -catenin signaling pathway*. Toxicol Appl Pharmacol, 1^o jul. 2012. 262(1): 11-21.
- 170 *Special Report: Policy. A review of human carcinogens-Part C: metals, arsenic, dusts, and fibres*. www.thelancet.com/oncology, mai. 2009. 10.
- 171 ZHITKOVICH, A. *Chromium in drinking water: sources, metabolism, and cancer risks*. Chem Res Toxicol, 17 out. 2011. 24(10): 1.617-1.629.
- 172 LA DOU, J. *The asbestos cancer epidemic*. Environ Health Perspect, 2004. 112: 285-290.
- 173 CLIN, B. et al. *Pulmonary Carcinoid Tumors and Asbestos Exposure*. Ann Occup Hyg, ago. 2012. 56(7): 789-795.
- 174 INSTITUTE OF MEDICINE; COMMITTEE ON ASBESTOS. *Selected health effects. Asbestos: selected cancers*. Washington D.C.: National Academies Press, 2006.
- 175 GERTIG, D. M. et al. *Prospective study of talc use and ovarian cancer*. J Natl Cancer Inst, 2 fev. 2000. 92(3): 249-252.
- 176 HARLOW, B.; CRAMER, D. W.; BELL, D. A.; WELCH, W. R. *Perineal exposure to talc and ovarian cancer risk*. Obstet Gynecol, jul. 1992. 80(1): 19-26.
- 177 ACHESON, E. D.; GARDNER, M. J.; PIPPARD, E. C.; GRIME, L. P. *Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: a 40-year follow-up*. Br J Ind Med, 1982. 39: 344-348.
- 178 KLUGER, N. *Tattoos, inks, and cancer*. The Lancet Oncolog, 2012. 13 (4): 161-168.
- 179 IARC. *1,3-Butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl chloride and vinyl bromide)*. IARC Risks Hum, 2008. 97: 185-309.
- 180 SCHÜTZE, M. et al. *Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study*. BMJ, 7 abr. 2011. 342: d1584.
- 181 HINDS, M. W.; KOLONEL, L. N.; LEE, J.; HIROHATA, T. *Associations between cancer incidence and alcohol/cigarette consumption among five ethnic in Hawaii*. Br J Cancer, jun. 1980. 41(6): 929-940.
- 182 DOLL, R.; PETO, R.; BOREHAM, J.; SUTHERLAND, I. *Mortality in relation to smoking: 50 years observations on male British doctors*. British Medical Journal, 2004. 328(7.455): 1.519-1.527.
- 183 McBRIDE, C. M.; OSTROFF, J. S. *Teachable moments for promoting smoking cessation: the context of cancer care and survivorship*. Cancer Control, 2003. 10(4): 325-333.
- 184 PARSONS, A.; DALEY, A.; BEGH, R.; AVEYARD, P. *Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis*. BMJ, 21 jan. 2010. 340: b5569.

- 185 BERK, P. D. et al. *Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.* N Engl J Med, 1981. 304(8): 441-447.
- 186 KEMPE, S. R.; IVANKOVIC, S. *Carcinogenic effect of cisplatin (cis-diammine-dichloro-platinum (II), CDDP) in BD IX rats.* J Cancer Res, 1986. 111(2): 133-136.
- 187 CANTERO, G.; PASTOR, N.; MATEOS, S.; CAMPANELLA, C.; CORTÉS, F. *Cisplatin induced endore duplication in CHO cells: DNA damage and inhibition of topoisomerase II.* Mutat Res, 25 jul. 2006. 599(1-2): 160-166.
- 188 COOK, L. S. et al. *Study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.* J Nat Cancer Inst, 20 set. 1995. 87(18): 1.359-1.364.
- 189 CHU, W. et al. *Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use.* Carcinogenesis, out. 2007. 28(10): 2.139-2.142.
- 190 HAAS, J. F. et al. *Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.* Br J Cancer, fev. 1997. 55(2): 213-18.
- 191 HAYANI, A.; MAHONEY, D. H.; J. R.; TAYLOR, L. D. *Therapy related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy.* J Neurooncol, set. 1992. 14(1): 57-62.
- 192 BHATTACHARYYA, S.; MEHTA, P. *The hepatoprotective potential of Spirulina and vitamin C supplementation in cisplatin toxicity.* Food Funct, 3 fev. 2012. 3(2): 164-169.
- 193 TOHAMY, A. A.; EL-GHOR, A. A.; EL-NAHAS, S. M.; NOSHY, M. M. *Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin.* Mutat Res, nov. 2003. 10; 541(1-2): 45-53.
- 194 IMAO, T. et al. *Risk factors for malignancy in Japanese renal transplant recipients.* Cancer, 15 mai. 2007. 109(10): 2.109-2.115.
- 195 ZHOU, B. et al. *Hormone replacement therapy and ovarian cancer risk: a metaanalysis.* Gynecol Oncol, mar. 2008. 108(3): 641-651.
- 196 IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 91. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy.* Lyon: International Agency for Research on Cancer, 2007.
- 197 LORIA, D.; BARRIOS, E.; ZANETTI, R. *Cancer and yerba mate consumption: a review of possible associations.* Rev Panam Salud Publica, jun. 2009; 25(6): 530-539.
- 198 SOMOROVSKÁ, M. et al. *Biomonitoring of genotoxic risk in workers in a rubber factory: comparison of the Comet assay with cytogenetic methods and immunology.* Mutat Res, 30 set. 1999. 445(2): 181-192.
- 199 NEBERT, D. W.; ROE, AL.; DIETER, M. Z.; SOLIS, W. A.; YANG, Y.; DALTON, T. P. *Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis.* Biochem Pharmacol, 1^o jan. 2000. 59(1): 65-85.
- 200 BROWN, L. M.; MORADI, T.; GRIDLEY, G.; PLATO, N.; DOSEMECI, M.; FRAUMENI JUNIOR, J. F. *Exposures in the painting trades and paint manufacturing industry and risk of cancer among men and women in Sweden.* J Occup Environ Med, mar. 2002. 44(3): 258-264.
- 201 BURGESS, J. L. et al. *Longitudinal decline in measured firefighter single-breath diffusing capacity of carbon monoxide values. A respiratory surveillance dilemma.* Am J Care Med, jan. 1999. 159(1): 119-124.
- 202 SOUTAR, C. A.; HURLEY, J. F.; MILLER, B. G.; COWIE, H. A.; BUCHANAN, D. *Dust concentrations and respiratory risks in coal miners: key risk estimates from the British pneumoconiosis field research.* Occup Environ Med, jun. 2004. 61(6): 477-481.

- 203 SCHERNHAMMER, E. S.; KROENKE, C. H.; LADEN, F.; HANKINSON, S. E. *Night work and risk of breast cancer*. Epidemiology, jan. 2006. 17(1): 108-111.
- 204 SCHERNHAMMER, E. S. et al. *Rotating night shifts and risk of breast cancer in women participating in the nurses' health study*. J Natl Cancer Inst, 17 out. 2001. 93(20): 1.563-1.568.
- 205 MEGDAL, S. P.; KROENKE, C. H.; LADEN, F.; PUKKALA, E.; SCHERNHAMMER, E. S. *Night work and breast cancer risk: a systematic review and meta-analysis*. Eur J Cancer, set. 2005. 41(13): 2.023-2.032.
- 206 FERNÁNDEZ, O. et al. *Professional quality of life of the residents physicians*. Arch med, 2007. 3(1).
- 207 CATANZARO, J. M., SMITH JUNIOR, J. G. *Propylene glycol dermatitis*. J Am Acad Dermatol, jan. 1991. 24(1): 90-95.
- 208 SPENCER, P. J. *New toxicity data for the propylene glycol ethers – a commitment to public health and safety*. Toxicol Lett, 28 mar. 2005. 156(1): 181-188.
- 209 EISENHARDT, S.; RUNNEBAUM, B.; BAUER, K.; GERHARD, I. *Nitromusk compounds in women with gynaecological and endocrine dysfunction*. Environ Res, 2001. 87(3): 123-130.
- 210 IONESCU, J. G. et al. *Increased levels of transition metals in breast cancer tissue*. Neuro Endocrinol Lett, dez. 2006. 27 Supl. 1: 36-39.
- 211 DARBRE, P. D. *Aluminium, antiperspirants and breast cancer*. J Inorg Biochem, set. 2005. 99(9): 1.912-1.919.
- 212 NAMER, M.; LUPORSI, E.; GLIGOROV, J.; LOKIEC, F.; SPIELMANN, M. *The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer*. (Artigo em francês.) Bull Cancer, set. 2008. 95(9): 871-880.
- 213 SCHLUMPF, M.; COTTON, B.; CONSCIENCE, M.; HALLER, V.; STEINMANN, B.; LICHTENSTEIGER, W. *In vitro and in vivo estrogenicity of UV screens*. Environ Health Perspect, mar. 2001. 109(3): 239-244.
- 214 VALERON, P. F. et al. *Differential effects exerted on human mammary epithelial cells by environmentally relevant organochlorine pesticides either individually or in combination*. Chem-Biol Interact, 14 ago. 2009. 180(3): 485-491.
- 215 KIMBROUGH, R. D. *Human health effects of polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs)*. Annu Rev Pharmacol Toxicol, 1987. 27: 87-111.
- 216 ACEVEDO, R. et al. *The contribution of hepatic steroid metabolism to serum estradiol and estrinol concentrations in nonylphenol treated MMTVneu mice and its potential effects on breast cancer incidence and latency*. J Appl Toxicol, set-out. 2005. 25(5): 339-353.
- 217 LABRECHE, F. P.; GOLDBERG, M. S. *Exposure to organic solvents and breast cancer in women: A hypothesis*. Am J Ind Med, 1997. 32: 1-14.
- 218 ADOLFSSON-ERICI, M.; PETTERSSON, M.; PARKKONEN, J.; STURVE, J. *Triclosan, a commonly used bactericide found in human milk and in the aquatic environment in Sweden*. Chemosphere, mar. 2002. 46(9-10): 1.485-1.489.
- 219 LIU, B.; WANG, Y.; FILLGROVE, K. L. ANDERSON, V. E. *Triclosan inhibits enoyl-reductase of type 1 fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells*. Cancer Chemotherapy and Pharmacology, 2002. 49: 187-193.
- 220 <http://breakingnews.ewg.org/2012sunscreens/>
- 221 BECKER, H.; HERZBERG, F.; SCHULTE, A.; KOLOSSA-GEHRING, M. *The carcinogenic potential of nanomaterials, their release from products and options for regulating them*. Int J Hyg Environ Health, jun. 2011. 214(3): 231-238.

- 222 IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 93. Carbon black, titanium dioxide, and talc*. Lyon: International Agency for Research on Cancer, 7-14 fev. 2006.
- 223 BISSONNETTE, R. *Update on sunscreens*. Skin Therapy Lett, jul-ago. 2008. 13(6): 5-7.
- 224 NICHOLS, J. A.; KATTIYAR, S. K. *Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms*. Arch Dermatol Res, mar. 2010. 302(2): 71-83.
- 225 MEDES. *Nutrientes Esenciales*. www.medes-salud.com.ar/nutrientes.hmt
- 226 CUEVAS, O. *El equilibrio a través de la alimentación*. Barcelona: Ed IFP, 1999.
- 227 MAURON, J. *Influence of processing on protein quality*. J Nutr Sci Vitaminol (Tóquio), 1990. 36 Supl. 1: S57-69.
- 228 SUÁREZ LÓPEZ, M.; KIZLANSKY, A.; LÓPEZ, L. *Assessment of protein quality in foods by calculating the amino acids score corrected by digestibility*. Nutr Hosp, jan-fev. 2006. 21(1): 47-51.
- 229 FAO. *Tabela de composição de alimentos*. 2003.
- 230 KIES, C. *Bioavailability: A factor in protein quality*. J Agric Food Chem, 1981. 29: 435-440.
- 231 LARSSON, S. C.; WOLK, A. *Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies*. Br J Cancer, 31 jan. 2012. 106(3): 603-607.
- 232 NORAT, T.; LUKANOVA, A.; FERRARI, P.; RIBOLI, E. *Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies*. Int J Cancer, 10 mar. 2002. 98(2): 241-256.
- 233 PALA, V. et al. *Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort*. Am J Clin. Nutr, set. 2009. 90(3): 602-612.
- 234 YOUNG, V. R.; PELLETT, P. L. *Plant proteins in relation to human protein and amino acid nutrition*. Am J Clin Nutr, mai. 1994. 59(5 Supl.): 1203S-1212S.
- 235 ALLEN, H. *Homemaker's guide to foods for pleasure and health*. EUA: Natural Hygiene Press, 1976.
- 236 WHO/FAO/UNU. *Protein and amino acid requirements in human nutrition. Technical Report Series 935*. Report of a Joint WHO/FAO/UNU Expert Consultation, 2007.
- 237 VARELA MOREIRAS, G. et al. *Valoración de la dieta española de acuerdo al Panel de Consumo Alimentario*. Ministerio de Medio Ambiente, y Medio Rural y Marino/Fundación Española de la Nutrición, 2008.
- 238 KOLAHDOOZ, F. et al. *Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis*. Am J Clin Nutr, jun. 2010. 91(6): 1.752-1.763.
- 239 DWYER, J. T. et al. *Diet, indicators of kidney disease, and later mortality among older persons in the NHANES I epidemiologic follow-up study*. Am J Public Health, 1994. 84: 1.299-1.303.
- 240 WESTMAN, E.; YANCY, W.; EDMAN, J. *Carbohydrate diet program*. Am J Med, 2002. 113: 30-36.
- 241 STEVENS, A.; ROBINSON, D. P.; TURPIN, J.; GROSHONG, T.; TOBIAS, J. D. *Sudden cardiac death of an adolescent during dieting*. South Med J, set. 2002. 95(9): 1.047-1.049.
- 242 KIM, J.; PARK, S.; NAM, B. H. *The risk of colorectal cancer is associated with the frequency of meat consumption in a population-based cohort in Korea*. Asian Pac J Cancer Prev, 2011. 12(9): 2.371-2.376.

- 243 CLINTON, S. K. et al. *Dietary fat and protein intake differ in modulation of prostate tumor growth, prolactin secretion and metabolism and prostate gland prolactin binding capacity rats.* J Nutr, fev. 1997. 127(2): 225-227.
- 244 HAWRLYLEWICZ, E. J. *Dietary protein enhancement of N-nitrosomethylurea-induced mammary carcinogenesis, and their effect on hormone regulation in rats.* Cancer Res, set. 1986. 46 (9): 4.395-4.399.
- 245 PASPATI, I. et al. *Hip fracture epidemiology in Greece during 1977-1992.* Calcif Tissue Int, 1998. 62(6): 542-547.
- 246 REID, D. M.; NEW, S. A. *Nutritional influences on bone mass.* Proceed Nutr Soc, 1997. 56: 977-987.
- 247 FUJITA, T.; FUKASE, M. *Comparison of osteoporosis and calcium intake between Japan and the United States.* Proc Soc Exp Biol Med, 1992. 200(2): 149-152.
- 248 SCHWARTZ, A. V. et al. *International variation in the incidence of hip fractures: cross-national project on osteoporosis for the World Health Organization Program for Research on Ageing.* Osteoporosis Int, 1999. 9(3): 242-253.
- 249 LANCASTER, M.; JENKINS, F.; PHILIP, J. *Toxicity associated with certain samples of ground-nuts.* Nature, 1961. 192: 1.096-1.097.
- 250 CAMPBELL, T. et al. *Aflatoxin M1 in human urine.* Nature, 1970. 227: 403-404.
- 251 MADHAVAN, T. V.; GOPALAN, C. *The effect of dietary protein on carcinogenesis of aflatoxin.* Arch Path, 1968. 85: 133-137.
- 252 MGBODILE, M. U. K.; CAMPBELL, T. C. *Effect of protein deprivation of male weanling rats on the kinetic oh hepatic microsomal enzyme activity.* J Nutr, 1972. 192: 53-60.
- 253 APPLETON B.; CAMPBELL, T. *Inhibition of aflatoxin initiated preneoplastic liver lesons by low dietary protein.* Nutr Cancer, 1982. 3: 200-206.
- 254 YOUNGMAN, L.; CAMPBELL, T. *High protein intake promotes the growth of preneoplastic foci in Fisher 344 rats: evidence that early remodeled foci retain the potential for future growth.* J Nutr, 1991. 121b: 1.454-1.461.
- 255 YOUNGMAN, L. D. *The growth and development of aflatoxin B induced preneoplastic lesions, tumors, metastasis and spontaneous tumors as they influenced by dietary protein level, type and intervention.* Tese de Ph.D. Ithaca: Cornell University, 1990.
- 256 SCHULSINGER, D. A.; ROOT, M. M.; CAMPBELL, T. C. *Effect of dietary protein quality on development of aflatoxin B-induced hepatic preneoplastic lesions.* J Nat Cancer Inst, 1989. 81: 1.241-1.245.
- 257 HU, J. et al. *Repression of hepatitis B virus transgene and HBV induced liver injury by low protein diet.* Oncogene, 1997. 15: 2.795-2.801.
- 258 Z'GRAGGEN, K. et al. *Promoting effect of a high-fat/high-protein diet in DMBA-induced ductal pancreatic cancer in rats.* Ann Surg, mai. 2001. 233(5): 688-695.
- 259 CAMPBELL, T. C.; CAMPBELL, T. M. *El estudio de China.* Málaga: Editorial Sirio, 2006.
- 260 ARMSTRONG, D.; DOLL, D. *Enviromental factors and cancer incidence and mortality in different countries, with special reference to dietary practices.* Int. J. Cancer, 15 abr. 1975. 15(4): 617-631.
- 261 TORFADOTTIR, J. E. *Milk intake in early life and risk of advanced prostate cancer.* Am J Epidemiol, 15 jan. 2012. 175(2): 144-153.
- 262 OMS. *Dieta, nutrição e doenças crônicas. Série de relatórios técnicos, 916.* Organização Mundial da Saúde, 2003.

- 263 LI, Q. et al. *Dietary fiber intake and risk of breast cancer by menopausal and estrogen receptor status*. Eur J Nutr, fev. 2013. 52(1): 217-223.
- 264 SÁNCHEZ, C. *Actividad inmunomoduladora de las plantas*. Fitoterapia, 2002. 2(2): 151-163.
- 265 CAPDEVILA, N. *El arabinosilano y la función inmunitaria*. Natura medicatrix, 2003. 22(6): 350-354.
- 266 CHAN, D. S.; LAU, R.; VIEIRA, R.; GREENWOOD, D. C.; KAMPMAN, E.; NORAT, T. *Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies*. BMJ, 10 nov. 2011. 343: d6617.
- 267 AUGUSTINE, L. S. et al. *Dietary glycemic index and glycemic load and breast cancer risk. A case control study*. Ann Oncol, nov. 2001. 12(11): 1.533-1.538.
- 268 FOSTER-POWELL, K.; HOLT, S.; BRAND-MILLER, J. *International tables of glycemic index and glycemic load values: 2002*. Am J Clin Nutr, jul. 2002. 76(1): 5-56.
- 269 HURSTING, S. D.; THORNQUIST, M.; HENDERSON, M. M. *Types of dietary fat and the incidence of cancer at five sites*. Prev Med, mai. 1990. 19(3): 242-253.
- 270 PANDALAI, P. K. et al. *The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth*. Anticancer Research, 1996. 16(2): 815-820.
- 271 WILLIAMS, C. D.; WHITLEY, B. M.; HOYO, C. et al. *A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer*. Nutr Res, jan. 2011. 31(1): 1-8.
- 272 SASAZUKI, S. et al. *Intake of n-3 and n-6 polyunsaturated fatty acids and development of colorectal cancer by subsite: Japan Public Health Center – based prospective study*. Int J Cancer, 1º out. 2011. 129(7): 1.718-1.729.
- 273 LEITZMANN, M. F. et al. *Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer*. Am J Clin Nutr, jul. 2004. 80(1): 204-216.
- 274 FAO. *Grasas y aceites en la nutrición humana. Consulta FAO/OMS de especialistas. Estudio FAO de Alimentação e Nutrição – 57*. FAO/OMS, 1997.
- 275 BRASKY, T. et al. *Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial*. Am J Epidemiol, 15 jun. 2011. 173(12): 1.429-1.439.
- 276 FERNANDEZ, E. *Fish consumption and cancer risk*. Am J Clin Nutr, 1999. 70: 85-90.
- 277 THOMPSON, L. *Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer*. Clin Cancer Res, 15 mai. 2005. 11(10): 3.828-3.835.
- 278 DEMARK-WAHNEFRIED, W. *Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features*. Urology, jul. 2001. 58(1): 47-52.
- 279 CHEN, J.; STAVRO, M.; THOMPSON, L. *Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor*. Nutr Cancer, 2002. 43(2): 187-192.
- 280 BOUGNOUX, P. et al. *Alpha linolenic acid content of adipose breast tissue: a hot determinant of the risk of early metastasis in breast cancer*. BJC, 1994. 70(2): 330-334.
- 281 DAS, U. N.; MADHAVI, N. *Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro*. Lipids Health Dis, 14 set. 2011. 10: 159.
- 282 SIMONSEN, N. et al. *Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study*. Am J Epidemiol, 1998. 147(4): 342-352.

- 283 WEILL, P. et al. *Effects of introducing linseed in livestock diet on blood fatty acid composition of consumers of animal products.* Ann Nutr Metab, 2002. 46(5): 182-191.
- 284 TINAJAS, A. *Ácidos grasos trans y sus consecuencias para la salud.* Jan. 1998. 55: 1.273.
- 285 BRYK, D. et al. *Trans fatty acids induce a proinflammatory response in endothelial cells through ROS-dependent nuclear factor- κ B activation.* J Physiol Pharmacol, abr. 2011. 62(2): 229-238.
- 286 MOZAFFARIAN, D.; PISCHON, T.; HANKINSON, S. *Dietary intake of trans fatty acids and systemic inflammation in women.* Am J Clin Nutr, 2004. 79: 606-612.
- 287 LÓPEZ-GARCÍA, E. et al. *Consumption of trans fatty acids is related to plasma biomarkers and endothelial dysfunction.* J Nutr, mar. 2005. 135(3): 562-566.
- 288 VALENZUELA, B. *Isomeric trans fatty acids I. origin and effects in human health.* Rev Chil Nutr, set. 2008. 35(3): 162-171.
- 289 MEYER, K.; KUSHI, L.; JACOBS, D.; EATSON, A. *Dietary fat incidence of type 2 diabetes in older Iowa women.* Diabetes Care, set. 2001. 24(9): 1.528-1.535.
- 290 KUBOW, S. *The influence of positional distribution of fatty acids in native, interesterified and structure-specific lipids on lipoprotein metabolism and atherogenesis.* J Nut Biochem, 1996. 7: 530-541.
- 291 CHARDIGNY, J. M. et al. *Do trans fatty acids from industrial produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results from the trans Fatty Acid Collaboration (TRANSFACT) study.* Am J Clin Nutr, mar. 2008. 87(3): 558-566.
- 292 DEMAN, L.; DEMAN, J. M. *Trans fatty acids in milk fat.* J Am Oil Chem Soc, 1983. 60: 1.095-1.098.
- 293 NATIONAAL KOMPAS VOLSGEZONDHEID. *Verkeersongevallen. Omvang van hetprobleem. Erkeersongevallen NAAR LEEFTIJD en geslacht, 2003-2007.* Ministério de Saúde Pública dos Países Baixos, 2004.
- 294 IP, C.; MARSHALL, J. *Trans fatty acids and cancer.* Nut Rev, mai. 1996. 54(5): 138-145.
- 295 CHAJES, V. et al. *Serum transmonounsaturated fatty acids are associated with an increased risk of breast cancer in the E3 N-EPIC study.* Am J Epidemiol, jun. 2008. 167(11): 1.312-1.320.
- 296 MOTARD-BELANGER, A. et al. *Study of the effect of trans fatty acids from ruminants on blood lipids and the risk factors for cardiovascular disease.* Am J Clin Nutr, mar. 2008. 87(3): 593-599.
- 297 DUBNOV, G.; BERRY, EM. *Omega 6/omega 3 fatty acid ratio: the Israeli paradox.* World Rev Nutr Diet, 2003. 92: 81-91.
- 298 FAMUCCI, L. M. et al. *Meat and component of meat and the risk of bladder cancer in the NIH-AARP Diet and Health Study.* Cancer, 15 set. 2010. 116(18): 4.345-4.353.
- 299 BOGNOUX, P. *Alpha linolenic acid content of adipose breast tissue: a host determinant of the risk of early metastasis in breast cancer.* BJC, 1994. 70(2): 330-334.
- 300 POUDEL-TANDUKAR, K. et al. *Dietary intakes of alpha-linolenic and linoleic acids are inversely associated with serum C-reactive protein levels among Japanese men.* Nutr Res, jun. 2009. 29(6): 363-370.
- 301 BRYK, D. et al. *Trans fatty acids induce a proinflammatory response in endothelial cells through ROS-dependent nuclear factor- κ B activation.* J Physiol Pharmacol, abr. 2011. 62(2): 229-238.
- 302 HE, Y. et al. *Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States.* Int J Epidemiol, 1991. 20(1): 76-81.

- 303 RASTOGIET, T. et al. *Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US*. Int. J Epidemiol, 2008. 37(1): 147-160.
- 304 HAKIM, I. A.; HARRIS, R. B.; RITENBAUGH, C. *Fat intake and risks of squamous cell carcinoma of the skin*. Nutr Cancer, 2000. 36(2): 155-162.
- 305 KELSEY, J. L.; GAMMON, M. D.; JOHN, E. M. *Reproductive factors and breast cancer*. Epidemiol Rev, 1993. 15(1): 36-47.
- 306 LIAO, M. L. et al. *A study of the association between squamous cell carcinoma and adenocarcinoma in the lung, and history of menstruation in Shanghai women, China*. Lung Cancer, mar. 1996. 14 Supl. 1: S215-221.
- 307 PIKE, M. C. *Age-related factors in cancers of the breast, ovary, and endometrium*. J Chronic Dis, 1987. 40 Supl. 2: 59S-69S.
- 308 RAUTALAHTI, M.; ALBANES, D.; VIRTANO, J. *Life time menstrual activity indicator of breast cancer risk*. Eur J Epidemiol, jan. 1993. 9(1): 17-25.
- 309 SORIANO, R.; PONCE DE LEÓN ROSALES, S.; GARCÍA, R.; GARCÍA-GARCÍA, E.; MÉNDEZ, J. P. *High knowledge about obesity and its health risks, with the exception of cancer, among Mexican individuals*. J Cancer Educ, jun. 2012. 27(2): 306-311.
- 310 ZAKI, A.; GABER, A.; GHANEM, E.; MOEMEN, M.; SHEHATA, G. *Abdominal obesity and endometrial cancer in Egyptian females with postmenopausal bleeding*. Nutr Cancer, nov. 2011. 63(8): 1.272-1.278.
- 311 MACCIÓ, A.; MADEDDU, C. *Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications*. Scientific World Journal, 2011. 11: 2.020-2.036.
- 312 HATA, K. et al. *C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms*. Int J Mol Sci, 2011. 12(11): 8.133-8.145.
- 313 LEVI, Z. et al. *Measured body mass index in adolescence and the incidence of colorectal cancer in a cohort of 1.1 million males*. Cancer Epidemiol Biomarkers Prev, dez. 2011. 20(12): 2.524-2.531.
- 314 SUN, B.; KARIN, M. *Obesity, inflammation, and liver cancer*. J Hepatol, mar. 2012. 56(3): 704-713.
- 315 ALDHAFIRI, F.; AL-NASSER, A.; AL-SUGAIR, A.; AL-MUTAIRI, H.; YOUNG, D.; REILLY, J. J. *Obesity and metabolic syndrome in adolescent survivors of standard risk childhood acute lymphoblastic leukemia in Saudi Arabia*. Pediatr Blood Cancer, 15 jul. 2012. 59(1): 133-137.
- 316 GIOVANNUCI, E. et al. *A prospective study of dietary fat and risk of prostate cancer*. J Natl Cancer Inst, 6 out. 1993. 85(19): 1.571-1.579.
- 317 LIGIBEL, J. *Obesity and breast cancer*. Oncology (Williston Park), out. 2011. 25(11): 994-1.000.
- 318 RIORDAN, H. D. et al. *A pilot study of continuous ascorbate in terminal cancer patients*. PR Healt Sci J, dez. 2005. 24(4): 269-276.
- 319 PADAVATTY, S. J. et al. *Intravenously administered vitamin C as cancer therapy: three cases*. CMAJ, 28 mar. 2006. 174(7): 937-942.
- 320 PADAYATTY, S. J. et al. *Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects*. PLoS One, jul. 2010. 5(7): e114114.
- 321 CHEN, Q. et al. *Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice*. Proc Natl Acad Sci EUA, 12 ago. 2008. 105(32): 11.105-11.109.

- 322 ESPEY, M. G. et al. *Pharmacologic ascorbate synergizes with gemcitabine in pre-clinical models of pancreatic cancer*. Free Radic Biol Med, 1^o jun. 2011. 50(11): 1.610-1.619.
- 323 CHEN, Q. et al. *Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues*. Proc Natl Acad Sci EUA, 20 set. 2005. 102(38): 13.604-13.609.
- 324 POLLARD, H. B.; LEVINE, M. A.; EIDELMAN, Q. Pollard M. *Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone refractory prostate cancer*. In Vivo, mai-jun. 2010. 24(3): 249-255.
- 325 DU, J. et al. *Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer*. Clin Cancer Res, 15 jan. 2010. 16(2): 509-520.
- 326 PHATI, S. S. et al. *Pharmacologic doses of ascorbic acid repress specificity protein (Sp) Transcription factors and Sp-regulated genes in colon cancer cells*. Nutr Cancer, out. 2011. 63(7): 1.133-1.142.
- 327 PARK, S. et al. *L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms*. Int J Biochem Cell Biol, nov. 2004. 36(11): 2.180-2.195.
- 328 CHA, J. et al. *Ascorbate depletion increases growth and metastasis of melanoma cells in vitamin C deficient mice*. Exp Oncol, dez. 2011. 33(4): 226-230.
- 329 VOLLBRACHT, C. et al. *Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany*. In Vivo, nov-dez. 2011. 25(6): 983-990.
- 330 HUTCHINSON, J. et al. *Vitamin C intake from diary recording and risk of breast cancer in the UK Dietary Cohort Consortium*. Eur J Clin Nutr, mai. 2012. 66(5): 561-568.
- 331 CABANILLAS, F. *Vitamin C and cancer: what can we conclude – 1609 patients and 33 years later?* PR Health Sci J, set. 2010. 29(3): 215-217.
- 332 LYKKESFELDT, J.; POULSEN, H. E. *Is vitamin C supplementation beneficial? Lessons learned from randomized controlled trials*. Br J Nutr, mai. 2010. 103(9): 1.251-1.259.
- 333 INSTITUTE OF MEDICINE. *Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline*. Washington, D. C.: National Academy Press, 2000.
- 334 HAVALA, S. *The American Dietetic Association. Being Vegetarian*. Minneapolis: Chronimed Publishing, 1996. 28.
- 335 SATIA, J. A.; LITTMAN, A.; SLATORE, C. G.; GALANKO, J. A.; White E. *Long-term use of beta-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: results from the Vitamins And Lifestyle (VITAL) study*. Am J Epidemiol, 1^o abr. 2009. 169(7): 815-828.
- 336 OMENN, G. S. et al. *Risk factors for lung cancer and for intervention effects CARET, the beta-carotene and retinol efficacy trial*. J Natl Cancer Inst, 6 nov. 1996. 88(21): 1.550-1.559.
- 337 FROST, J. T.; HILL, L. *Vitamin D deficiency in a nonrandom sample of Southeast Alaska natives*. J Am Diet Assoc, set. 2008. 108(9): 1.508-1.511.
- 338 CEDRIC, F. et al. *Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study*. Lancet, 18 nov. 1989. 2(8.673): 1.176-1.178.
- 339 TRAVERA-MENDOZA, L. E.; WHITE, J. *Cell defenses and the sunshine vitamin*. Sci Am, nov. 2007. 297(5): 62-5, 68-70, 72.

- 340 PACINI, S.; PUNZI, T.; MORUCCI, G.; GULISANO, M.; RUGGIERO, M. *Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells*. Anticancer Res, jan. 2012. 32(1): 45-52.
- 341 COLSTON, K.; BERGER; COOMBES, R. *Possible role for vitamin D in controlling breast cancer cell proliferation*. Lancet, 28 jan. 1988. 1(8.631): 188-1891.
- 342 TRUMP, D. L.; MUINDI, J.; FAKIH, M.; YU, W. D.; JOHNSON, C. S. *Vitamin D compounds: clinical development as cancer therapy and prevention agents*. Anticancer Res, jul-ago. 2006. 26(4A): 2.551-2.556.
- 343 SPINA, C. S.; TANGPRICHA, V.; USKOKOVIC, M.; ADORINIC, L.; MAEHR, H.; HOLICK, M. F. *Vitamin D and Cancer*. Anticancer Res, jul-ago 2006. 26(4A): 2.515-2.524.
- 344 NORTON, R.; O'CONNELL, M. A. *Vitamin D: potential in the prevention and treatment of lung cancer*. Anticancer Res, jan. 2012. 32(1): 211-221.
- 345 BISCHOFF-FERRARI, H. A. *Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials*. JAMA. 11 mai. 2005. 293(18): 2.257-2.264.
- 346 GRANT, W. B. *A review of the role of solar ultraviolet-B irradiance and vitamin D in reducing risk of dental caries*. Dermato endocrinol, jul. 2011. 3(3): 193-198.
- 347 BISCHOFF-FERRARI, H. *Health effects of vitamin D*. Dermatol Ther, jan-fev. 2010. 23(1): 23-30.
- 348 SOUBERBIELLE, J. C. et al. *Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice*. Autoimmun Rev, set. 2010. 9(11): 709-715.
- 349 GRANT, W. B. *Ecological studies of the UVB-vitamin D-cancer Hypothesis*. Anticancer Res, jan. 2012. 32(1): 223-236.
- 350 CICARMA, E.; POROJNICU, A. C.; LAGUNOVA, Z.; DAHLBACK, A.; JUZENIENE, A.; MOAN, J. *Sun and sun beds: inducers of vitamin D and skin cancer*. Anticancer Res, set. 2009. 29(9): 3.495-3.500.
- 351 TANG, J. Y. et al. *Calcium plus vitamin D supplementation and the risk of non-melanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial*. J Clin Oncol, 1^o ago. 2011. 29(22): 3.078-3.084.
- 352 LEFKOWITZ, E.; GARLAND, C. *Sunlight, vitamin D, and ovarian cancer mortality rates in US women*. Int J Epidemiol, 1994. 23(6): 1.133-1.136.
- 353 MOAN, J. et al. *Solar radiation, vitamin D and cancer incidence and mortality in Norway*. Anticancer Res, set. 2009. 29(9): 3.501-3.509.
- 354 ORELL-KOTIKANGAS, H. et al. *High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis*. Head Neck, out. 2012. 34(10): 1.450-1.455.
- 355 PAZDIORA, P. et al. *Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study*. Anticancer Res, out. 2011. 31(10): 3.619-3.621.
- 356 BRESLAU, N. A. et al. *Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism*. J Clin Endocrinol Metab, jan. 1988. 66(1): 140-146.
- 357 LANGMAN, C. B. *Calcitriol metabolism during chronic metabolic acidosis*. Semin Nephrol, 1989. 9: 65-71.
- 358 GONZÁLEZ SOLANELLAS, M. et al. *Vitamin D deficiency in women of reproductive age*. Aten Primaria, 2008. 40: 393-399.
- 359 AGUADO, P. et al. *Low vitamin D levels in outpatient postmenopausal women from a Rheumatology Clinic in Madrid, Spain: Their relationship with bone mineral density*. Osteoporos Int, 2000. 11(9): 739-744.

- 360 VAN DER WIELEN, R. P. et al. *Serum vitamin D concentrations among elderly people in Europe*. Lancet, 22 jul. 1995. 346(8.969): 207-210.
- 361 McKENNA M. J. *Differences in vitamin D status between countries in young adults and the elderly*. Am J Med, 1992. 93: 67-69.
- 362 BYRNE, P. M. et al. *Vitamin D supplementation in the elderly. Review of safety and effectiveness of different regimes*. Calcified Tissue Int, 1995. 56: 518-520.
- 363 PEELH, D. et al. *Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells*. Cancer Res, 1^{er} fev. 1994. 54(3): 805-810.
- 364 REINHOLD, V. *How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology*. Anticancer Res, set. 2009. 29 (9): 3.675-3.684.
- 365 LAPPE, J. M.; TRAVERS-GUSTAFSON, K. M.; DAVIES, T. *Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial*. AJCN, 2007. 85: 1.586-1.591.
- 366 WELLAND, D. *¿Es importante la vitamina D?* Mente y Cerebro, 2010. 43: 47.
- 367 CANADIAN CANCER SOCIETY. *La société canadienne du cancer annonce ses recommandations concernant la vitamine D*. 2007.
- 368 TSAVACHIDOU, D. et al. *Selenium and vitamin E: cell type – and intervention – specific tissue effects in prostate cancer*. J Natl Cancer Inst, 2009. 101(5): 306-320.
- 369 LIN, J. et al. *Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial*. J Natl Cancer Inst, 2009. 101(1): 14-23.
- 370 BAIRATI, I. et al. *A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients*. J Natl Cancer Inst, 2005. 97(7): 481-488.
- 371 JAIN, S. MUNVER, R. SAWCZUK, I. S. *Vitamin E and selenium do not decrease prostate cancer incidence: vitamin E may actually increase it*. Evid Based Med, out. 2012. 17(5): 151-152.
- 372 MOYAD, M.A. *Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?* Urology, abr. 2002. 59; 4 Supl. (1): 9-19.
- 373 SHUMIN, Z. et al. *Dietary carotenoids and vitamins A, C, and E and risk of breast cancer*. J Natl Cancer Inst, 17 mar. 1999. 91(6): 547-556.
- 374 KIRSH, V. et al. *Supplemental and dietary vitamin E, β -carotene, and vitamin C intakes and prostate cancer risk*. J Natl Cancer Inst, 15 fev. 2006. 98(4): 245-254.
- 375 HUANG, H. Y. *Multivitamin/mineral supplements and prevention of chronic disease*. Evid Rep Technol Assess, mai. 2006. (139): 1-117.
- 376 CANTOR, K. P. *Drinking water and cancer*. Cancer Causes Control, 1997. 8(3): 292-308.
- 377 WIGLE, D. T.; MAO, Y.; SEMENCIW, R.; SMITH, M. H.; TOFT, P. *Contaminants in drinking water and cancer risks in Canadian cities*. Can J Public Health, set-out. 1986. 77(5): 335-342.
- 378 THOUEZ, J. P.; BEAUCHAMP, Y.; SIMARD, A. *Cancer and the physicochemical quality of drinking water in Quebec*. Soc Sci Med Med Geogr, fev. 1981. 15D(1): 213-223.
- 379 KOMULAINEN, H. et al. *Carcinogenicity of the drinking water mutagen 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone in the rat*. J Natl Cancer Inst, 1997. 89 (12): 848-856.
- 380 VILLANUEVA, C.; KOGEVINAS, M.; GRIMALT, J. *Chlorination of drinking water in Spain and bladder cancer*. Gac Sanit, 2001. 15(1): 48-53.
- 381 CRAGLE, D. L.; SHY, C. M.; STRUBA, R.; SIFF, E. J. "A case control study of colon cancer and water chlorination in North Carolina." In: JOLLEY, R. L. (ed.). *Water chlorination*

- chemistry, environmental impact and health effects. Chelsea (MI): Lewis Publishers, 1985. 153-159.
- 382 DOYLE, T. J. et al. *The association of drinking water source and chlorination by-products with cancer incidence among postmenopausal women in Iowa: a prospective cohort study.* Am J Public Health, jul. 1997. 87(7): 1.168-1.176.
- 383 VILLANUEVA, C. M. et al. *Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools.* Am J Epidemiol, 15 jan. 2007. 165(2): 148-156.
- 384 CHEVRIER, C. et al. *Assessing swimming pool water.* Environ Sci Technol, 15 jan. 2007. 41(2): 363-372.
- 385 KOGEVINAS, M. et al. *Genotoxic effects in swimmers exposed to disinfection by products in indoor swimming pools.* Environ Health Perspect, nov. 2010. 118(11): 1.531-1.537.
- 386 VILLANUEVA, C. M. et al. *Bladder cancer and exposure to water disinfection by products through ingestion, bathing, showering, and swimming in pools.* Am J Epidemiol, 15 jan. 2007. 165(2): 148-156.
- 387 CLARK, R.; GOODRICH, J. *Drinking water and cancer mortality.* Sci Total Environ, set. 1986. 53(3): 153-172.
- 388 YANG, C. Y.; CHENG, M. F.; TSAI, S. S.; HUNG, C. F. *Fluoride in drinking water and cancer mortality in Taiwan.* Environ Res, mar. 2000. 82(3): 189-193.
- 389 IARC. *Some drinking water disinfectants and contaminants, including arsenic.* IARC scientific publications. Lyon: International Agency for Research on Cancer, 2002. 84.
- 390 BARCELÓ, L.; LÓPEZ DE ALD, M. J. *Contaminación y calidad química del agua: el problema de los contaminantes emergentes.* Fundación Nueva Cultura del Agua Panel científico-técnico de seguimiento de la política de aguas Convenio Universidad de Sevilla-Ministerio de Medio Ambiente.
- 391 VALCÁRCCEL, Y.; GONZÁLEZ ALONSO, S.; RODRÍGUEZ-GIL, J. L.; GIL, A.; CATALÁ, M. *Detection of pharmaceutically active compounds in the rivers and tap water of the Madrid Region (Spain) and potential ecotoxicological risk.* Chemosphere, set. 2011. 84(10): 1.336-1.348.
- 392 VALCÁRCCEL, Y. et al. *Drugs of abuse in surface and tap waters of the Tagus River basin: Heterogeneous photo Fenton process is effective in their degradation.* Environ Int, mai. 2012. 41C: 35-43.
- 393 WAGNER, M.; OEHLMANN, J. *Endocrine disruptors in bottled mineral water: total estrogenic burden and migration from plastic bottles.* Environ Sci Pollut Res Int, mai. 2009. 16(3): 278-286.
- 394 BILES, J. E.; McNEAL, T. P.; BEGLEY, T. H.; HOLLIFIELD, H. C. *Determination of bisphenol A in reusable polycarbonate food-contact plastics and migration to food-simulating liquids.* J Agric Food Chem. 1997. 45(9): 3.541-3.544.
- 395 SHOTYK, W.; KRACHLER, M. *Contamination of bottled waters with antimony leaching from polyethylene terephthalate (PET) increases upon storage.* Environ Sci Technol, 2007. 41: 1.560-1.563.
- 396 DI BELLA, G.; SAITTA, M.; LO CURTO, S. *Production process contamination of citrus essential oils by plastic materials.* J Agric Food Chem, 2001. 49: 3.705-3.708.
- 397 BISCARDI, D. et al. *Evaluation of the migration of mutagens/carcinogens from PET bottles into mineral water by Tradescantia/micronuclei test, comet assay on leukocytes.* Sci Total Environ, 20 jan. 2003. 302(1-3): 101-108.

- 398 EMOTO, M. *Mensajes del agua: La belleza oculta del agua*. 11ª ed. Barcelona: La Liebre de Marzo, 2010.
- 399 RADIN, D.; HAYSEN, G.; EMOTO, M.; KIZU, T. *Double-blind test of the effects of distant intention on water crystal formation*. Explore (NY), set-out. 2006. 2 (5): 408-411.
- 400 EMOTO, M. *Healing with water*. J Altern Complement Med, fev. 2004. 10 (1): 19-21.
- 401 D'INCALCI, M.; STEWARD, W. P.; GESCHER, A. J. *Use of cancer chemopreventive phytochemicals as antineoplastic agents*. Lancet Oncol, nov. 2005. 6(11): 899-904.
- 402 MANN, C. D. et al. *Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis*. Eur J Cancer Prev, fev. 2009. 18(1): 13-25.
- 403 THOMASSE, S. C.; BERRY, D. P.; GARCEA, G.; MARCZYLO, T.; STEWARD, W. P.; GESCHER, A. J. *Dietary polyphenolic phytochemicals – promising cancer chemopreventive agents in humans? A review of their clinical properties*. Int J Cancer, 1ª fev. 2007. 120(3): 451-458.
- 404 GORDON, M. *Significance of dietary antioxidants for health*. Int J Mol Sci, 2012. 13(1): 173-179.
- 405 BLOCK, G.; PATTERSON, B.; SUBAR, A. *Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence*. Nutr Cancer, 1992. 18(1): 1-29.
- 406 VAINIO, H.; WEIDERPASS, E. *Fruit and vegetables in cancer prevention*. Nutr Cancer, 2006. 54(1): 111-142.
- 407 SHU, L.; CHEUNG K. L.; KHOR, T. O.; CHEN, C.; KONG, A. N. *Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis*. Cancer Metastasis Rev, set. 2010. 29(3): 483-502.
- 408 KONIJETI, R. et al. *Chemoprevention of prostate cancer with lycopene in the TRAMP model*. Prostate, 1ª out. 2010. 70(14): 1.547-1.554.
- 409 TANAKA, T.; SHNIMIZU, M.; MORIWAKI, H. *Cancer chemoprevention by carotenoids*. Molecules, 14 mar. 2012. 17(3): 3.202-3.242.
- 410 CHOUDHARY, S. P.; TRAN, L. S. *Phytosterols: perspectives in human nutrition and clinical therapy*. Curr Med Chem, 2011. 18(29): 4.557-4.567.
- 411 TSAI, C. Y. et al. *Effect of soy saponin on the growth of human colon cancer cells*. World J Gastroenterol, 21 jul. 2010. 16(27): 3.371-3.376.
- 412 WENG, C. J.; YEN, G. C. *Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities*. Cancer Metastasis Rev, jun. 2012. 31(1-2): 323-351.
- 413 PRIYADARSINI, R. et al. *The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-κβ inhibition*. Eur J Pharmacol, 15 dez. 2010. 649(1-3): 84-91.
- 414 WANG, G. et al. *Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death*. Int J Nanomedicine, 2012. 7: 271-280.
- 415 ZHOU, W. et al. *Dietary polyphenol quercetin targets pancreatic cancer stem cells*. Int J Oncol, set. 2010. 37(3): 551-561.
- 416 *The dietary bioflavonoid quercetin synergizes with epigallocatechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition*. J Mol Signal, 18 ago. 2010. 5:14.
- 417 ANTO, R. J.; GEORGE, J.; BABU, K. V.; RAJASEKHARAN, K. N.; KUTTAN, R. *Anti-mutagenic and anticarcinogenic activity of natural and synthetic curcuminoids*. Mutat Res, set. 1996. 370(2): 127-131.

- 418 SZLISZKA, E.; KROL, W. *Soy isoflavones augment the effect of TRAIL-mediated apoptotic death in prostate cancer cells*. *Oncol Rep*, set. 2011. 26(3): 533-541.
- 419 VERMA, S. P.; GOLDIN, B. R.; LIN, P. S. *The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids*. *Environ Health Perspect*, dez. 1998. 106(12): 807-812.
- 420 NÖTHLINGS, U. et al. *Flavonols and pancreatic cancer risk*. *Am J Epidemiol*, 2007. 166(8): 924-931.
- 421 GATES, M. A.; et al. *A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer*. *Int J Cancer*, 15 nov. 2007. 121(10): 2.225-2.232.
- 422 DUO, J.; YING, G. G.; WANG, G. W.; ZHANG, L. *Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation*. *Mol Med Report*, jun. 2012. 5(6): 1.453-1.456.
- 423 GARCÍA-TIRADO, J.; RIEGER-REYES, C.; SAZ-PEIRÓ, P. *Effect of flavonoids in the prevention of lung cancer: systematic review*. *Med Clin (Barc)*, 6 out. 2012. 139(8): 358-363.
- 424 AQIL, F. et al. *Antioxidant and antiproliferative activities of anthocyanin/ ellagitannin-enriched extracts from syzygium cumini L. (Jamun, the Indian Blackberry)*. *Nutr Cancer*, abr. 2012. 64(3): 428-438.
- 425 WEDICK, N. M. et al. *Dietary flavonoid intakes and risk of type 2 diabetes in US men and women*. *Am J Clin Nutr*, abr. 2012. 95(4): 925-933.
- 426 HSEU, Y. C. et al. *Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes*. *Food Chem Toxicol*, 22 fev. 2012. 50(5): 1.245-1.255.
- 427 WHITLEY, A. C.; STONER, G. D.; DARBY, M. V.; WALLE, T. *Intestinal epithelial cell accumulation of the cancer preventive polyphenol ellagic acid-extensive binding to protein and DNA*. *Biochem Pharmacol*, 15 set. 2003. 66(6): 907-915.
- 428 ALLEN, C. T.; PEDEN-ADAMS, M. M.; EUDALY, J.; KEIL, D. E. *Subchronic exposure to ellagic acid impairs cytotoxic T-cell function and suppresses humoral immunity in mice*. *Immunopharmacol Immunotoxicol*, ago. 2003. 25(3): 409-422.
- 429 VERHOEVEN, D. T.; GOLDBOHN, R. A.; VAN POPPEL, G.; VERHAGEN, H.; VAN DEN BRANDT, P. A. *Epidemiological studies on brassica vegetables and cancer risk*. *Cancer Epidemiol Biomarkers Prev*, set. 1996. 5(9): 733-748.
- 430 VERHOEVEN, D. T.; VERHAGEN, H.; GOLDBOHN, R. A.; VAN DEN BRANDT, P. A.; VAN POPPEL, G. *A review of mechanisms underlying anticarcinogenicity by brassica vegetables*. *Chem Biol Interact*, 28 fev. 1997. 103(2): 79-129.
- 431 JOHNSON, I. T. *Mechanisms and anticarcinogenic effects of diet-related apoptosis in the intestinal mucosa*. *Nutr Res Rev*, dez. 2001. 14(2): 229-256.
- 432 SMITH, T.; MITHEN, R.; JOHNSON, I. *Effects of brassica vegetable juice on the induction of apoptosis and aberrant crypt foci in rat colonic mucosal crypts in vivo*. *Carcinogenesis*, 2003. 24(3): 491-495.
- 433 LI, Y. et al. *Sulforaphane inhibits pancreatic cancer through disrupting Hsp90p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90*. *J Nutr Biochem*, dez. 2012. 23(12): 1.617-1.626.
- 434 CHIAO, J. W.; CHUNG, F. L.; KANCHERLA, R.; AHMED, T.; MITTELMAN, A.; CONAWAY, C. C. *Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells*. *Int J Oncol*, mar. 2002. 20(3): 631-636.

- 435 CRAMERA, J.; TERAN-GARCIA, M.; JEFFERY, E. *Enhancing sulforaphane absorption and excretion in healthy men through the combined consumption of fresh broccoli sprouts and a glucoraphanin-rich powder*. Br J Nutr, set. 2011. 13: 1-6.
- 436 RUNGAPAMESTRY, V.; DUNCAN, A. J.; FULLER, Z.; RATCLIFFE, B. *Effect of cooking brassica vegetables on the subsequent hydrolysis and metabolic fate of glucosinolates*. Proc Nutr Soc, fev. 2007. 66(1): 69-81.
- 437 HE, Y. H.; FRIESEN, M. D.; RUCH, R. J.; SCHUT, H. A. *Indole-3-carbinol as a chemopreventive agent in 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) carcinogenesis: inhibition of PhIP-DNA adduct formation, acceleration of PhIP metabolism, and induction of cytochrome P450 in female F344 rats*. Food Chem Toxicol, jan. 2000. 38(1): 15-23.
- 438 JIN, L.; QI, M.; CHEN, D. Z.; ANDERSON, A.; YANG, G. Y.; ARBEIT, J. M.; AUBORN, K. J. *Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice*. Cancer Res, 15 ago. 1999. 59(16): 3.991-3.997.
- 439 BELL, M. C. et al. *Placebo-controlled trial of indole-3-carbinol in the treatment of CIN*. Gynecol Oncol, ago. 2000. 78(2): 123-129.
- 440 BELL, M. C. et al. *Preliminary results of the use of indole-3-carbinol in the treatment of CIN*. Gynecol Oncol, ago. 2000. 78(2): 123-129.
- 441 BAILEY, G. S.; HENDRICKS, J. D.; SHELTON, D. W.; NIXON J. E.; PAWLOWSKI N.E. *Enhancement of carcinogenesis by the natural anti-carcinogen indole-3-carbinol*. J Natl Cancer Inst, mai. 1987. 78(5): 931-934.
- 442 VAN POPPEL, G.; VERHOEVEN, D. T.; VERHAGEN, H.; GOLDBOEHM, R. A. *Brassica vegetables and cancer prevention. Epidemiology and mechanisms*. Adv Exp Med Biol, 1999. 472: 159-168.
- 443 PULEO, A. *Physiological effects of cabbage with reference to its potential as a dietary cancer-inhibitor and its use in ancient medicine*. J Ethnopharm, 1983. 9: 261-272.
- 444 LAM, S. et al. *A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia*. J Natl Cancer Inst, 3 jul. 2002. 94(13): 1.001-1.009.
- 445 CHEN, C. H.; DEGRAFFENRIED, L. A. *Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status*. Phytomedicine, 15 jun. 2012. 19(8-9): 763-767.
- 446 CHEN, D. et al. *Capsaicin induces cycle arrest by inhibiting cyclin-dependent-kinase in bladder carcinoma cells*. Int J Urol, jul. 2012. 19(7): 662-668.
- 447 ELLISON, N. et al. *Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients*. J Clin Oncol, ago. 1997. 15(8): 2.974-2.980.
- 448 CERELLA, C.; DICATO, M.; JACOB, C.; DIEDERICH, M. *Chemical properties and mechanisms determining the anti-cancer action of garlic derived organic sulfur compounds*. Anticancer Agents Med Chem, mar. 2011. 11(3): 267-271.
- 449 ZHOU, Y. et al. *Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis*. Gastroenterology, jul. 2011. 141(1): 80-89.
- 450 KHATIWADA, J.; VERGHESE, M.; DAVIS, S.; WILLIAMS, L. L. *Green tea, phytic acid, and inositol in combination reduced the incidence of azoxymethane-induced colon tumors in Fisher 344 male rats*. J Med Food, nov. 2011. 14(11): 1.313-1.320.
- 451 NORAZALINA, S.; NORHAIZAN, M. E.; HAIRUSZAH, I.; NORASHAREENA, M. S. *Anticarcinogenic efficacy of phytic acid extracted from rice bran on azoxymethane-induced colon carcinogenesis in rats*. Exp Toxicol Pathol, mai. 2010. 62(3): 259-268.

- 452 GRAF, E.; EATON, J. W. *Antioxidant functions of phytic acid*. Free Radic Biol Med, 1990. 8(1): 61-69.
- 453 CHOLEWA, K. et al. *The influence of phytic acid on TNF-alpha and its receptors genes' expression in colon cancer Caco-2 cells*. Acta Pol Pharm, jan-fev. 2008. 65(1): 75-79.
- 454 GRAF, E.; EATON, J. W. *Suppression of colonic cancer by dietary phytic acid*. Nutr Cancer, 1993. 19(1): 11-19.
- 455 DUFFY, M. J. *Proteases as prognostic markers in cancer*. Clin Cancer Res, abr. 1996. 2(4): 613-618.
- 456 PALAVALLI, M. H.; NATARAJAN, S. S.; WANG, T. T.; KRISHNAN, H. B. *Imbibition of soybean seeds in warm water results in the release of copious amounts of bowman-birk protease inhibitor, a putative anticarcinogenic agent*. J Agric Food Chem, 28 mar. 2012. 60(12): 3.135-3.143.
- 457 KOBAYASHI, H.; SUZUKI, M.; KANAYAMA, N.; TERAOKA, T. *A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation*. Clin Exp Metastasis, 2004. 21(2): 159-166.
- 458 LOSSO, J. N. *The biochemical and functional food properties of the bowman-birk inhibitor*. Crit Rev Food Sci Nutr, jan. 2008. 48(1): 94-118.
- 459 CHAO, A. et al. *Meat consumption and risk of colorectal cancer*. JAMA, 12 jan. 2005. 293(2): 172-182.
- 460 BINGHAM, A.; HUGHES, R.; CROSS, A. *Effect of white versus red meat on endogenous N-nitrosation in the human colon and further evidence of a dose response*. J Nutr, nov. 2002. 132(11 Supl): 3.522S-3.525S.
- 461 HOGG, N. *Red meat and colon cancer: heme proteins and nitrite in the gut. A commentary on diet-induced endogenous formation of nitroso compounds in the GI tract*. Free Radic Biol Med, 2007. 43: 1.037-1.039.
- 462 O'HANLON, L. *High meat consumption linked to gastric-cancer risk*. Lancet Oncol, abr. 2006. 7(4): 287.
- 463 RODRIGUEZ, C. et al. *Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort*. Cancer Epidemiol Biomarkers Prev, fev. 2006. 15(2): 211-216.
- 464 GARCIA-CLOSAS, R. et al. *Food, nutrient and heterocyclic amine intake and the risk of bladder cancer*. Eur J Cancer, jul. 2007. 43(11): 1.731-1.740.
- 465 TAPPEL, A. *Heme of consumed red meat can act as a catalyst of oxidative damage and could initiate colon, breast and prostate cancers, heart disease and other diseases*. Med Hypotheses, 2007. 68(3): 562-564.
- 466 SINHA, R.; CROSS, A. J.; GRAUBARD, B. I.; LEITZMANN, M. F.; SCHATZKIN, A. *Meat intake and mortality: a prospective study of over half a million people*. Arch Intern Med, 23 mar. 2009. 169(6): 562-571.
- 467 LAUBER, S. N.; GOODERHAM, N. J. *The cooked meat derived genotoxic carcinogen 2-amino-3-methylimidazo[4,5-b]pyridine has potent hormone-like activity: mechanistic support for a role in breast cancer*. Cancer Res, 1st out. 2007. 67(19): 9.597-9.602.
- 468 BRUNING-FANN, C. S.; KANEENE, J. B. *The effects of nitrate, nitrite and N-nitroso compounds on human health: a review*. Vet Hum Toxicol, dez. 1993. 35(6): 521-538.
- 469 SZYMANSKA-CHABOWSKA, J.; ANTONOWICZ-JUCHNIEWICZ, J.; ANDRZEJAK, R. *Some aspects of arsenic toxicity and carcinogenicity in living organism with special regard to*

- its influence on cardiovascular system, blood and bone marrow.* Int J Occup Med Environ Health, 2002. 15(2): 101-116.
- 470 DURANDO, M. et al. *Bisphenol A exposure induces preneoplastic lesions in the mammary gland in Wistar rats.* Environ Health Perspect, jan. 2007. 115(1): 80-86.
- 471 HO, S.; TANG, W.; BELMONTE DE FRAUSTO, J.; PRINS, G. *Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.* Cancer Res, 2006. 66: 5.624-5.632.
- 472 LARSSON, S.; BERGKVIST; WOLK, A. *Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort.* Am J Clin Nutr, nov. 2004. 80(5): 1.353-1.357.
- 473 CRAMER, D. W. et al. *Galactose consumption and metabolism in relation to the risk of ovarian cancer.* Lancet, 8 jul. 1989. 2(8.654): 66-71.
- 474 GERRITS, W. J.; DECUYPERE, E.; VERSTEGEN, M. W.; KARABINAS, V. *Effect of protein and protein-free energy intake on plasma concentrations of insulin-like growth factor I and thyroid hormones in preruminant calves.* J Anim Sci, mai. 1998. 76(5): 1.356-1.363.
- 475 FONTANA, L.; WEISS, E. P.; VILLAREAL, D. T.; KLEIN, S.; HOLLOSZY, J. O. *Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans.* Aging Cell, out. 2008. 7(5): 681-687.
- 476 WANG, C. et al. *Review of salt consumption and stomach cancer risk: Epidemiological and biological evidence.* World J Gastroenterol, 14 mai. 2009. 15(18): 2.204-2.213.
- 477 FREEMAN, H. J. *Adult celiac disease and its malignant complications.* Gut Liver, dez. 2009. 3(4): 237-246.
- 478 MUELLER, T.; VOIGT, W. *Fermented wheat germ extract-nutritional supplement or anti-cancer drug?* Nutr J, 5 set. 2011. 10: 89.
- 479 MUELLER, T.; JORDAN, K.; VOIGT, W. *Promising cytotoxic activity profile of fermented wheat germ extract (AveMar®) in human cancer cell lines.* J Exp Clin Cancer Res, 16 abr. 2011. 30: 42.
- 480 CHANG, S.; BUSWELL, J. *Mushroom nutraceuticals.* World J Microbiol Biotechnol, 1996. 12: 473-476.
- 481 EL-DEMERDASH, F.; YOUSEF, M.; ABOU EL-NAGA, N. *Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats.* Food Chem Toxicol, jan. 2005. 43(1): 57-63.
- 482 BOERSMA, H. *Interaction between the cytostatic effects of quercetin and 5-fluorouracil in two human colorectal cancer cell lines.* Phytomedic, dez. 1994. 1(3): 139-244.
- 483 WANG, G. et al. *Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death.* Int J Nanomedicine, 2012. 7: 271-280.
- 484 KANG, T. B; LIANG, N. C. *Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells.* Biochem Pharmacol, nov. 1997. 54(9): 1.013-1.018.
- 485 QIN, Y.; HE, L. Y.; CHEN, Y.; WANG, W. Y.; ZHAO, X. H.; WU, M. Y. *Quercetin affects leptin and its receptor in human gastric cancer MGC-803 cells and JAK-STAT pathway.* Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, jan. 2012. 28(1): 12-16.
- 486 DAE-HEE, L.; MIROSLAW, S.; YONG, J. L. *Role of Bax in quercetin-induced apoptosis in human prostate cancer cells.* Biochem Pharmacol, jun. 2008. 75(12): 2.345-2.355.
- 487 CHEN, S. S.; MICHAEL, A.; BUTLER-MANUEL, S. A. *Advances in the treatment of ovarian cancer – a potential role of antiinflammatory phytochemicals.* Discov Med, jan. 2012. 13(68): 7-17.

- 488 VIDYA, P. R.; SENTHIL, M. R.; MAITREYI et al. *The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF- κ B inhibition*. Eur J Pharmacol, dez. 2010. 649(1-3): 84-91.
- 489 DU, G. et al. *Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice*. Int Immunopharmacol, jul. 2010. 10(7): 819-826.
- 490 MURAKAMI, A.; ASHIDA, H.; TERAOKA, J. *Multitargeted cancer prevention by quercetin*. Cancer Lett, out. 2008. 269(2): 315-325.
- 491 WACH, A.; PYRZYŃSKA, K.; BIESAGA M. *Quercetin content in some food and herbal samples*. Food Chemistry, 2007. 100(2): 699-704.
- 492 NESSA, M. U. et al. *Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models*. Anticancer Res, nov. 2011. 31(11): 3.789-3.797.
- 493 CHEN, C.; ZHOU, J.; JI, C. *Quercetin: A potential drug to reverse multidrug resistance*. Life Sci, set. 2010. 87(11-12): 333-338.
- 494 WONG, M. Y.; CHIU, C. N. *Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model*. Nanomedicine, dez. 2011. 7(6): 834-840.
- 495 DIHAL, A. A. et al. *Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2*. Cancer Lett, 18 jul. 2006. 238(2): 248-259.
- 496 KHONKARN, R.; MANKHETKORN, S.; WIM, E.; OKONOGI, S. *PEG-OCL micelles for quercetin solubilization and inhibition of cancer cell growth*. Eur J Pharm and Biopharm, out. 2011. 79(2): 268-275.
- 497 MERTENS-TALCOTT, S.; PERCIVAL, S. *Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells*. Cancer Lett, 10 fev. 2005. 218(2): 141-151.
- 498 WANG, P. et al. *Effects of quercetin on the apoptosis of the human gastric carcinoma cells*. Toxicol In Vitro, mar. 2012. 26(2): 221-228.
- 499 RUSSO, M. et al. *The flavonoid quercetin in disease prevention and therapy: Facts and fancies*. Biochem Pharmacol, 1^a jan. 2012. 83(1): 6-15.
- 500 DEVIPRIYA, S.; GANAPATHY, V.; SRINIVASULU, C. *Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin*. Chemic Biol Interact, 25 ago. 2006. 62(2): 106-113.
- 501 KAINDL, U. et al. *The dietary antioxidants resveratrol and quercetin protect cells from exogenous pro-oxidative damage*. Food Chem Toxicol, abr. 2008. 46(4): 1.320-1.326.
- 502 CAMARGO, C. A. et al. *Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats*. Biochem Biophys Res Commun, 25 mar. 2011. 406(4): 638-634.
- 503 SCHWARZ, D.; KISSELEV, P.; ROOTS, I. *CYP1A1 genotype-selective inhibition of benzo[a] pyrene activation by quercetin*. Eur J Cancer, jan. 2005. 41(1): 151-158.
- 504 BOOTS, A. W.; HAENEN, G. R.; BAST, A. *Health effects of quercetin: From antioxidant to nutraceutical*. Eur J Pharmacol, 13 mai. 2008. 585(2-3): 325-337.
- 505 ZHOU, W. et al. *Dietary polyphenol quercetin targets pancreatic cancer stem cells*. Int J Oncol, set. 2010. 37(3): 551-561.
- 506 MILNER, J. A. *Garlic: Its anticarcinogenic and antitumorogenic properties*. Nutr Rev, nov. 1996. 54(11 Pt 2): S82-S86.

- 507 ROSS, S. A.; FINLEY, J. W.; MILNER, J. A. *Allyl sulfur compounds from garlic modulate aberrant crypt formation*. J Nutr, mar. 2006. 136(3 Supl.): 8.52S-8.54S.
- 508 GONZÁLEZ, C. A. et al. *Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST)*. Int J Cancer, 2006. 118(10): 2.559-2.566.
- 509 GAO, C. M.; TAKEZAKI T.; DING J. H.; LI M. S.; TAJIMA K. *Protective effect of allium vegetables against both esophageal and stomach cancer: A simultaneous case-referent study of a high-epidemic area in Jiangsu Province, China*. Jpn J Cancer Res, jun. 1999. 90(6): 614-621.
- 510 CHAN, J. M.; WANG, F.; HOLLY, E. A. *Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area*. Cancer Epidemiol Biomarkers Prev, set. 2005. 14(9): 2.093-2.097.
- 511 TILLI, C. M. et al. *The garlic-derived organosulfur component ajoene decreases basal cell carcinoma tumor size by inducing apoptosis*. Arch Dermatol Res, jul. 2003. 295(3): 117-123.
- 512 HONG, Y. S.; HAM, Y. A.; CHOI, J. H.; KIM, J. *Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax, and p53 in non small cell lung cancer cell lines*. Exp Mol Med, 30 set. 2000. 32(3): 127-134.
- 513 CHALLIER, B.; PERARNAU, J. M.; VIEL, J. F. *Garlic, onion and cereal fibre as protective factors for breast cancer: A French case-control study*. Eur J Epidemiol, dez. 1998. 14(8): 737-747.
- 514 STEINMETZ, K. A.; KUSHI, L. H.; BOSTICK, R. M.; FOLSOM, A. R.; POTTER, J. D. *Vegetables, fruit, and colon cancer in the Iowa Women's Health Study*. Am J Epidemiol, 1^a jan. 1994. 39(1): 1-15.
- 515 HSING, A. W. et al. *Allium vegetables and risk of prostate cancer: A population-based study*. J Nat Cancer Inst, 2002. 94(21): 1.648-1.651.
- 516 SHENOY, N. R.; CHOUGHULEY, A. S. *Inhibitory effect of diet related sulphydryl compounds on the formation of carcinogenic nitrosamines*. Cancer Lett, 1992. 65(3): 227-232.
- 517 L'VOVA, G. N.; ZASUKHINA, G. D. *Modification of repair DNA synthesis in mutagen-treated human fibroblasts during adaptive response and the antimutagenic effect of garlic extract*. Genetika 2002. 38(3): 306-309.
- 518 KNOWLES, L. M.; MILNER, A. *Possible Mechanism by Which Allyl Sulfides Suppress Neoplastic Cell Proliferation*. J Nutr, mar. 2001. 131(3s): 1.061S-1.066S.
- 519 HIGDON, J. V.; DELAGE, B.; WILLIAMS, D. E.; DASHWOOD, R. H. *Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis*. Pharmacol Res, mar. 2007. 55(3): 224-236.
- 520 HERR, I.; BÜCHLER, M. W. *Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer*. Cancer Treat Rev, ago. 2010. 36(5): 377-383.
- 521 SINGH, S. V. et al. *Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species*. J Biol Chem, 20 mai. 2005. 280(20): 19.911-19.924.
- 522 DAVIS, R.; SINGH, K. P.; KURZROCK, R.; SHANKAR, S. *Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors*. Oncol Rep, dez. 2009. 22(6): 1.473-1.478.
- 523 SINGH, S. V. et al. *Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells*. Cancer Res, 1^a mar. 2009. 69(5): 2.117-2.125.

- 524 MICHNOVICZ, J. J.; BRADLOW, H. L. *Induction of estradiol metabolism by dietary indole-3-carbinol in humans*. J Natl Cancer Inst, 6 jun. 1990. 82(11): 947-949.
- 525 CORNBLATT, B. S. et al. *Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast*. Carcinogenesis, jul. 2007. 28(7): 1.485-1.490.
- 526 STEINKELLNER, H. et al. *Effects of cruciferous vegetables and their constituents on drug metabolizing enzymes involved in the bioactivation of DNA-reactive dietary carcinogens*. Mutat Res, 1º set. 2001. 480-481: 285-297.
- 527 LAMPE, J. W.; PETERSON, S. *Brassica, biotransformation and cancer risk: genetic polymorphisms alter the preventive effects of cruciferous vegetables*. J Nutr, out. 2002. 132(10): 2.991-2.994.
- 528 KALPANA DEEPA PRIYA, D.; GAYATHRI, R.; SAKTHISEKARAN, D. *Role of sulforaphane in the anti-initiating mechanism of lung carcinogenesis in vivo by modulating the metabolic activation and detoxification of benzo(a)pyrene*. Biomed Pharmacother, fev. 2011. 65(1): 9-16.
- 529 FAN, S.; MENG, Q.; AUBORN, K.; CARTER, T.; ROSEN, E. M. *BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells*. Br J Cancer, 2006. 94: 407-426.
- 530 BOSETTI, C. et al. *Cruciferous vegetables and cancer risk in a network of case-control studies*. Ann Oncol, ago. 2012. 23(8): 2.198-2.203.
- 531 BROCK, K. E. et al. *Fruit, vegetables, fibre and micronutrients and risk of US renal cell carcinoma*. Br J Nutr, 28 set. 2012. 108(6): 1.077-1.085.
- 532 LIU, B.; MAO, Q.; LIN, Y.; ZHOU, F.; XIE, L. *The association of cruciferous vegetables intake and risk of bladder cancer: a meta-analysis*. World J Urol, fev. 2013. 31(1): 127-133.
- 533 IZUTANI, Y.; YOGOSAWA, S.; SOWA, Y.; SAKAI, T. *Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells*. Int J Oncol, mar. 2012. 40(3): 816-824.
- 534 BRYANT, C. et al. *Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells*. Mol Cancer, 2 mar. 2010. 9: 47.
- 535 KRISTAL, A. R.; LAMPE, J. W. *Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence*. Nutr Cancer, 2002. 42: 1-9.
- 536 NECHUTA, S. J. et al. *“Cruciferous vegetable intake after diagnosis of breast cancer and survival: a report from the shanghai breast cancer survival study. Abstract #LB-322.”* In: *Annual Meeting of the American Association for Cancer Research*, 31 mar-4 abr. 2012. Chicago, Il.
- 537 HIGDON, J. V.; DELAGE, B.; WILLIAMS, D. E.; DASHWOOD, R. H. *Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis*. Pharmacol Res, mar. 2007. 55(3): 224-236.
- 538 CORNBLATT, B. S. et al. *Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast*. Carcinogenesis, jul. 2007. 28(7): 1.485-1.490.
- 539 KIRSH, V. A. et al. *Prospective study of fruit and vegetable intake and risk of prostate cancer*. J Natl Cancer Inst, 2007. 99(15): 1.200-1.209.
- 540 ZHANG, C. X.; HO, S. C.; CHEN, Y. M.; FU, J. H.; CHENG, S. Z.; LIN, F. Y. *Greater vegetable and fruit intake is associated with a lower risk of breast cancer among Chinese women*. Int J Canc, 1º jul. 2009. 125(1): 181.
- 541 BOSETTI, C. et al. *Cruciferous vegetables and cancer risk in a network of case-control studies*. Ann Oncol, ago. 2012. 23(8): 2.198-2.203.

- 542 LATTE, K. P.; APPEL, K. E.; LAMPEN, A. *Health benefits and possible risks of broccoli – an overview*. Food Chem Toxicol, dez. 2011. 49(12): 3.287-3.309.
- 543 SKROVÁNKOVÁ, S. *Seaweed vitamins as nutraceuticals*. Adv Food Nutr Res, 2011. 64: 357-369.
- 544 MIŠURCOVÁ, L.; AMBROŽOVÁ, J.; SAMEK, D. *Seaweed lipids as nutraceuticals*. Adv Food Nutr Res, 2011. 64: 339-355.
- 545 YUAN, Y. V.; WALSH, N. A. *Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds*. Food Chem Toxicol, jul. 2006. 44(7): 1.144-1.150.
- 546 ROZEMA, J. et al. *The role of UV-B radiation in aquatic and terrestrial ecosystems an experimental and functional analysis of the evolution of UV-absorbing compounds*. J Photo Chem Photobiol B, 2002. 66(1): 2-12.
- 547 MHADHEBI, L.; LAROCHE-CLARY, A.; ROBERT, J.; BOURAOUI, A. *Antioxidant, anti-inflammatory, and antiproliferative activities of organic fractions from the Mediterranean brown seaweed Cystoseirasedoides*. Can J Physiol Pharmacol, 24 nov. 2011.
- 548 LAN-HONG ZHENG. et al. *Antitumor peptides from marine organisms*. Mar Drugs, 2011. 9(10): 1.840-1.859.
- 549 YAMASAKI-MIYAMOTO, Y.; YAMASAKI M.; TACHIBANA, H.; YAMADA, K. *Fucoidan induces apoptosis through activation of caspase-8 on human breast cancer MCF-7 cells*. J Agric Food Chem, 23 set. 2009. 57(18): 8.677-8.682.
- 550 TEAS, J. et al. *Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women*. J Nutr, mai. 2009. 139(5): 939-944.
- 551 AquaMUNE, a brown seaweed extract, improves metabolism, immune response, energy and chelates heavy metals. Posit Health News, primavera de 1998. (16): 18.
- 552 ZHANG, Z.; TERUYA, K.; ETO, H.; SHIRAHATA, S. *Fucoidan extract induces apoptosis in MCF-7 cells via a mechanism involving the ROS-dependent JNK activation and mitochondria-mediated pathways*. PLoS One, 2011. 6(11): e27441.
- 553 FUKAHORI, S. et al. *Fucoidan, a major component of brown seaweed, prohibits the growth of human cancer cell lines in vitro*. Mol Med Report, jul-ago 2008. 1(4): 537-542.
- 554 ROCHA, F. D. et al. *Potential cytotoxic activity of some Brazilian seaweeds on human melanoma cells*. Phytother Res, fev. 2007. 21(2): 170-175.
- 555 ERMAKOVA, S. et al. *Fucoidans from brown seaweeds Sargassumhornery, Eclonia cava, Costariacostata: structural characteristics and anticancer activity*. Appl Biochem Biotechnol, jul. 2011. 164(6): 841-850.
- 556 YAMASAKI-MIYAMOTO, Y.; YAMASAKI, M.; TACHIBANA, H.; YAMADA, K. *Fucoi-dan induces apoptosis through activation of caspase-8 on human breast cancer MCF-7 cells*. J Agric Food Chem, 23 set. 2009. 57(18): 8.677-8.682.
- 557 HANEJI, K. et al. *Fucoidan extracted from CladosiphonokamuranusTokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells*. Nutr Cancer, 2005. 52(2): 189-201.
- 558 ITOH, H.; NODA, H.; AMANO, H.; ITO, H. *Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassumthunbergii*. Anti-cancer Res, set-out. 1995. 15(5B): 1937-1947.
- 559 PENG, J.; YUAN, J. P.; WU, C. F.; WANG, J. H. *Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health*. Mar Drugs, 2011. 9(10): 1.806-1.828.

- 560 VETVICKA, V. *Beta Glucan-immunostimulant, adjuvant, potential drug*. World J Clin Oncol, 10 fev. 2011. 2(2): 115-119.
- 561 VETVICKA, V. et al. *Orally administered marine (1-3)-beta-D-glucanPhycarine stimulates both humoral and cellular immunity*. Int J Biol Macromol, 10 mar. 2007. 40(4): 291-298.
- 562 FURUSAWA, E.; FURUSAWA, S. *Anticancer potential of Viva-Natural, a dietary seaweed extract, on Lewis lung carcinoma in comparison with chemical immunomodulators and on cyclosporine-accelerated AKR leukemia*. Oncology, 1989. 46(5): 343-348.
- 563 CUMASHI, A. *A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds*. Glycobiology, mai. 2007. 17(5): 541-552.
- 564 TOKUDOME, S.; KURIKI, K.; MOORE, M. A. *Seaweed and cancer prevention*. Jpn J Cancer Res, Set. 2001. 92(9): 1.008-1.009.
- 565 YANG, Y. J.; NAM, S. J.; KONG, G.; KIM, M.; K. *A case-control study on seaweed consumption and the risk of breast cancer*. Br J Nutr, mai. 2010. 103(9): 1.345-1.353.
- 566 HIGASHI-OKAI, K.; OTANI, S.; OKAI, Y. *Potent suppressive effect of a Japanese edible seaweed, Enteromorpha prolifera (Sujiao-nori) on initiation and promotion phases of chemically induced mouse skin tumorigenesis*. Cancer Lett, 1^a jun. 1999. 140 (1-2): 21-25.
- 567 FURUSAWA, E.; FURUSAWA, S. *Antitumor potential of low-dose chemotherapy manifested in combination with immunotherapy of Viva-Natural, a dietary seaweed-extract, on Lewis lung carcinoma*. Cancer Lett, 9 abr. 1990. 50(1): 71-78.
- 568 FUNAHASHI, H. et al. *Wakame seaweed suppresses the proliferation of 7,12dimethylbenz(a)-anthracene-induced mammary tumors in rats*. Jpn J Cancer Res, set. 1999. 90(9): 922-927.
- 569 NAKAMURA, Y.; NARUKAWA, T.; YOSHINAGA, J. *Cancer risk to Japanese population from the consumption of inorganic arsenic in cooked hijiki*. J Agric Food Chem, 9 abr. 2008. 56(7): 2.536-2.540.
- 570 ROSE, M. et al. *Arsenic in seaweed-forms, concentration and dietary exposure*. Food Chem Toxicol, jul. 2007. 45(7): 1.263-1.267.
- 571 *Japan to raise Fukushima crisis level to worst*, NHK World, 12 abr. 2011. 05:47 +0900 (JST).
- 572 BUSBY, C. *The health outcome of the Fukushima catastrophe. Initial analysis from risk model of the European Committee on Radiation Risk, ECRR*. Reino Unido: Green Audit Aberystwyth, 30 mar. 2011.
- 573 YABLOKOV, I.; SCHMITZ, F.; SCOTT CATO, M. *ECRR 2010. The 2010 recommendations of the European Committee on Radiation Risk*. BUSBY, C.; BERTELL, R; BRUSSELS, A. (eds.). Disponível em www.euradcom.org
- 574 TONDEL, M. et al. *Increased incidence of malignancies in Sweden after the Chernobyl accident*. Am J Industr Medic, 2006. 49(3): 159-168.
- 575 COSTA, R.; CUNHA, V.; CARVALHO, R. *The immunomodulator role of D-glucans as coadjuvant for cancer therapy*. Rev Bras Nutr Clin, 2006. 21(2): 163-166.
- 576 HARA, M.; HANAOKA, M.; KOBAYASHI, M. *Cruciferous vegetables, mushrooms and gastrointestinal cancer risk in a multicenter, hospital based case control study in Japan*. Nutr Cancer, 2003. 46 (2): 138-1347.
- 577 CHAN, G. C.; CHAN, W. K.; SZE, D. M. *The effects of beta-glucan on human immune and cancer cells*. Hematol Oncol, 10 jun. 2009. 2: 25.
- 578 LIN, Y. L.; LIANG, Y. C.; LEE, S. S.; CHIANG, B. L. *Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic*

- cells by the NF-kappa β and p38 mitogen-activated protein kinase pathways. *J Leukoc Biol*, 2005. 78: 533-543.
- 579 VOLMAN, J. J. et al. *Effects of mushroom-derived beta-glucan-rich polysaccharide extracts on nitric oxide production by bone marrow-derived macrophages and nuclear factor-kappa β transactivation in Caco-2 reporter cells: can effects be explained by structure?* *Mol Nutr Food Res*, fev. 2010. 54(2): 268-276.
- 580 CUTLER, R. R. *The immune system and some natural agents that may help it fight disease.* *British J ClinPhytomed*, 2003. 2: 6.
- 581 DEMIR, G.; KLEIN, H. O.; MANDEL-MOLINAS, N.; TUZUNER, N. *Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer.* *Int Immuno Pharmacol*, 2007. 7: 113-116.
- 582 WERNER, G. H.; JOLLES, P. *Immunostimulating agents: what next?* *Eur J Biochem*, 15 nov. 1996. 242(1): 1-19.
- 583 ELIZA, W. L.; FAI, C. K.; CHUNG, L. P. *Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis.* *Recent Pat Inflamm Allergy Drug Discov*, jan. 2012. 6(1): 78-87.
- 584 AHN, W. S. et al. *Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy.* *Int J Gynecol Cancer*, jul-ago. 2004. 14(4): 589-594.
- 585 WONG, C. K. et al. *Immunomodulatory effects of yunzhi and danshen capsules in health subjects-a randomized, double-blind, placebo-controlled, crossover study.* *Int Immuno Pharmacol*, fev. 2004. 4(2): 201-211.
- 586 PETROVA, R. D. *New scientific approaches to cancer treatment: can medicinal mushrooms defeat the curse of the century?* *Int J Med Mushrooms*, 2012. 14(1): 1-20.
- 587 ZHANG, M.; HUANG, J.; XIE, X.; HOLMAN, C. D. *Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women.* *Int J Cancer*, 15 mar. 2009. 124(6): 1.404-1.408.
- 588 NANBA, H. *El hongo Maitake, potente anticancerígeno y adaptógeno.* *Natura Medicatrix*, 1996. 43: 1-4.
- 589 KODAMA, N.; KOMUTA, K.; SAKAI, N.; NANBA, H. *Effects of D-fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells.* *Biol Pharm Bull*, 2002. 25: 1.647-1.650.
- 590 KODAMA, N.; KOMUTA, K.; NANBA, H. *Can Maitake MD-Fraction aid cancer patients?* *Altern Med Rev*, jun. 2002. 7(3): 236-269.
- 591 MARTIN, K. R.; BROPHY, S. K. *Commonly consumed and specialty dietary mushrooms reduce cellular proliferation in MCF-7 human breast cancer cells.* *Exp. Biol. Med.* (Maywoo), nov. 2010. 235(11): 1.306-1.314.
- 592 KODAMA, N.; MIZUNO, S.; NANBA, H.; SAITO, N. *Potential antitumor activity of a lowmolecular-weight protein fraction from Grifola frondosa through enhancement of cytokine production.* *J Med Food*, fev. 2010. 13(1): 20-30.
- 593 ISRAILIDES, C. et al. *In vitro cytostatic and immunomodulatory properties of the medicinal mushroom Lentinula edodes.* *Phytomedicine*, jun. 2008. 15(6-7): 512-519.
- 594 INOUE, M. et al. *Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled study.* *Biotherapy*, 1993. 6(1): 13-18.

- 595 FUJIMIYA, Y. et al. *Selective tumoricidal effect of soluble proteoglycan extracted from the basidiomycete, Agaricusblazei* Murill, mediated via natural killer cell activation and apoptosis. *Cancer Immunol Immunother*, mai. 1998. 46(3): 147-159.
- 596 SORIMACHI, K.; AKIMOTO, K.; INAFUKU, K.; OKUBO, A.; YAMAZAKI, S. *Secretion of TNF[gamma], IL-8 and nitric oxide by macrophages activated with Agaricusblazei* Muril fractions in vitro. *Cell Struct Funct*, 2001. 26: 103-108.
- 597 KOBAYASHI, H. et al. *Suppressing effects of daily oral supplementation of betaglucan extracted from Agaricusblazei* Murill on spontaneous and peritoneal disseminated metastasis in mouse model. *J Cancer Res Clin Oncol*, ago. 2005. 131(8): 527-538.
- 598 SUZUKI, T. et al. *Clinical trial with himematsutakelwade strain 101 powder with patients with malignant tumors (Study on long term administration and side effects)*. Solicitação ao Food and Drug Administration (FDA). EUA, 2000.
- 599 SILVA, D. *Ganoderma lucidum (Reishi) in cancer treatment*. *Integr Cancer Ther*, dez. 2003. 2(4): 358-364.
- 600 CHAN, W. et al. *Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy*. *J Altern Complement Med*, dez. 2005. 11(6): 1.047-1.057.
- 601 ZHAO, S.; YE, G.; FU, G.; CHENG, J. X.; YANG, B. B.; PENG, C. *Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin*. *Int J Oncol*, mai. 2011. 38(5): 1.319-1.327.
- 602 WENG, C. J.; YEN, G. C. *The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis*. *Clin Exp Metastasis*, mai. 2010. 27(5): 361-369.
- 603 KONNO, S. *Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy*. *Int J Med Gen*, 30 jul. 2009. 2: 91-108.
- 604 KARPPI, J. et al. *Serum lycopene and the risk of cancer: The Kuopio ischaemic Heart Disease Risk Factor (KIHD) study*. *Ann Epidemiol*, jul. 2009. 19(7): 512-518.
- 605 SMERÁK, P.; DEMPVÁ, H.; HOUSKA, M. *Antimutagenic effects of lycopene and tomato pureé*. *J Med Food*, dez. 2010. 13 (6): 1.443-1.450.
- 606 PALOZZA, P. et al. *Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines*. *Carcinogenesis*, out. 2010. 31(10): 1.813-1.821.
- 607 FORD, N. A. et al. *Lycopene and apo-12i-lycopenal reduce cell proliferation and alter cell cycle progression in human prostate cancer cell*. *Nutr Cancer*, 2011. 63(2): 256-263.
- 608 LIN, M. C.; WANG, F. Y.; KUO, Y. H.; TANG, F. Y. *Cancer chemopreventive effects of lycopene: Suppression of MMP-/Expression and cell invasion in human colon cancer cells*. *J Agric Food Chem*, 26 out. 2011. 59(20): 11.304-11.318.
- 609 YANG, C. M.; LU, I. H.; CHEN, H. Y.; HU, M. L. *Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARγ/XRγ/ABCA1 pathway*. *J Nutr Biochem*, jan. 2012. 23(1): 8-17.
- 610 GUIL-GUERRERO, J. L.; RAMOS, R.; RODRIGUEZ, I.; LÓPEZ-SÁNCHEZ, C. *Cytotoxicity screening of several tomato extracts*. *J Med Food*, jan-fev. 2011. 14(1-2): 40-45.
- 611 GIOVANNUCCI, E. *Commentary: Serum Lycopene and prostate cancer progression: a reconsideration of finding from the prostate cancer prevention trial*. *Cancer Causes Control*, jul. 2011. 22(7): 1.055-1.059.
- 612 BOWEN, P. et al. *Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis*. *Exp Biol Med (Maywood)*, nov. 2002. 227(10): 886-893.

- 613 LU, R. et al. *Lycopene: features and potential significance in the oral cancer and precancerous lesions*. J Oral Pathol Med, mai. 2011. 40(5): 361-368.
- 614 GIOVANNUCCI, E. et al. *A prospective study of tomato products, lycopene, and prostate cancer risk*. J Natl Cancer Inst, 6 mar. 2002. 94(5): 391-398.
- 615 BEILBY, J.; AMBROSINI, G. L.; ROSSI, E.; DE KLERK, N. H.; MUSK, A. W. *Serum levels of folate, lycopene, B-carotene, retinol and vitamin E and prostate cancer risk*. Eur J Clin Nutr, out. 2010. 64(10): 1.235-1.238.
- 616 RAO, A.; WASEEM, Z.; AGARWAL, S. *Lycopene content of tomatoes and tomato products and their contribution to dietary lycopene*. Food Research Int, dez. 1998. 31(10): 737-741.
- 617 FIELDING, J.; KEVIN, R.; COOPER, P. *Increases in plasma lycopene concentration after consumption of tomatoes cooked with olive oil*. Asia Pac J Clin Nutr, 2005. 14(2): 131-136.
- 618 SHI, J.; et al. *Effect of heating and exposure to light on the stability of lycopene in tomato purée*. Food Control, mai. 2008. 19: 514-520.
- 619 RÍOS, J. L. et al. *Cucurbitacins as inducers of cell death and a rich source of potential anti-cancer compounds*. Curr Pharm Des, 2012. 18(12): 1.663-1.676.
- 620 LEE, D. H.; IWANSKI, G. B.; THOENNISSSEN, H. *Cucurbitacin: ancient compound shedding new light on cancer treatment*. Scientific World J, 5 mar. 2010. 10: 413-418.
- 621 BORNEO, R.; LEÓN, A. E. *Whole grain cereals: functional components and health benefits*. Food Funct, 3 fev. 2012. 3(2): 110-119.
- 622 BEATINI, M.; DAVINI, M. D.; FAZIO, A. *The relation between fecal pH and cancer of the colon*. Minerva Chir, 15 out. 1988. 43(19): 1.571-1.573.
- 623 GIBSON, G. R.; BEATTY, E. R.; WANG, X.; CUMMINGS, J. H. *Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin*. Gastroenterology, abr. 1995. 108(4): 975-982.
- 624 FUCHS, C. S. et al. *Dietary fiber and the risk of colorectal cancer and adenoma in women*. N Engl J Med, 21 jan. 1999. 340(3): 169-176.
- 625 SCHOEN, R. E. et al. *Increased blood glucose and insulin, body size and incident colorectal cancer*. J Natl Cancer Inst, 7 jul. 1999. 91(13): 1.147-1.154.
- 626 HU, F. B. et al. *Prospective study of adult onset. diabetes mellitus (type 2) and risk of colorectal cancer in women*. J Natl Cancer Inst, 17 mar. 1999. 91(6): 542-547.
- 627 STOLL, B. A. *Western nutrition and the insulin resistance syndrome: a link to breast cancer*. Eur J Clin Nutr, 1999. 53: 83-87.
- 628 JACOBS JR, D. R.; MARQUART, L.; SLAVIN, J.; KUSHI, L. H. *Whole-grain intake and cancer: an expanded review and meta-analysis*. Nutr Cancer, 1998. 30(2): 85-96.
- 629 CHATENOU, L. et al. *Whole grain food intake and cancer risk*. Int J Cancer, 3 jul. 1998. 77(1): 24-28.
- 630 SPANOU, C. et al. *Flavonoid glycosides isolated from unique legume plant extracts as novel inhibitors of xanthine oxidase*. PLoS One, 2012. 7(3): e32214.
- 631 SHI, J. et al. *Saponins from edible legumes: chemistry, processing, and health benefits*. J Med Food, primavera de 2004. 7(1): 67-78.
- 632 XU, B.; CHANG, S. *Comparative study on antiproliferation properties and cellular antioxidant activities of commonly consumed food legumes against nine human cancer cells*. Food Chemistry, 1ª out. 2012. 34 (3): 1.287-1.296.
- 633 XU, B.; CHANG, S. *Effect of soaking, boiling, and steaming on total phenolic content and antioxidant activities of cool season food legumes*. Food Chemistry, 1ª set. 2008. 110(1): 1-13.

- 634 AUNE, D. et al. *Legume intake and the risk of cancer: a multisite case-control study in Uruguay*. Cancer Causes Control, nov. 2009. 20(9): 1.605-1.615.
- 635 INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC). www.iarc.fr
- 636 ZIEGLER, R. G. et al. *Migration patterns and breast cancer risk in Asian-American*. J Natl Cancer Inst, nov. 1993. 17; 85(22): 1.819-1.827.
- 637 LINOS, E. et al. *Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis*. J Natl Cancer Inst, 1º out. 2008. 100(19): 1.352-1.360.
- 638 MENSE, S. M.; HEI, T. K.; GANJU, R. K.; BHAT, H. K. *Phytoestrogens and breast cancer prevention: possible mechanisms of action*. Environ Healt Perspect, abr. 2008. 116(4): 426-433.
- 639 WARD, H. et al. *Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study*. Breast Cancer Res, 2008. 10(2): R32.
- 640 KIM, Y. M.; YANG, S.; XU, W.; LIS, S.; YANG, X. *Continuous in vitro exposure to low-dose genistein induces genomic instability in breast epithelial cells*. Cancer Genet Cytogenet, 15 out. 2008. 186(2): 78-84.
- 641 TOMAR, R. S.; SHIAO, R. *Early life and adult exposure to isoflavones and breast cancer risk*. J Environ Sci Healt C Environ Carcinog Ecotoxicol Rev, abr-jun. 2008. 26(2): 113-173.
- 642 IWASAKI, M. et al. *Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group*. J Clin Oncol, 1º abr. 2008. 26(10): 1.677-1.683.
- 643 HILAKIVI-CLARKE, L.; ANDRADE, J. E.; HELFERICH, W. *Is soy consumption good or bad for the breast?* J Nutr, dez. 2010. 140(12): 2.326S-2.334S.
- 644 MESSINA, M. J.; LOPRINZI, C. L. *Soy for breast cancer survivors: a critical review of the literature*. J Nutr, nov. 2001. 131(11 Supl): 3.095S-3.108S.
- 645 SHU, X. O. et al. *Soy food intake and breast cancer survival*. JAMA, 9 dez. 2009. 302(22): 2.437-2.443.
- 646 AMERICAN CANCER SOCIETY. *Soy may counteract tamoxifen used by breast cancer patients*. 20 jun. 2007.
- 647 BAR-EL, D. S.; REIFEN, R. *Soy as an endocrine disruptor: cause for caution?* J Pediatr Endocrinol Metab, set. 2010. 23(9): 855-861.
- 648 NAROD, S. A. *Hormone replacement therapy and the risk of breast cancer*. Nat Rev Clin Oncol, 2 ago. 2011. 8(11): 669-676.
- 649 BERAL, V. *Million Women Study collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study*. Lancet, 9 ago. 2003. 362(9.382): 419-427.
- 650 GLASS, A. G.; LACEY JR, J. V.; CARREON, J. D.; HOOVER, R. N. *Breast cancer incidence. 1980-2006: combined roles of menopausal hormone therapy. Screening mammography. And estrogen receptor status*. J Natl Cancer Inst, 1º ago. 2007. 99(15): 1.152-1.161.
- 651 BULL, D. et al. *Ovarian cancer and hormone replacement therapy in the Million Women Study*. Lancet, 19 mai. 2007. 369(9.574): 1.703-1.710.
- 652 ZBUK, K.; ANAND, S. S. *Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries*. J Epidemiol Community Health, jan. 2012. 66(1): 1-7.
- 653 SILVERMAN, B. G.; SIEGELMANN-DANIELI, N.; BRAUNSTEIN, R.; KOKIA, E. S. *Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy*. Cancer Epidemiol, fev. 2011. 35(1): 11-16.

- 654 ANDRES, S.; ABRAHAM, K.; APPEL, K. E.; LAMPEN A. *Risk and benefits of dietary isoflavones for cancer*. Crit Rev Toxicol, jul. 2011. 41(6): 463-506.
- 655 RABIAU, N. et al. *miRNAs differentially expressed in prostate cancer cell lines after soy treatment*. In Vivo, nov-dez. 2011. 25(6): 917-921.
- 656 SZLISZKA, E.; CZUBA, Z. P.; MERTAS, A.; PARADYSZ, A.; KROL, W. *The dietary isoflavone biochanin – A sensitizes prostate cancer cells to TRAIL-induced apoptosis*. Urol On-col, abr. 2013. 31(3): 331-342.
- 657 HILLMAN, G. C.; SINGH-GUPTA, V. *Soy isoflavones sensitize cancer cells to radiotherapy*. Free Radic Biol Med, 15 jul. 2011. 51(2): 289-298.
- 658 SHARMA, P. et al. *Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation Therapy*. J Urol, nov. 2009. 182(5): 2.265-2.272.
- 659 IDE, H. et al. *Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen*. Prostate, 1^a jul. 2010. 70(10): 1.127-1.133.
- 660 GRAINGER, E. M. et al. *A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen*. Nutr Cancer, 2008. 60(2): 145-154.
- 661 AKHTER, M. et al. *Dietary soy and isoflavone intake and risk of colorectal cancer in the Japan public health center-based prospective study*. Cancer Epidemiol Biomarkers Prev, ago. 2008. 17(8): 2.128-2.135.
- 662 BANDERA, E. V. et al. *Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study*. BMC Womens Health, 23 set. 2011. 11: 40.
- 663 YANG, W. S. et al. *Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies*. Am J Clin Nutr, dez. 2011. 94(6): 1.575-1.583.
- 664 HILLMAN, G. G. et al. *Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury*. Radiother Oncol, nov. 2011. 101(2): 329-336.
- 665 ANDRES, S.; ABRAHAM, K.; APPEL, K. E.; LAMPEN, A. *Risks and benefits of dietary isoflavones for cancer*. Crit Rev Toxicol, jul. 2011. 41(6): 463-506.
- 666 KITTS, D. D.; YUAN, Y. V.; WIJEWICKREME, A. N.; THOMPSON, L. U. *Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone*. Mol Cell Biochem, dez. 1999. 202(1-2): 91-100.
- 667 KANGAS, L. et al. *Antioxidant and antitumor effects of hydroxymatairesinol (HM3000, HMR), a lignan isolated from the knots of spruce*. Eur J Cancer Prev, 2002. 11: S48-57.
- 668 DEMARK-WAHNEFRIED, W. et al. *Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery*. Cancer Epidemiol Biomarkers Prev, dez. 2008. 17(12): 3.577-3.587.
- 669 DEMARK-WAHNEFRIED, W. et al. *Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features*. Urology, Jul. 2001. 58(1): 47-52.
- 670 CLEMONS, M.; GOSS, P. E. *Mechanisms of disease: estrogen and the risk of breast cancer*. N Engl J Med, 25 jan. 2001. 344(4): 276-285.
- 671 LINSEISEN, J.; PILLER, R.; HERMANN, A.; CHANG-CLAUDE, J. *Dietary phytoestrogen intake and premenopausal breast cancer risk in a german case-control study*. Int J Cancer, 10 jun. 2004. 110(2): 284-290.
- 672 THOMPSON, L. U.; CHEN, J. M.; LI, T.; STRASSER-WEIPPL, K.; GOSS, P. E. *Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer*. Clin Cancer Res, 15 mai. 2005. 11(10): 3.828-3.835.

- 673 ULRICA, W. et al. *Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo*. PLoS One, 2011. 6(9): e25720.
- 674 CHEN, J.; THOMPSON, L. U. *Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro*. Breast Cancer Res Treat, jul. 2003. 80(2): 163-170.
- 675 FISHER, B. et al. *Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study*. J Natl Cancer Inst, 16 nov. 2005. 97(22): 1.652-1.662.
- 676 CHEN, J.; STAVRO, P. M.; THOMPSON, L. U. *Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor*. Nutr Cancer, 2002. 43(2): 187-192.
- 677 THOMPSON, L.; RICKARD, S.; ORCHESON, L.; SEIDL, M. M. *Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis*. Carcinogenesis, jun. 1996. 17(6): 1.373-1.376.
- 678 SERRAINO, M.; THOMPSON, L. U. *The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis*. Nutr Cancer, 1992. 17(2): 153-159.
- 679 ANSENBURGER, et al. *Decreased severity of ovarian cancer and increased survival in hens fed a flaxseed enriched diet for one year*. Gynecol Oncol, mai. 2010. 117(2): 341-347.
- 680 BUCK, K. et al. *Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer*. Br J Cancer, 11 out. 2011. 105 (8): 1.151-1.157.
- 681 BROUWER, I. A.; KATAN, M. B.; ZOCK, P. L. *Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: a meta-analysis*. J Nutr, abr. 2004. 134(4): 919-922.
- 682 SHAHIDI, F.; LIYANA-PATHIRANA, C. M.; WALL, D. S. *Antioxidant activity of white and black sesame seeds and their hull fractions*. Food Chemistry, 2006. 99(3): 478-483.
- 683 FUJIMOTO, A. et al. *Apoptosis-inducing action of two products from oxidation of sesamol, an antioxidative constituent of sesame oil: a possible cytotoxicity of oxidized antioxidant*. Toxicol In Vitro, set. 2010. 24(6): 1.720-1.726.
- 684 CHAO-CHIEN, C. et al. *A novel role of sesamol in inhibiting NF- κ B-mediated signaling in platelet activation*. J Biomed Sci, 14 dez. 2011. 18: 93.
- 685 SHARMA, S.; KAUR, I. P. *Development and evaluation of sesamol as an antiaging agent*. Int J Dermatol, mar. 2006. 45(3): 200-208.
- 686 JACKLIN, A. et al. *The sesame seed oil constituent, sesamol, induces growth arrest and apoptosis of cancer and cardiovascular cells*. Ann N Y Acad Sci, 2003. 1.010: 374-380.
- 687 PIANJING, P. et al. *Estrogenic activities of sesame lignans and their metabolites on human breast cancer cells*. J Agric Food Chem, 12 jan. 2011. 59(1): 212-221.
- 688 COULMAN, K. D. et al. *Whole sesame seed is as rich a source of mammalian lignan precursors as whole flaxseed*. Nutr Cancer, 2005. 52(2): 156-165.
- 689 WU, W. H. et al. *Sesame ingestion affects sex hormones, antioxidant status, and blood lipids in postmenopausal women*. J Nutr, mai. 2006. 136(5): 1.270-1.275.
- 690 LEE, C. C. et al. *Sesamin inhibits macrophage-induced vascular endothelial growth factor and matrix metalloproteinase-9 expression and proangiogenic activity in breast cancer cells*. Inflammation, jun. 2011. 34(3): 209-221.
- 691 HARIKUMAR, K. B. et al. *Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products*. Mol Cancer Res, mai. 2010. 8(5): 751-761.

- 692 CARVALHO, M. et al. *Human cancer cell antiproliferative and antioxidant activities of Juglans regia L.* Food Chem Toxicol, jan. 2010. 48(1): 441-447.
- 693 NAGEL, J. M. et al. *Dietary walnuts inhibit colorectal cancer growth in mice by suppressing angiogenesis.* Nutrition, jan. 2012. 28(1): 67-75.
- 694 HARDMAN, W. E.; ION, G. *Suppression of implanted MDA-MB 231 human breast cancer growth in nude mice by dietary walnut.* Nutr Cancer, 2008. 60(5): 666-674.
- 695 MILLS, P. K. et al. *Cohort study of diet, lifestyle, and prostate cancer in Adventist men.* Cancer, 1^a ago. 1989. 64(3): 598-604.
- 696 GONZÁLEZ, C. A.; SALAS-SALVADÓ, J. *The potential of nuts in the prevention of cancer.* Br J Nutr, nov. 2006. 96 Supl. 2: S87-94.
- 697 KUBO, I.; NITODA, T.; TOCOLI, F. E.; GREEN, I. R. *Multifunctional cytotoxic agents from Anacardium occidentale.* Phytother Res, jan. 2011. 5(1): 38-45.
- 698 OTTAGGIO, L. et al. *Taxanes from shells and leaves of corylus avellana.* J Nat Prod, jan. 2008. 71(1): 58-60.
- 699 SICILIA, T.; NIEMEYER, H. B.; HONIG, D. M.; METZLER, M. *Identification and stereochemical characterization of lignans in flaxseed and pumpkin seeds.* J Agric Food Chem, 26 fev. 2003. 51(5): 1.181-1.188.
- 700 XIA, H. C.; LI, F.; LI, Z.; ZHANG, Z. C. *Purification and characterization of Moschatin, a novel type I ribosome-inactivating protein from the mature seeds of pumpkin (Cucurbita moschata), and preparation of its immunotoxin against human melanoma cells.* Cell Res, out. 2003. 13 (5): 369-374.
- 701 OWEN, R. W. et al. *Olives and olive oil in cancer prevention.* Eur J Cancer Prev, ago. 2004. 13(4): 319-326.
- 702 MENENDEZ, J. A.; VELLON, L.; COLOMER, R; LUPU R. *Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin™) in breast cancer cells with Her-2/neu oncogene amplification.* Ann Oncol, mar. 2005. 16 (3): 359-371.
- 703 COLOMER, R.; MENÉNDEZ, J, A. *Mediterranean diet, olive oil and cancer.* Clin Transl Oncol, jan. 2006. 8(1): 15-21.
- 704 MENENDEZ, J. A. et al. *Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells.* Eur J Cancer, fev. 2001. 37(3): 402-413.
- 705 BASNET, P.; SKALKO-BASNET, N. *Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment.* Molecules, 3 jun. 2011. 16(6): 4.567-4.598.
- 706 HOSSAIN, D. S.; BHATTACHARYYA, S.; DAS, T.; SA, G. *Curcumin: The multi-targeted therapy for cancer regression.* Front Biosci (Schol Ed), 1^a jan. 2012. 4: 335-355.
- 707 GUPTA, S. C.; PATCHVA, S.; KOH, W.; AGGARWAL, B. B. *Discovery of curcumin, a component of the golden spice, and its miraculous biological activities.* Clin Exp Pharmacol Physiol, mar. 2012. 39(3): 283-299.
- 708 ZHANG, X. et al. *A novel mono-carbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production.* Mol Med Report, mar. 2012. 5(3): 739-744.
- 709 BAYET-ROBERT, M. et al. *Phase I dose escalation trial of docetaxel plus curcumin in patient with advanced and metastatic breast cancer.* Cancer Biol Ther, jan. 2010. 9(1): 8-14.
- 710 TZE FANG, W. et al. *Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition.* Gynecologic Oncology, jul. 2011. 122(1): 141-148.

- 711 LU, J. J.; CAI, Y. J.; DING, J. *Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cell*. Mol all Biochem, ago. 2011. 354(1-2): 247-252.
- 712 DARVESH, A. S.; AGGARWAL, B. B.; BISHAYEE, A. *Curcumin and liver cancer: A review*. Curr Pharm Biotechnol, jan. 2012. 13(1): 218-228.
- 713 PRAKOBWONG, S. et al. *Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cell through modulation of multiple cell signaling pathways*. Carcinogenesis, set. 2011. 32(9): 1.372-1.380.
- 714 CHEN, Q. Y. et al. *Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines*. Int J Oncol, mai. 2012. 40(5): 1.561-1.568.
- 715 BISTHT, S. et al. *Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer*. Mol Cancer Ther, ago. 2010. 9(8): 2.255-2.264.
- 716 ALI, S. et al. *Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells*. Cancer Lett, 28 jun. 2012. 319(2): 173-181.
- 717 TEITEN, M. H. et al. *Anti-proliferative potential of curcumin in androgen-dependent prostate cancer cells occurs through modulation of the Wingless signaling pathway*. Int J Oncol, mar. 2011. 38(3): 603-611.
- 718 PRAKOBWONG, S. et al. *Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cell through modulation of multiple cell signaling pathways*. Carcinogenesis, set. 2011. 32(9): 1.372-1.380.
- 719 YE, F.; ZHANG, G. H.; GUAN, B. X.; XU, X. C. *Suppression of esophageal cancer cell growth using curcumin, (–)-epigallocatechin-3-gallate and lovastatin*. World J Gastroenterol, 14 jan. 2012. 18(2): 126-135.
- 720 DIKMEN, M.; CANTURK, Z.; OZTURK, Y.; TUNALI, Y. *Investigation of the apoptotic effect of curcumin in human leukemia HL-60 cells by using flow cytometry*. Cancer Biother Radiopharm, dez. 2010. 25(6): 749-755.
- 721 WILKEN, R.; VEENA, M. S.; WANG, M. B.; SRIVATSAN, E. S. *Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma*. Mol Cancer, 7 fev. 2011. 10: 12.
- 722 MAZZARINO, L. et al. *Curcumin-loaded lipid and polymeric nanocapsules stabilized by nonionic surfactants: an in vitro and in vivo antitumor activity on B 16-F10 melanoma and macrophage uptake comparative study*. J. Biomed Nanotechnol, jun. 2011. 7(3): 406-414.
- 723 MA, D.; TREMBLAY, P.; MAHNGAR, K.; COLLINS, J.; HUDLICKY, T.; PANDEY, S. L. *Selective cytotoxicity against human osteosarcoma cells by a novel synthetic C-1 analogue of 7-deoxypancratistatin is potentiated by curcumin*. PLoS One, 2011. 6(12): e28780.
- 724 SHEHZAD, A.; WAHID, F.; LEE, Y. S. *Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials*. Arch Pharm (Weinheim), set. 2010. 343(9): 489-499.
- 725 GUPTA, S. C.; PATCHVA, S.; KOH, W.; AGGARWAL, B. B. *Discovery of curcumin, a component of the golden spice, and its miraculous biological activities*. Clin Exp Pharmacol Physiol, mar. 2012. 39(3): 283-299.
- 726 SCHAFFER, M.; SCHAFFER, P. M.; ZIDAN, J.; SELA, G. B. *Curcuma as a functional food in the control of cancer and inflammation*. Curry Opin Clin Nutr Metab Care, nov. 2011. 14(8): 588-597.

- 727 WATSON, J. L. et al. *Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling*. Mol Carcinog, jan. 2010. 49(1): 13-24.
- 728 KIM, S. R. et al. *Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion*. Endocrinology, fev. 2012. 153(2): 554-563.
- 729 MALEK, S. N. et al. *Phytochemical and cytotoxic investigations of curcuma mangga rhizomes*. Molecules, 31 mai. 2011. 16(6): 4.539-4.548.
- 730 QUIROGA, A. et al. *Anti-breast cancer activity of curcumin on the human oxidation resistant cells ZR-75-1 with gamma-glutamyltranspeptidase inhibition*. J Exp The Oncol, 2010. 8(3): 261-266.
- 731 GRIESSER, M. et al. *Autoxidative and cyclooxygenase-2 catalyzed transformation of the dietary chemopreventive agent curcumin*. J Biol Chem, 14 jan. 2011. 286(2): 1.114-1.124.
- 732 YUE, G. G. et al. *Evaluation of in vitro anti-proliferative and immunomodulatory activities of compounds isolated from Curcuma longa*. Food Chem Toxicol, ago-set. 2010. 48(8-9): 2.011-2.020.
- 733 OLIVERA, A. et al. *Inhibition of the NF- κ B signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): Anti-inflammatory and anti-cancer properties*. Int Immunopharmacol, fev. 2012. 12(2): 368-377.
- 734 TSAL, M. S. et al. *Synergistic effect of curcumin and cisplatin via down regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1)*. Mol Pharmacol, jul. 2011. 80(1): 136-146.
- 735 CHATTERJEE, S. J.; Pandey, S. *Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy*. Cancer Biol Ther, 15 jan. 2011. 11(2): 216-228.
- 736 GANTA, S.; DEVALAPALLY, H.; AMIJI, M. *Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation*. J Pharm Sci, nov. 2010. 99(11): 4.630-4.641.
- 737 GOEL, A.; AGGARWAL, B. B. *Curcumin. The golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs*. Nutr Cancer, 2010. 62(7): 919-930.
- 738 YALLAPU, M. M. et al. *Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth*. J Ovarian Res, 29 abr. 2010. 3: 11.
- 739 AGGARWAL, B. B.; SUNDARAM, C.; MALANI, N.; ICHIKAWA, H. *Curcumin: the Indian solid gold*. Adv Exp Med Biol, 2007. 595: 1-75.
- 740 BISTHT, S. et al. *Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer*. Mol Cancer Ther, ago. 2010. 9(8): 2.255-2.264.
- 741 YALLAPU, M. M.; JAGGI, M.; CHAUHAN, S. C. *Curcumin nanoformulations: a future nanomedicine for cancer*. Drug Discov Today, jan. 2012. 17(1-2): 71-80.
- 742 MANIKANDAN, R. et al. *Synergistic anticancer activity of curcumin and catechin: An in vitro study using human cancer cell lines*. Res Tech, fev. 2012. 75(2): 112-116.
- 743 SHANMUGAM, M. K.; KANNAIVAN, R.; SETHI, Q. *Targeting cell signaling and apoptotic pathways by dietary agent: role in the prevention and treatment of cancer*. Nutr Cancer, 2011. 63(2): 161-173.

- 744 YALLAPU, M. M.; GUPTA, B. K.; JAGGI, M.; CHAUHAN, S. C. *Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.* J Colloid Interface Sci, 1^o nov. 2010. 351(1): 19-29.
- 745 STRIMPAKOS, A. S.; SHARMA, R. A. *Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials.* Antioxid Redox Signal, mar. 2008. 10(3): 511-545.
- 746 BELCARO, G. et al. *Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients.* Altern Med Rev, dez. 2010. 15(4): 337-344.
- 747 GUIMARÃES, M. R. et al. *Potent anti-inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo.* J Periodontal Res, abr. 2011. 46(2): 269-279.
- 748 MIRIYALA, S.; PANCHATCHARAM, M.; RENGARAJULU, P. *Cardioprotective effects of curcumin.* Adv Exp Med Biol, 2007. 595: 359-377.
- 749 MYTHRI, R. B. et al. *Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease.* Mol Cell Biochem, jan. 2011. 347(1-2): 135-143.
- 750 BELKACEMI, A.; DOGGUI, S.; DAO, L.; RAMASSAMY, C. *Challenges associated with curcumin therapy in Alzheimer disease.* Expert Rev Mol Med, 4 nov. 2011. 13: e34.
- 751 RAJASEKARAN, S. A. *Therapeutic potential of curcumin in gastrointestinal diseases.* World J Gastrointest Pathophysiol, 15 fev. 2011. 2(1): 1-14.
- 752 SHOBA, G. et al. *Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.* Planta Med, mai. 1998. 64(4): 353-358.
- 753 SURESH, D.; SRINIVASAN, K. *Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats.* Indian J Med Res, mai. 2010. 131: 682-691.
- 754 ANGELO, L. S.; KURZROK, R. *Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia.* Clin Cancer Res, 15 fev. 2009. 15(4): 1.123-1.125.
- 755 YUNOS, N. M.; BEALE, P.; YU, J. Q.; HUQ, F. *Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.* Anticancer Res, abr. 2011. 31(4): 1.131-1.140.
- 756 FERLAY, J.; SHIN, H. R.; BRAY, F.; FORMAN, D.; MATHERS, C.; PARKIN, D. M. *Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.* Int J Cancer, 15 dez. 2010. 127(12): 2.893-2.917.
- 757 DWIVEDI, V. et al. *Cytotoxic potential of Indian spices (extracts) against esophageal squamous carcinoma cells.* Asian Pac J Cancer Prev, 2011. 12(8): 2.069-2.073.
- 758 SHUKLA, Y.; SINGH, M. *Cancer preventive properties of ginger: a brief review.* Food Chem Toxicol, mai. 2007. 45(5): 683-690.
- 759 RHODE, J. et al. *Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells.* BMC Complement Altern Med, 20 dez. 2007. 7: 44.
- 760 KARNA, P. et al. *Benefits of whole ginger extract in prostate cancer.* Br J Nutr, fev. 2012. 107(4): 473-484.
- 761 MANUSIRIVITHAYA, S. et al. *Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin.* Int J Gynecol Cancer, nov-dez. 2004. 14(6): 1.063-1.069.
- 762 SATIA-ABOUTA, J.; PATTERSON, R. E.; NEUHOUSER, M. L.; ELDER, J. *Dietary acculturation: applications to nutrition research and dietetics.* J Am Diet Assoc, 2002. 102(8): 1.105-1.118.

- 763 BUIATTI, E. et al. *A case-control study of gastric cancer and diet in Italy*. Int J Cancer, 1989. 44(4): 611-616.
- 764 AL-KALALDEH, J. Z.; ABU-DAHAB, R.; AFIFI, F. U. *Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells*. Nutr Res, abr. 2010. 30(4): 271-278.
- 765 RABI, T.; BISHAYEE, A. *Terpenoids and breast cancer chemoprevention*. Breast Cancer Res Treat, mai. 2009. 115(2): 223-239.
- 766 KOH, S. J. et al. *Sensitization of ionizing radiation-induced apoptosis by ursolic acid*. Free Radic Res, mar. 2012. 46(3): 339-345.
- 767 JOHNSON, J. J. *Carnosol: a promising anti-cancer and anti-inflammatory agent*. Cancer Lett, 1^o jun. 2011. 305(1): 1-7.
- 768 LÓPEZ-JIMÉNEZ, A.; GARCÍA-CABALLERO, M.; MEDINA, M. A.; QUESADA, A. R. *Anti-angiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary*. Eur J Nutr, fev. 2013. 52(1): 85-95.
- 769 HO, C. T. et al. *Chemistry and antioxidative factors in rosemary and sage*. Biofactors, 2000. 13(1-4): 161-166.
- 770 MOHEBATI, A. et al. *Carnosol, a constituent of zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis*. Cancer Prev Res (Phila), abr. 2012. 5(4): 593-602.
- 771 TAI, J.; CHEUNG, S.; WU, M.; HASMAN, D. *Antiproliferation effect of Rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro*. Phytomedicine, 15 mar. 2012. 19(5): 436-443.
- 772 YESIL-CELIK TAS, O.; SEVIMLI, C.; BEDIR, E.; VARDAR-SUKAN, F. *Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines*. Plant Foods Hum Nutr, jun. 2010. 65(2): 158-163.
- 773 LIN, Y.; SHI, R.; WANG, X.; SHEN, H. M. *Luteolin, a flavonoid with potential for cancer prevention and therapy*. Curr Cancer Drug Targets, nov. 2008. 8(7): 634-646.
- 774 CHIANG, L. C. et al. *Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells*. Cancer Lett, 18 jun. 2006. 237(2): 207-214.
- 775 REN, H. Y.; TANG, X. W. *Anti-proliferation and chemo-sensitization effects of apigenin on human lung cancer cells*. Zhejiang Da Xue Xue Bao Yi Xue Ban, set. 2011. 40(5): 508-514.
- 776 CHOI, E. J.; KIM, G. H. *Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells*. J Nutr Biochem, abr. 2009. 20(4): 285-290.
- 777 ZHONG, Y. et al. *Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53*. Eur J Cancer, dez. 2010. 46(18): 3.365-3.374.
- 778 RUELA-DE-SOUSA, R. R.; FUHLER, G. M.; BLOM, N.; FERREIRA, C. V.; AOYAMA, H.; PEPPELENBOSCH, M. P. *Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy*. Cell Death Dis, 2010. 1: e19.
- 779 SHUKLA, S.; GUPTA, S. *Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation*. Free Radic Biol Med, 15 mai. 2008. 44(10): 1.833-1.845.
- 780 LAMY, S. et al. *The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-beta phosphorylation*. Cancer Prev Res (Phila), nov. 2008. 1(6): 452-459.

- 781 HOWELLS, L. M. et al. *Chemopreventive effects of Cuminum cyminum in chemically induced forestomach and uterine cervix tumors in murine model systems*. Nutr Cancer, 2003. 47(2): 171-180.
- 782 LU, H. F. et al. *Antitumor activity of capsaicin on human colon cancer cells in vitro and colo 205 tumor xenografts in vivo*. J Agric Food Chem, 22 dez. 2010. 58(24): 12.999-13.005.
- 783 BANERJEE, S.; PANDA, C. K.; DAS, S. *Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer*. Carcinogenesis, ago. 2006. 27(8): 1.645-1.654.
- 784 ACHARYA, A.; DAS, I.; SINGH, S.; SAHA, T. *Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis*. Recent Pat Food Nutr Agric, jun. 2010. 2(2): 166-177.
- 785 DOU, D.; AHMAD, A.; YANG, H.; SARKAR, F. H. *Tumor cell growth inhibition is correlated with levels of capsaicin present in hot peppers*. Nutr Cancer, 2011. 63(2): 272-281.
- 786 RAO, B. N. *Bioactive phytochemicals in Indian foods and their potential in health promotion and disease prevention*. Asia Pac J Clin Nutr, 2003. 12(1): 9-22.
- 787 RAO, A. R.; HASHIM, S. *Chemopreventive action of oriental food-seasoning spices mixture Garam masala on DMBA-induced transplacental and translactational carcinogenesis in mice*. Nutr Cancer, 1995. 23(1): 91-101.
- 788 SINGH, A.; RAO, A. R. *Evaluation of the modulatory influence of food additive-garam masala on hepatic detoxication system*. Indian J Exp Biol, dez. 1992. 30(12): 1.142-1.145.
- 789 HALVORSEN, B. L. et al. *Content of redox-active compounds (ie, antioxidants) in foods consumed in the United States*. Am J Clin Nutr, 2006. 84(1): 95-135.
- 790 DAVIS, M. K. *Review of the evidence for an association between infant feeding and childhood cancer*. Int J Cancer Suppl, 1998. 11: 29-33.
- 791 MATHUR, G. P. et al. *Breastfeeding and childhood cancer*. Indian Pediatr, mai. 1993. 30(5): 651-657.
- 792 FAN, Y. et al. *Unravelling the mystery of stem/progenitor cells in human breast milk*. PLoS One, 28 dez. 2010. 5(12): e14.421.
- 793 CASTILLO BELÉN, J. R.; RAMS VERANES, A.; CASTILLO BELÉN, A.; RIZO RODRÍGUEZ, R.; CÁDIZ LAHENS, A.; *Lactancia materna e inmunidad. Impacto social*. MEDISAN, 2009. 13(1).
- 794 BEZAULT, J.; BHIMANI, R.; WIPROVNICK, J.; FURMANSKI, P. *Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice*. Cancer Res, 1^a mai. 1994. 54(9): 2.310-2.312.
- 795 ZHU, Y. P.; SU, Z. W.; LI, C. H. *Growth-inhibition effects of oleic acid, linoleic acid, and their methyl esters on transplanted tumors in mice*. J Natl Cancer Inst, 6 set. 1989. 81(17): 1.302-1.306.
- 796 VAN ASWEGEN, C. H.; DU PLESSIS, D. J. *Can linoleic acid and gamma-linolenic acid be important in cancer treatment?* Med Hypotheses, dez. 1994. 43(6): 415-417.
- 797 HÅKANSSON, A.; ZHIVOTOVSKY, B.; ORRENIUS, S.; SABHARWAL, H.; SVANBORG, C. *Apoptosis induced by a human milk protein*. Proc Natl Acad Sci EUA, 15 ago. 1995. 92(17): 8.064-8.068.
- 798 SVANBORG, C. et al. *HAMLET kills tumor cells by an apoptosis-like mechanism-cellular, molecular, and therapeutic aspects*. Adv Cancer Res, 2003. 88: 1-29.
- 799 HÅKANSSON, A.; ANDRÉASSON, J.; ZHIVOTOVSKY, B.; KARPMAN, D.; ORRENIUS, S.; SVANBORG, C. *Multimeric alpha-lactalbumin from human milk induces apoptosis through a direct effect on cell nuclei*. Exp Cell Res, 1^a fev. 1999. 246(2): 451-460.

- 800 SVENSSON, M. et al. *Molecular characterization of alpha-lactalbumin folding variants that induce apoptosis in tumor cells*. J Biol Chem, 5 mar. 1999. 274(10): 6.388-6.396.
- 801 SVENSSON, M.; MOSSBERG, A. K.; PETTERSSON, J.; LINSE, S.; SVANBORG, C. *Lipids as cofactors in protein folding: stereo-specific lipid-protein interactions are required to form HAMLET (human alpha-lactalbumin made lethal to tumor cells)*. Protein Sci, dez. 2003. 12(12): 2.805-2.814.
- 802 SVENSSON, M.; HAKANSSON, A.; MOSSBERG, A. K. et al. *Conversion of alpha-lactalbumin to a protein inducing apoptosis*. Proc Natl Acad Sci EUA, 11 abr. 2000. 97(8): 4.221-4.226.
- 803 SVENSSON, M. et al. *Alpha-lactalbumin unfolding is not sufficient to cause apoptosis, but is required for the conversion to HAMLET (human alpha-lactalbumin made lethal to tumor cells)*. Protein Sci, dez. 2003. 12(12): 2.794-2.804.
- 804 SVENSSON, M.; FAST, J.; MOSSBERG, A. K. et al. *Alpha-lactalbumin unfolding is not sufficient to cause apoptosis, but is required for the conversion to HAMLET (human alpha-lactalbumin made lethal to tumor cells)*. Protein Sci, dez. 2003. 12(12): 2.794-2.804.
- 805 HAKANSSON, A.; HAKANSSON, H.; MOSSBERG, A. K.; SVANBORG, C. *Apoptosis-like death in bacteria induced by HAMLET, a human milk lipid-protein complex*. PLoS One, 10 mar. 2011. 6(3): e17717.
- 806 FISCHER, W. et al. *Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival*. Cancer Res, 15 mar. 2004. 64(6): 2.105-2.112.
- 807 GUSTAFSSON, L. et al. *Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid*. N Engl J Med, 24 jun. 2004. 350(26): 2.663-2.672.
- 808 MOSSBERG, A. K. et al. *Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells)*. Int J Cancer, 15 set. 2007. 121(6): 1.352-1.359.
- 809 ROUGH, M. et al. *Qualitative analysis of cancer patients experiences using donated human milk*. J Hum Lact, 2009. 25(2): 211-219.
- 810 RIVERÓN CORTEGUERA, R. *Valor inmunológico de la leche materna*. Rev Cubana Pediatr, 1998. 67(2): 116-133.
- 811 GOLDBLUM, R. M. et al. *Antibody-forming cells in human calostrum after oral immunization*. Nature, 1975. 257: 797-798.
- 812 KAUL, D.; SINGH, J. *Leukaemic inhibitory factor in human milk*. Current Science, 25 mar. 2001. 80(6): 737.
- 813 AGUILAR CORDERO, M. J. *Breast feeding: an effective method to prevent breast cancer*. Nutr Hosp, nov-dez. 2010. 25(6): 954-958.
- 814 LIPWORTH, L.; RENEE, B.; DIMITRIOS, T. *History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature*. J Natl Cancer Inst, 16 fev. 2000. 92(4): 302-312.
- 815 MORÁN RODRÍGUEZ, M.; NAVEIRO RILO, J. C.; BLANCO FERNÁNDEZ, E.; CABAÑEROS ARIAS, I.; RODRÍGUEZ FERNÁNDEZ, M.; PERAL CASADO, A.; *Prevalencia y duración de la lactancia materna. Influencia sobre el peso y la morbilidad*. Nutr Hosp, mar-abr. 2009. 24(2): 213-217.
- 816 KELSEY, J. L.; GAMMON, M. D.; JOHN, E. M. *Reproductive factors and breast cancer*. Epidemiol Rev, 1993. 15: 36-47.

- 817 PARKIN, D. M. et al. *Cancer incidence in five continents*. Lyon: IARC Scientific Publication, 1997.
- 818 WOODMAN, I. *Breast-feeding reduced risk of breast cancer, says study*. BMJ, 27 jul. 2002. 325(7.357): 184.
- 819 ZHENG, T. et al. *Lactation and breast cancer risk: a case control study in Connecticut*. Br J Cancer, 1^a jun. 2001. 84(11): 1.472-1.476.
- 820 GOLDIN, B. R.; GORBACH, S. L. *Effect of Lactobacillus acidophilus dietary supplements on 1,2 dimethylhydrazine dihydrochloride-induced intestinal cancer in rats*. J Natl Cancer Inst, 1980. 64: 263-265.
- 821 Pool-ZOBEL, B. L. et al. *Lactobacillus and Bifidobacterium-mediated antigenotoxicity in the colon of rats*. Nutr Cancer, 1996. 26: 365-380.
- 822 PERDIGON, G.; VALDEZ, J. C.; RACHID, M. *Antitumour activity of yoghurt: study of possible immune mechanisms*. J Dairy Res, 1998. 65: 129-138.
- 823 MATSUZAKI, T. *Immunomodulation by treatment with Lactobacillus casei strain Shirota*. Int J Food Microbiol, 26 mai. 1998. 41(2): 133-140.
- 824 CHALLA, A.; RAO, D. R.; CHAWAN, C. B.; SHACKELFORD, L. *Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats*. Carcinogenesis, 1997. 18: 517-521.
- 825 REDDY, G. V.; FRIEND, B. A.; SHAHANI, K. M.; FARMER, R. E. *Antitumour activity of yogurt components*. J Food Prot, 1983; 46: 8-11.
- 826 ROWLAND, I. R.; RUMNEY, C. J.; COUTTS, J. T.; LIEVENSE, L. C. *Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats*. Carcinogenesis, 1989. 19: 281-285.
- 827 ROBERFROID, M. B.; BORNET, F.; BOULEY, C.; CUMMINGS, J. H. *Colonic microflora: nutrition and health. Summary and conclusions of an International Life Sciences Institute (ILSI) [Europe] workshop held in Barcelona, Spain*. Nutr Rev, 1995. 53: 127-130.
- 828 SÝKORA, J. et al. *Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study*. J Clin Gastroenterol, 2005. 39: 692-698.
- 829 CAMPBELL, J. M.; FAHEY JR, G. C.; WOLF, B. W. *Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal shortchain fatty acids, pH and microflora in rats*. J Nutr, 1997. 127: 130-6.
- 830 ROWLAND, I. R.; RUMNEY, C. J.; COUTTS, J. T.; LIEVENSE, L. C. *Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats*. Carcinogenesis, 1998. 19: 281-285.
- 831 RENNER, H. W.; MÜNZNER, R. *The possible role of probiotics as dietary antimutagens*. Mutat Res, 1991. 262: 239-245.
- 832 KOPP-HOOLIHAN, L. *Prophylactic and therapeutic uses of probiotics: a review*. J Am Diet Assoc, fev. 2001. 101(2): 229-238.
- 833 ASO, Y.; AKAZAN, H. *Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer*. BLP Study Group. Urol Int, 1992. 49(3): 125-129.
- 834 FOTIADIS, C. I.; STOIDIS, C. N.; SPYROPOULOS, B. G.; ZOGRAFOS, E. D. *Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer*. World J Gastroenterol, 14 nov. 2008. 14(42): 6.453-6.457.

- 835 LIDBECK, A. et al. *Impact of Lactobacillus acidophilus supplements on the faecal microflora and soluble faecal bile acids in colon cancer patients*. Microbial Ecol Health Dis, 1991. 4: 81-488.
- 836 WEISBURGER, J. H.; CHUNG, F. L. *Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols*. Food Chem Toxicol, 2002. 40: 1.145-1.154.
- 837 SUZUKI, E. et al. *Green tea consumption and mortality among Japanese elderly people: The prospective Shizuoka elderly cohort*. Ann Epidemiol, out. 2009. 19(10): 732-739.
- 838 MUKHTAR, H.; AHMAD, N. *Tea polyphenols: prevention of cancer and optimizing health*. Am J Clin Nutr, 2000. 71: 1.698S-1.702S.
- 839 YANG, C. S.; WANG, H. *Mechanistic issues concerning cancer prevention by tea catechins*. Mol Nutr Food Res, jun. 2011. 55(6): 819-831.
- 840 CHOW, H. H.; HAKIM, I. A. *Pharmacokinetic and chemoprevention studies on tea in humans*. Pharmacol Res, ago. 2011. 64(2): 105-112.
- 841 PONGSUWAN, W. et al. *High-throughput technique for comprehensive analysis of Japanese green tea quality assessment using ultra-performance liquid chromatography with time-of-flight mass spectrometry (UPLC/TOF MS)*. J Agric Food Chem, 26 nov. 2008. 56(22): 10.705-10.708.
- 842 MAK, J. C. *The potential role of green tea catechins in various disease therapies: progress and promise*. Clin Exp Pharmacol Physiol, mar. 2012. 39(3): 265-273.
- 843 COOPER, R.; MORRÉ, D. J.; MORRÉ, D. M. *Medicinal benefits of green tea: part II. Review of anticancer properties*. J Altern Complement Med, ago. 2005. 11(4): 639-652.
- 844 AHMAD, N.; GUPTA, S.; MUKHTAR, H. *Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor $\kappa\beta$ in cancer cells versus normal cells*. Arch Biochem Biophys, 15 abr. 2000. 376(2): 338-346.
- 845 SINGH, M. et al. *Tea polyphenols induce apoptosis through mitochondrial pathway an by inhibiting nuclear factor-kappa β and Akt activation in human cervical cancer cells*. Oncol Res, 2011. 19(6): 245-257.
- 846 KATIYAR, S. K.; ELMETS, C. A. *Green tea polyphenolic antioxidants and skin photo-protection*. Int J Oncol, jun. 2001. 18(6): 1.307-1.313.
- 847 RAO, S. D.; PAGIDAS, K. *Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells*. Anticancer Res, jul. 2010. 30(7): 2.519-2.523.
- 848 THAKUR, V. S.; GUPTA, K.; GUPTA, S. *Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases*. Carcinogenesis, fev. 2012. 33(2): 377-384.
- 849 JANKUN, J.; SELMAN, S. H.; SWIERCZ, R.; SKRZYPCZAK-JANKUN, E. *Why drinking green tea could prevent cancer?* Nature, 5 jun. 1997. 387(6.633): 561.
- 850 YANG, X. W. et al. *Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells*. Hepatol Res, mai. 2012. 42(5): 494-501.
- 851 SUGANUMA, M.; SAHA, A.; FUJIKI, H. *New cancer treatment strategy using combination of green tea catechins and anticancer drugs*. Cancer Sci, fev. 2011. 102(2): 317-323.
- 852 STEAMS, M. E.; WANG, M. *Synergistic effects of the Green Tea extract Epigallocatechin-3-gallate and taxane in eradication of malignant human prostate Tumors*. Trans Oncol, jun. 2011. 4(3): 147-156.

- 853 KUMAR, M.; SHARMA, V. L.; SEHGAL, A.; JAIN, M. *Protective effects of green and white tea against benzo(a)pyrene induced oxidative stress and DNA damage in murine model.* Nutr Cancer, 2012. 64(2): 300-306.
- 854 COOPER, R.; MORRÉ, D. J.; MORRÉ, D. M. *Medicinal benefits of green tea: Part I. Review of noncancer health benefits.* J Altern Complement Med, jun. 2005. 11(3): 521-528.
- 855 BUTLER, L. M.; WU, A. H. *Green and black tea in relation to gynecologic cancers.* Mol Nutr Food Res, jun. 2011. 55(6): 931-940.
- 856 HENNING, S. M.; WANG, P.; HEBER, D. *Chemopreventive effects of tea in prostate cancer: green tea versus black tea.* Mol Nutr Food Res, jun. 2011. 55(6): 905-920.
- 857 BAPTISTA, J.; TAVARES, J.; CARVALHO, R. *Comparison of catechins and aromas among different green teas using HPLC/SPME-GC.* Food Res Int, dez. 1998. 31(10): 729-736.
- 858 *Green tea (Camelia Sinensis) for the prevention of cancer.* Cochrane Database Sys Rev, 8 jul. 2009. (3): CD005004.
- 859 HAKIM, I. A.; HARRIS, R. B.; WEISGERBER, U. M. *Tea intake and squamous cell carcinoma of the skin: influence of type of tea beverages.* Cancer Epidemiol Biomarkers Prev, 2000. 9: 727-9731.
- 860 COOPER, R. *Green tea and theanine: health benefits.* Int J Food Sci Nutr, mar. 2012. 63 Supl. 1: 90-97.
- 861 TANG, N.; WU, Y.; ZHOU, B.; WANG, B.; YU, R. *Green tea, black tea consumption and risk of lung cancer: a meta-analysis.* Lung Cancer, set. 2009. 65(3): 274-283.
- 862 JIAN, L.; XIE, L. P.; LEE, A. H.; BINNS, C. W. *Protective effect of green tea against prostate cancer: a case-control study in southeast China.* Int J Cancer, 2004. 108: 130-135.
- 863 NAKACHI, K. et al. *Influence of drinking green tea on breast cancer malignancy among Japanese patients.* Jpn J Cancer Res, 1998. 89: 254-261.
- 864 IMAI, K.; SUGA, K.; NAKACHI, K. *Cancer-preventive effects of drinking green tea among a Japanese population.* Prev Med, 1997. 26: 769-775.
- 865 NAKACHI, K.; EGUCHI, H.; IMAI, K. *Can teatime increase one's lifetime?* Ageing Res Rev, jan. 2003. 2(1): 1-10.
- 866 YANG, C. S.; MALIAKAL, P.; MENG, X. *Inhibition of carcinogenesis by tea.* Ann Rev Pharmacol Toxicol, 2002. 42: 25-54.
- 867 SUGANUMA, M. et al. *Green tea and cancer chemoprevention.* Mutat Res, 1999. 428: 339-44.
- 868 ZHANG, M.; LEE, A. H.; BINNS, C. W.; XIE, X. *Green tea consumption enhances survival of epithelial ovarian cancer.* Int J Cancer, 10 nov. 2004. 112(3): 465-469.
- 869 GREENLEE, R. T.; MURRAY, T.; BOLDEN, S.; WINGO, P. A. *Cancer statistics 2000.* CA Cancer J Clin, jan-fev. 2000. 50(1): 7-33.
- 870 GIACOSA, A. et al. *Alcohol and wine in relation to cancer and other diseases.* Eur J Cancer Prev, jan. 2012. 21(1): 103-108.
- 871 MO, W. et al. *Resveratrol inhibits proliferation and induces apoptosis through the hedgehog signaling pathway in pancreatic cancer cell.* Pancreatology, 2012. 11(6): 601-609.
- 872 PANARO, M. A. et al. *Anti-inflammatory effects of resveratrol occur via inhibition of lipopolysaccharide-induced NF- κ B activation in Caco-2 and SW 480 human colon cancer cells.* Br J Nutr, jan. 2012. 117: 1-10.
- 873 BAE, S. et al. *Resveratrol alters microRNA expression profiles in A549 human non-small cell lung cancer cells.* Moll Cells, set. 2011. 32(3): 243-249.
- 874 LIN, H. et al. *Notch-1 activation-dependent p53 restoration contributes to resveratrol-induced apoptosis in glioblastoma cells.* Oncol Rep, out. 2011. 26(4): 925-930.

- 875 DHAR, S.; HICKS, C.; LEVENSON, A. S. *Resveratrol and prostate cancer: promising role for microRNAs*. Mol Nutr Food Res, ago. 2011. 55(8): 1.219-1.229.
- 876 KARTAL, M.; SAYDAM, G.; SAHIN, F.; BARAN, Y. *Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells*. Nutr Cancer, mai. 2011. 63(4): 637-644.
- 877 HUSSAIN, A. R. et al. *Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines*. PLoS One, 2011. 6(9): e24703.
- 878 DENISSOVA, N. G. et al. *Resveratrol protects mouse embryonic stem cells from ionizing radiation by accelerating recovery from DNA strand breakage*. Carcinogenesis, jan. 2012. 33(1): 149-155.
- 879 RASHID, A. et al. *Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and m TOR pathway*. Radiat Oncol, 26 out. 2011. 6: 144.
- 880 KAI, L.; LEVENSON, A. S. *Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells*. Anticancer Res, out. 2011. 3(10): 3.323-3.330.
- 881 SANTANDREU, F. M.; VALLE, A.; OLIVER, J.; ROCA, P. *Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells*. Cell Physiol Biochem, 2011. 28(2): 219-228.
- 882 NESSA, M. U.; BEALE, P.; CHAN, C.; YU, Q.; HUG, F. *Combination of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells*. Anticancer Res, jan. 2012. 32(1): 53-59.
- 883 GUTIÉRREZ MAYDATA, A. *Vino, polifenoles y protección a la salud*. Rev Cubana Aliment Nutr, 2002. 16(2): 134-141.
- 884 MASSUELLI, L. et al. *Resveratrol and diallyl disulfide enhance curcumin- induced sarcoma cell apoptosis*. Front Biosci, 1^a jan. 2012. 17: 498-508.
- 885 LU, X. Y.; HU, S.; JIN, Y.; QIU, L. Y. *Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol*. Drug Dev Ind Pharm, mar. 2012. 38(3): 314-322.
- 886 SCOTT, E.; STEWARD, W. P.; GESCHER, A. J.; BRWN, K. *Resveratrol in human cancer chemoprevention – choosing the “right” dose*. Mol Nutr Food Res, jan. 2012. 56(1): 7-13.
- 887 MIKKO, S. *Interactions of alcohol and tobacco in gastrointestinal cancer*. J Gastroenterol Hepatol, mar. 2012. 27 Supl. 2: 135-139.
- 888 DE LORGERIL, M.; SALEN, D. *Alcool, vin et santé*. Mônaco: Alpen Editions, 2007.
- 889 BAGLIETTO, L.; ENGLISH, D. R.; GERTIG, D. M.; HOPPER, J. L.; GILES, G. G. *Does dietary folate intakes modify effect of alcohol consumption on breast cancer risk. Prospective cohort study*. BMJ, 8 out. 2005. 331(7.520): 807.
- 890 VETVICKA, V.; VETVICKOVA, J. *Combination of glucan, resveratrol and vitamin C demonstrates strong anti-tumor potencial*. Anticancer Res, jan. 2012. 32(1): 81-87.
- 891 GARCÍA-AGUIRRE, K. K.; ZEPEDA-VALLEJO, L. G.; RAMÓN-GALLEGOS, E.; ALVÁREZ-GONZÁLEZ, I.; MADRIGAL-BUJADAR, E. *Genotoxic and cytotoxic effects produced by acetogenins obtained from Annona cherimolia Mill*. Biol Pharm Bull, dez. 2008. 31(12): 2.346-2.349.
- 892 COCHRANE, C. B.; NAIR, P. K.; MELNICK, S. J.; RESEK, A. P.; RAMACHANDRAN, C. *Anticancer effects of Annona glabra plant extracts in human leukemia cell lines*. Anticancer Res, mar-abr. 2008. 28(2A): 965-971.

- 893 SURESH, H. M. et al. *In vitro* antiproliferative activity of *Annona reticulate* roots on human cancer cell lines. *Pharmacognosy Res*, jan. 2011. 3(1): 9-12.
- 894 DAI, Y. et al. *Selective growth inhibition of human breast cancer cells by graviola fruit extract in vitro and in vivo involving downregulation of EGFR expression*. *Nutr Cancer*, 2011. 63(5): 795-801.
- 895 El Kar, C.; Ferchichi, A.; Attia, F.; Bouajila, J. *Pomegranate (Punica granatum) Juices: Chemical Composition, Micronutrient Cations, and Antioxidant Capacity*. *J Food Sci*, ago. 2011. 76(6): C795-800.
- 896 JOSEPH, M. M.; ARAVIND, S. R.; VARGHESE, S.; MINI, S.; SREELEKHA, T. T. *Evaluation of antioxidant, antitumor and immunomodulatory properties of polysaccharide isolated from fruit rind of Punica granatum*. *Mol Med Report*, fev. 2012. 5(2): 489-496.
- 897 WEISBURG, J. H. et al. *Pomegranate extract a prooxidant with antiproliferative and proapoptotic activities preferentially towards carcinoma cells*. *Anticancer Agent Med Chem*, 1^o out. 2010. 10(8): 634-644.
- 898 ADAM, L.; SEERAM, N. P.; AGGARWAL, B. B. *Pomegranate juice, total pomegranate ellagitannins and punicalagin suppress inflammatory cell signaling in colon cancer*. *J Agric Food*, 2006. 54: 980-985.
- 899 NAIR, V.; DAI, Z.; KHAN, M.; CIOLINO, H. P. *Pomegranate extract induces cell cycle arrest and alters cellular phenotype of human pancreatic cancer cell*. *Anticancer Res*, set. 2011. 31(9): 2.699-2.704.
- 900 DIKMEN, M.; OZTURK, N.; OZTURK, Y. *The antioxidant potency of Punica granatum L. fruit peel reduces cell proliferation and induces apoptosis on breast cancer*. *J Med Food*, dez. 2011. 14(12): 1.638-1.646.
- 901 KASIMSETTY, S. G.; BIALONSKA, D.; REDDY, M. K.; THORNTON, C.; WILLETT, K. L.; FERREIRA, D. *Effect of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells*. *J Agric Food Chem*, 25 nov. 2009. 57(22): 10.636-10.644.
- 902 KASIMSETTY, S. G.; BIALONSKA, D.; REDDY, M. K.; THORNTON, C.; WILLETT, K. L.; FERREIRA, D. *Effect of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells*. *J Agric Food Chem*, 25 nov. 2009. 57(22): 10.636-10.644.
- 903 KASIMSETTY, S. G.; BIALONSKA, D.; REDDY, M. K.; MA, G.; KHAN, S. I.; FERREIRA, D. *Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins*. *J Agric Food Chem*, 24 fev. 2010. 58(4): 2.180-2.187.
- 904 BANERJEE, S.; KAMHAMPATI, S.; HAGUEL, I.; BANERJEE, S. K. *Pomegranate sensitizes tamoxifen action in ER-positive breast cancer cells*. *J Cell Commun Signal*, dez. 2011. 5(4): 317-324.
- 905 CAVIR, K. et al. *Pomegranate seed extract attenuates chemotherapy-induced acute nephrotoxicity and hepatotoxicity in rats*. *J Med Food*, out. 2011. 14(10): 1.254-1.282.
- 906 PANTUCK, A. J.; ZOMORODIAN, N.; BELLDEGRUN, A. S. *Phase II study of pomegranate juice for men with prostate cancer and increasing PSA*. *Curr Urol Rep*, jan. 2006. 7(1): 7.
- 907 TANAKA, T.; TANAKA, M.; KUNO, T. *Cancer chemoprevention by citrus pulp and juices containing high amount of β -cryptoxanthin and hesperidin*. *J Biomed Biotechnol*, 2012. 2012: 516.981.

- 908 KIM, H.; MOON, J. Y.; MOSADDIK, A.; CHO, S. K. *Induction of apoptosis in human cervical carcinoma HeLa cells by polymethoxylated flavone rich Citrus grandis Osbeck (Dangyuja) leaf extract.* Food Chem Toxicol, ago-set. 2010. 48(8-9): 2.435-2.442.
- 909 LEE, YC. et al. *Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/P13K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells.* Mol Cell Biochem, jan. 2011. 347(1-2): 103-115.
- 910 PRACTHEESHKUMAR, P.; RAPHAEL, T. J.; KUTTAN, G. *Nomilin inhibits metastasis via induction of apoptosis and regulates the activation of transcription factor and the cytokine profile in B16F-10-cells.* Integr Cancer Ther, mar. 2012. 11(1): 48-60.
- 911 CAMARGO, C. A.; GOMES-MARCONDES, M. C.; WUTZKI, N. C.; AOYAMA, H. *Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor levels in rats with walker 256 carcinosarcoma.* Anticancer Res, jan. 2012. 32(1): 129-133.
- 912 YE, L.; CHAN, F. L.; CHEN, S.; LEUNG, L. K. *The citrus flavones hesperetin inhibits growth of aromatase-expressing MCF-7 tumor in ovariectomized athymic mice.* J Nutr Biochem, out. 2012. 23(10): 1.230-1.237.
- 913 ALSHATWI, A. A. et al. *Apoptosis-mediated inhibition of human breast cancer cell proliferation by lemon citrus extract.* Asian Pac J Cancer Prev, 2011. 12(6): 1.555-1.559.
- 914 STEEVENS, J.; SCHOUTEN, L. J.; GOLDBOHN, R. A.; VAN DEN BRANDT, P. A. *Vegetables and fruits consumption and risk of esophageal and gastric cancer subtypes in the Nether-land cohort study.* Int J Cancer, 1º dez. 2011. 129(11): 2.681-2.693.
- 915 LEE, D. H. et al. *Flavonoids isolated from Korea Citrus aurantium L. induce G2/M phase arrest and apoptosis in human gastric cancer AGS cells.* Evid Based Complement Alternat Med, 2012. 51.590.
- 916 CHIDAMBARA MURTHY, K. N. et al. *Citrus limonin and its glucoside inhibit colon adenocarcinoma cell proliferation through apoptosis.* J Agric Food Chem, 23 mar. 2011. 59(6): 2.314-2.323.
- 917 SABARINATHAN, D.; MAHALAKSHMI, P.; VANISREE, A. J. *Naringenin promote apoptosis in cerebrally implanted C6 glioma cells.* Mol Cell Biochem, dez. 2010. 345(1-2): 215-222.
- 918 LEE, S. et al. *Extracts from Citrus unshiu promote immune-mediated inhibition of tumor growth in a murine renal cell carcinoma model.* J Ethnopharmacol, 16 fev. 2011. 133(3): 973-979.
- 919 ÁLVAREZ-GONZÁLEZ, I.; MADRIGAL-BUJADAR, E.; SÁNCHEZ-GARCÍA, V. Y. *Inhibitory effect of grapefruit juice on the genotoxic damage induced by ifosfamide in mouse.* Plant Food Hum Nutr, dez. 2010. 65(4): 369-373.
- 920 LI, W. Q. et al. *Citrus consumption and cancer incidence: the Ohsaki cohort study.* Int J Cancer, 15 out. 2010. 127(8): 1.913-1.922.
- 921 SUN, J.; CHU, Y.; WU, X.; LIU, R. H. *Antioxidant and antiproliferative activities of common fruits.* J Agric Food Chem, 2002. 50: 7.449-7.454.
- 922 SUN, J.; LIU R. H. *Apple phytochemical extracts inhibit proliferation of estrogen-dependent and estrogen-independent human breast cancer cells through cell cycle modulation.* J Agric Food Chem, 24 dez. 2008. 56(24): 11.661-11.667.
- 923 GERHAUSER, C. *Cancer chemopreventive potential of apples, apple juice, and apple components.* Planta Med, out. 2008. 74(13): 1.608-1.624.
- 924 WOLFE, K.; WU, X.; LIU, R. H. *Antioxidant activity of apple peels.* J Agric Food Chem, 29 jan. 2003. 51(3): 609-614.

- 925 WOJDYŁO, A.; OSZMIAŃSKI, J.; LASKOWSKI, P. *Polyphenolic compounds and antioxidant activity of new and old apple varieties*. J Agric Food Chem, 13 ago. 2008. 56(15): 6.520-6.530.
- 926 HAMMERSTONE, J.; LAZARUS, S.; SCHMITZ, H. *Procyanidin content and variation in some commonly consumed foods*. J Nutr, 2000. 130: 2.086S-2.092S.
- 927 AWAD, M.; WAGENMAKERS, P.; DE JAGER, A. *Effects of light on flavonoid and chlorogenic acid levels in the skin of Jonagold apples*. Scientia Hort, 2001. 88: 289-298.
- 928 AWAD, M.; DE JAGER, A. *Relationships between fruit nutrients and concentrations of flavonoids and chlorogenic acid in Elstar apple skin*. Scientia Hort, 2002. 92: 265-276.
- 929 KOCH, T. C. et al. *Prevention of colon carcinogenesis by apple juice in vivo: impact of juice constituents and obesity*. Mol Nutr Food Res, out. 2009. 53(10): 1.289-1.302.
- 930 EBERHARDT, M.; LEE, C.; LIU, H. R. *Antioxidant activity of fresh apples*. Nature, 2000. 405: 903-904.
- 931 FESKANICH, D. et al. *Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women*. J Natl Cancer Inst, 15 nov. 2000. 92(22): 1.812-1.823.
- 932 YOON, H.; LIU, R. H. *Effect of selected phytochemicals and apple extracts on NF-kappa β activation in human breast cancer MCF-7 cells*. J Agric Food Chem, 18 abr. 2007. 55(8): 3.167-3.173.
- 933 LIU, R. H.; LIU, J.; CHEN, B. *Apples prevent mammary tumors in rats*. J Agric Food Chem, 23 mar. 2005. 53(6): 2.341-2.343.
- 934 LE MARCHAND, L. et al. *Intake of flavonoids and lung cancer*. J Natl Canc Inst, 2000. 92: 154-160.
- 935 LEONTOWICZ, M. et al. *Apple and pear peel and pulp and their influences on plasma lipids and antioxidant potential in rats fed cholesterol-containing diets*. J Agric Food Chem, 10 set. 2003. 51(19): 5.780-5.785.
- 936 ANITHA, P.; PRIYADARSINI, R. V.; KAVITHA, K.; THIYAGARAJAN, P.; NAGINI, S. *Ellagic acid coordinately attenuates Wnt/ β -catenin and NF- κ B signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis*. Eur J Nutr, fev. 2013. 52(1): 75-84.
- 937 SEERAM, N. P. et al. *Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro*. J Agric Food Chem, 13 dez. 2006. 54(25): 9.329-9.339.
- 938 LABRECQUE, L. et al. *Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound*. Carcinogenesis, 2005. 26(4): 821-826.
- 939 WANG, N. et al. *Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer*. Breast Cancer Res Treat, ago. 2012. 134(3): 943-955.
- 940 STONER, G. D. *Foodstuffs for preventing cancer: the preclinical and clinical development of berries*. Cancer Prev Res (Phila), mar. 2009. 2(3): 187-194.
- 941 McCUNE, L. M.; KUBOTA, C.; STENDELL-HOLLIS, N. R.; THOMSON, C. A. *Cherries and health: a review*. Crit Rev Food Sci Nutr, jan. 2011. 51(1): 1-12.
- 942 KANG, S. Y.; SEERAM, N. P.; NAIR, M. G.; BOURQUIN, L. D. *Tart cherry anthocyanins inhibit tumor development in Apc(Min) mice and reduce proliferation of human colon cancer cells*. Cancer Lett, 8 mai. 2003. 194(1): 13-19.
- 943 NUTAKUL, W. et al. *Inhibitory effects of resveratrol and pterostilbene on human colon cancer cell: a side-by-side comparison*. J Agric Food Chem, 26 out. 2011. 59(20): 10.964-10.970.

- 944 YU, M. H. et al. *Induction of apoptosis by immature fruits of Prunus salicina Lindl. cv. Soldam in MDA-MB-231 human breast cancer cells.* Int J Food Sci Nutr, fev. 2007. 58(1): 42-53.
- 945 LEE, S. H. et al. *Immunostimulatory effects of oriental plum (Prunus salicina Lindl.).* Comp Immunol Microbiol Infect Dis, set. 2009. 32(5): 407-417.
- 946 KIM, H. J.; YU, M. H.; LEE, I. S. *Inhibitory effects of methanol extract of plum (Prunus-salicina L., cv. "Soldam") fruits against benzo(alpha)pyrene-induced toxicity in mice.* Food Chem Toxicol, nov. 2008. 46(11): 3.407-3.411.
- 947 NORATTO, G.; PORTER, W.; BYRNE, D.; CISNEROS-ZEVALLOS, L. *Identifying peach and plum polyphenols with chemopreventive potential against estrogen-independent breast cancer cells.* J Agric Food Chem, 24 jun. 2009. 57(12): 5.219-5.226.
- 948 YU, M. H. et al. *Effect of immature plum on PMA-induced MMP-9 expression in human hepatocellular carcinoma.* Nat Prod Res, 2009. 23(8): 704-718.
- 949 LEA, M. A. et al. *Inhibition of growth and induction of differentiation of colon cancer cells by peach and plum phenolic compounds.* Anticancer Res, jul-ago. 2008. 28(4B): 2.067-2.076.
- 950 KEEN, C. L. *Chocolate: food as medicine/medicine as food.* J Am Coll Nutr. Out. 2001. 20(5 Suppl): 436S-439S; discussão 440S-442S.
- 951 RAMLJAK, D. et al. *Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells.* Mol Cancer Ther, abr. 2005. 4(4): 537-546.
- 952 HAMMERSTONE, J.; LAZARUS, S.; SCHMITZ, H. *Procyanidin content and variation in some commonly consumed foods.* J Nutr, 2000. 130: 2.086S-2.092S.
- 953 NATSUME, M. et al. *Analyses of polyphenols in cacao liquor, cocoa, and chocolate by normal-phase and reversed-phase HPLC.* Biosci Biotechnol Biochem, dez. 2000. 64(12): 2.581-2.587.
- 954 WANG, J. J.; SANDERSON, B. J.; ZHANG, W. *Cytotoxic effect of xanthones from pericarp of the tropical fruit mangosteen (Garcinia mangostana Linn.) on human melanoma cells.* Food Chem Toxicol, set. 2011. 49(9): 2.385-2.391.
- 955 TORRES, M. P. et al. *Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism.* Cancer Lett, 1º out. 2012. 323(1): 29-40.
- 956 VEERARAGHAVAN, J. et al. *Impact of curcumin, raspberry extract, and neem leaf extract on rel protein-regulated cell death/radiosensitization in pancreatic cancer cells.* Pancreas, out. 2011. 40(7): 1.107-1.119.
- 957 NIEDZWIECKI, A.; ROOMI, M. W.; KALINOVSKY, T.; RATH, M. *Micronutrient synergy – a new tool in effective control of metastasis and other key mechanisms of cancer.* Cancer Metastasis Rev, set. 2010. 29(3): 529-542.
- 958 MORGAN, G.; WARD, R.; BARTON, M. *The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.* Clin Oncol (R Coll Radiol), dez. 2004. 16(8): 549-560.
- 959 MILLER, A. B. *Diet and cancer. A review.* Acta Oncol, 1990. 29(1): 87-95.
- 960 ALDERCREUTZ, H. *Western diet and Western disease: some hormonal and biochemical mechanisms and associations.* Scand J Clin Lab Invest Suppl, 1990. 201: 323.
- 961 KONIG, U. et al. *Assessment of the safety of foods derived from genetically modified (GM) crops.* Food Chem Toxicol, 2004. 42: 1.047-1.088.

- 962 DE VENDÔMOIS, J. S.; ROULLIER, F.; CELLIER, D.; SÉRALINI, G. E. *A comparison of the effects of three GM corn varieties on mammalian health*. Int J Biol Sci, 10 dez. 2009. 5(7): 706-726.
- 963 DOMINGO, J. L.; GINÉ BORDONABA, J. *A literature review on the safety assessment of genetically modified plants*. Environ Int, mai. 2011. 37(4): 734-742.
- 964 DALDY, Y. *Food production without artificial fertilisers*. Nature, 8 jun. 1990. 145(3.684): 905.
- 965 SCHUPHAN, W. *Effects of the application of inorganic and organic manures on the market quality and on the biological value of agricultural products*. Qualitasplantarum, 1972. 21(4): 381-398.
- 966 HEATON, S. "Assessing organic food quality: Is it better for you?" In: *Proceedings of the UK Organic Research 2002 Conference*. POWELL, J. et al. (eds.). Organic Centre Wales. Institute of Rural Studies, University of Wales Aberystwyth, 2002. 55-60.
- 967 WOESE, K.; LANGE, D.; BOESS, C. *A comparison of organically and conventionally grown foods – Results of a review of the relevant literature*. J Sci Food Agric, jul. 1997. 74(3): 281-293.
- 968 WORTINGTON, V. *Effect of agricultural methods on nutritional quality: a comparison of organic with conventional crops*. Alternative Therapies Health Med, 1998. 4: 58-69.
- 969 DOMÍNGUEZ, A.; RAIGÓN, M. D.; SOLER, D. *Hacia la citricultura de calidad con la producción ecológica*. Vida Rural, mai. 2003. 169: 36-40.
- 970 GIVENS, D.; BAXTER, S.; MINIHANE, A. M.; SHAW, E. *Health benefits of organic food: Effects of the environment*. Ed Cabi, 2008.
- 971 BEYZA E.; AKIF. *The effect of cooking methods on mineral and vitamin contents of African catfish*. Food Chemistry, 2009. 115(2): 419-422.
- 972 MAURON, J. *Influence of processing on protein quality*. J Nutr Sci Vitaminol (Tóquio), 1990. 36 Supl. 1: 57-69S.
- 973 O'BRIEN, J.; MORRISSEY, P. A. *Nutritional and toxicological aspects of the Maillard browning reaction in foods*. Crit Rev Food Sci Nutr, 1989. 28: 211-248.
- 974 MOORE, M. A.; PARK, C. B.; TSUDA, H. *Soluble and insoluble fiber influences on cancer development*. Crit Rev Oncol Hematol, 1998. 27: 229-242.
- 975 O'BRIEN, J.; MORRISSEY, P. A. *Nutritional and toxicological aspects of the Maillard browning reaction in foods*. Crit Rev Food Sci Nutr, 1989. 28: 211-248.
- 976 DOOLITTLE, D. J. et al. *Effect of cooking methods on the mutagenicity of food and on urinary mutagenicity of human consumer*. Food Chem Toxicol, out. 1989. 27(10): 657-666.
- 977 SINHA, R. *An epidemiologic approach to studying heterocyclic amines*. Mutat Res, 30 set. 2002. 506-507: 197-204.
- 978 WESTER, P. W. et al. *Carcinogenic activity of benzo[a]pyrene in a 2 year oral study in Wistar rats*. Food Chem Toxicol, mar. 2012. 50(3-4): 927-935.
- 979 WILSON, K. M.; GIOVANNUCCI, E.; STAMPFER, M. J.; MUCCI, L. A. *Dietary acrylamide and risk of prostate cancer*. Int J Cancer, 15 jul. 2012. 131(2): 479-487.
- 980 VLASSARA, H. et al. *Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy*. Proc Natl Acad Sci USA, 26 nov. 2002. 99(24): 15.596-15.601.
- 981 GNAGNARELLA, P.; GANDINI, S.; LA VECCHIA, C. *Glycemic index, glycemic load, and cancer risk: a meta-analysis*. Am J Clin Nutr, jun. 2008. 87(6): 1.793-1.801.

- 982 AUGUSTIN, L. S. et al. *Dietary glycemic index and glycemic load, and breast cancer risk: a case-control study*. Ann Oncol, nov. 2001. 12(11): 1.533-1.538.
- 983 DE STEFANI, E. et al. *Dietary sugar and lung cancer: a case-control study in Uruguay*. Nutr Cancer, 1998. 31: 132-137.
- 984 FRANCESCHI, S. et al. *Dietary glycemic load and colorectal cancer risk*. Ann Oncol, fev. 2001. 12(2): 173-178.
- 985 JOSHI, A. D.; JOHN, E. M.; KOO, J.; INGLES, S. A, STERN, M. C. *Fish intake, cooking practices, and risk of prostate cancer: results from a multi-ethnic case-control study*. Cancer Causes Control, mar. 2012. 23(3): 405-420.
- 986 PUNNEN, S.; HARDIN, J.; CHENG, I.; KLEIN, E. A.; WITTE, J, S. *Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer*. PLoS One. 2011. 6(11): e27711.
- 987 FU, Z. et al. *Association of meat intake and meat-derived mutagen exposure with the risk of colorectal polyps by histologic type*. Cancer Prev Res (Phila), out. 2011. 4(10): 1.686-1.697.
- 988 DANIEL, C. R. et al. *Meat-cooking mutagens and risk of renal cell carcinoma*. Br J Cancer, 27 set. 2011. 105(7): 1.096-1.104.
- 989 WOZIWODZKA, A.; TARASEWICZ, M.; PIOSIK J. *Heterocyclic aromatic amines, food derived mutagens: metabolism and relevance to cancer susceptibility*. Postepy Biochem, 2010. 56(4): 435-446.
- 990 MICOZZI, M. S.; BEECHER. G. R.; TAYLOR, P. R.; KHACIK, F. *Carotenoid analyses of selected raw and cooked foods associated with a lower risk for cancer*. J Natl Cancer Inst, 1990. 82: 282-285.
- 991 SONG, K.; MILNER, J. A. *The influence of heating on the anticancer properties of garlic*. J Nutr, mar. 2001. 131(3s): 1.054S-1.057S.
- 992 CONAWAY, C. C. et al. *Disposition of glucosinolates and sulforaphane in humans after ingestion of steamed and fresh broccoli*. Nutr Cancer, 2000. 38(2): 168-178.
- 993 DEWANTO, V.; WU, X.; ADOM, K. K.; LIU, R. H. *Thermal processing enhances the nutritional value of tomatoes by increasing total antioxidant activity*. J Agric Food Chem, 8 mai. 2002. 50(10): 3.010-3.014.
- 994 Prentice, R. L. et al. *Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial*. JAMA, 2006. 295(6): 629-642.
- 995 AUNE, D. et al. *Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies*. Ann Oncol, jun. 2012. 23(6): 1.394-1.402.
- 996 TANAKA, K. et al. *Obesity and liver cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the Japanese population*. Jpn J Clin Oncol, mar. 2012. 42(3): 212-221.
- 997 WOLIN, K. Y.; CARSON, K.; COLDITZ, G. A. *Obesity and cancer*. Oncologist, 2010. 15(6): 556-565.
- 998 MOREY, M. C. et al. *Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial*. JAMA, 13 mai. 2009. 301(18): 1.883-1.891.
- 999 VERGNAUD, A. C. et al. *Fruit and vegetable consumption and prospective weight change in participants of the European Prospective Investigation into Cancer and Nutrition-Physical Activity, Nutrition, Alcohol, Cessation of Smoking, Eating Out of Home, and Obesity study*. Am J Clin Nutr, jan. 2012. 95(1): 184-193.

- 1000 ARIAS, E.; ANDERSON, R. N.; KUNG, H. C.; MURPHY, S. L.; KOCHANNEK, K. D. *Deaths: final data for 2001*. Natl Vital Stat Rep, 18 set. 2003. 52(3): 1-115.
- 1001 LINK L. B., POTTER J. D.. *Raw versus cooked vegetables and cancer risk*. Cancer Epidemiol Biomarkers Prev, set. 2004. 13(9): 1.422-1.435.
- 1002 BROWN, L. M. et al. *Dietary factors and the risk of squamous cell esophageal cancer among Black and White men in the United States*. Cancer Causes, 1998. 9: 467-474.
- 1003 KEY, T. J.; THOROGOOD, M.; APPLEBY, P. N.; BURR, M. L. *Dietary habits and mortality in 11.000 vegetarians and health conscious people: results of a 17 year follow up*. BMJ, 28 set. 1996. 313(7.060): 775-779.
- 1004 MASALA, G. et al. *Fruit and vegetables consumption and breast cancer risk: the EPIC Italy study*. Breast Cancer Res Treat, abr. 2012. 132(3): 1.127-1.136.
- 1005 PAXTON, R. J. et al. *A randomized parallel-group dietary study for stages II-IV ovarian cancer survivors*. JAMA, 13 mai. 2009. 301(18): 1.883-1.891.
- 1006 BROCK, K. E. et al. *Fruit, vegetables, fibre and micronutrients and risk of US renal cell carcinoma*. Br J Nutr, 20 dez. 2011. 1-9.
- 1007 BUTLER, L. M. et al. *A vegetable-fruit-soy dietary pattern protects against breast cancer among postmenopausal Singapore Chinese women*. Am J Clin Nutr, abr. 2010. 91(4): 1.013-1.019.
- 1008 MIGLIO, C.; CHIAVARO, E.; VISCONTI, A.; FOGLIANO, V.; PELLEGRINI, N. *Effects of different cooking methods on nutritional and physicochemical characteristics of selected vegetables*. J Agric Food Chem, 9 jan. 2008. 56(1): 139-147.
- 1009 YUAN, G. F.; SUN, B.; YUAN, J.; WANG, Q. M. *Effects of different cooking methods on health-promoting compounds of broccoli*. Zhejiang Univ Sci B, Ago. 2009. 10(8): 580-588.
- 1010 NALAN, G.; PINAR, Y.; EMEL, C. *Effects of cooking methods on the proximate composition and mineral contents of rainbowtrout (Oncorhynchus mykiss)*. Food Chemistry, 2004. 84(1): 19-22.
- 1011 KHACHIK, F. et al. *Effect of food preparation on qualitative and quantitative distribution of major carotenoid constituents of tomatoes and several green vegetables*. J Agric Food Chem, 1992. 40(3): 390-398.
- 1012 DEWANTO, V.; WU, X.; ADOM, K. K.; LIU, R. H. *Thermal processing enhances the nutritional value of tomatoes by increasing total antioxidant activity*. J Agric Food Chem, 8 mai. 2002. 50(10): 3.010-3.014.
- 1013 FEDELI, E. *Physical-chemical aspects of the frying process*. Grasas y Aceites, 1998. 49(3-4): 261-264.
- 1014 SCHATTEBERG 3rd, H. J.; GENO, P. W.; HSU, J. P.; FRY, W. G.; PARKER, R. P. *Effect of household preparation on levels of pesticide residues in produce*. JAOAC Int, nov-dez. 1996. 79(6): 1.447-1.453.
- 1015 BOGNAR, A. *Comparative study of frying to other cooking techniques influence on the nutritive value*. Grasas y Aceites, 1998. 49(3-4): 250-260.
- 1016 BEIN, K.; LEIKAUF, G. D. *Acrolein – a pulmonary hazard*. Mol Nutr Food Res, set. 2011. 55(9): 1.342-1.360.
- 1017 ANDERSON, K. E. et al. *Pancreatic cancer risk: Associations with meat-derived carcinogen intake in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort*. Mol Carcinog, jan. 2012. 5(1): 128-123.
- 1018 CUESTA, C.; SÁNCHEZ, F. J. *Quality control during repeated fryings*. Grasas y aceites. 1998. 49(3-4): 310-318.

- 1019 RODRIGUEZ-ESTRADA, M. T.; PENAZZI, G.; CABONI, M. F.; BERTACCO, G.; LERCKER, G. *Effect of different cooking methods on some lipid and protein components of hamburgers*. Meat Sci, mar. 1997. 45(3): 365-375.
- 1020 STOTT-MILLER, M.; NEUHOUSER, M. L.; STANFORD, J. L. *Consumption of deep-fried foods and risk of prostate cancer*. Prostate, 17 jan. 2013.
- 1021 KOMETANI, T. et al. *Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway*. Cancer Lett, 8 jun. 2009. 278(1): 27-33.
- 1022 PFAU, W. et al. *Heterocyclic amines: human carcinogens in cooked food?* Nutr Metab Cardiovasc Dis, ago. 2001. 11(4 Supl): 82-86.
- 1023 KNIZE, M. G.; DOLBEARE, F. A.; CARROLL, K. L.; MOORE 2nd, D. H.; FELTON, J. S. *Effect of cooking time and temperature on the heterocyclic amine content of fried beef patties*. Food Chem Toxicol, jul. 1994. 32(7): 595-603.
- 1024 KOUTROS, S. et al. *Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer*. Cancer Res, 1^a mar. 2009. 69(5): 1.877-1.884.
- 1025 DANIEL, C. R. et al. *Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma*. Am J Clin Nutr, jan. 2012. 95(1): 155-162.
- 1026 KAZEROUNI, N.; SINHA, R.; HSU, C. H.; GREENBERG, A.; ROTHMAN, N. *Analysis of 200 food items for benzo[a]pyrene and estimation of its intake in an epidemiologic study*. Food Chem Toxicol, mai. 2001. 39(5): 423-436.
- 1027 NATELLA, F.; BELELLI, F.; RAMBERTI, A.; CACCINI, C. *Microwave and traditional cooking methods: effect of cooking on antioxidant capacity and phenolic compounds content of seven vegetables*. J Food Bioch, 2010. 34(4): 796-810.
- 1028 VALLEJO, F.; TOMÁS-BARBERÁN, F.; GARCÍA-VIGUERA, C. *Glucosinolates and vitamin C content in edible parts of broccoli florets after domestic cooking*. Eur Food Res Technol, 2002. 215(4): 310-316.
- 1029 LEE, H.; WANG, Q.; YANG, F.; TAO, P.; LI, H.; HUANG, Y.; LI, J. Y. *SULT1A1 Arg213His polymorphism, smoked meat, and breast cancer risk: A case-control study and meta-analysis*. DNA Cell Biol, mai. 2012. 31(5): 688-699.
- 1030 GOMAA, E. A.; GRAY, J. I.; RABIE, S.; LOPEZ-BOTE, C.; BOOREN, A. M. *Polycyclic aromatic hydrocarbons in smoked food products and commercial liquid smoke flavourings*. Food Addit Contam, set-out. 1993. 10(5): 503-521.
- 1031 KUBO, A.; CORLEY, D. A.; JENSEN, C. D.; KAUR, R. *Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus*. Nutr Res Rev, dez. 2010. 23(2): 230-246.
- 1032 LAZAREVIC, K.; NAGORNI, A.; RANCIC, N. S. *Milutinovic dietary factors and gastric cancer risk: hospital-based case control study*. J BUON, jan-mar. 2010. 15(1): 89-93.
- 1033 DOST, K.; IDELI, C. *Determination of polycyclic aromatic hydrocarbons in edible oils and barbecued food by HPLC/UV-Vis detection*. Food Chem, 1^a jul. 2012. 133(1): 193-199.
- 1034 QIU, J. X. et al. *Influence of medicinal herbs decocted with different utensils on colony formation of gastric carcinoma cells*. J Tradit Chin Med, jun. 1989. 9(2): 125-127.
- 1035 KLAUNIG, J. E.; HOCEVAR, B. A.; KAMENDULIS, L. M. *Mode of action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and human relevance*. Reprod Toxicol, jul. 2012. 33(4): 410-418.
- 1036 "Le teflón: un nouveau scandale sanitaire?" L'Ecologiste, set-out-nov. 2005. 16.

- 1037 HU, X. Z.; HU, D. C. *Effects of perfluorooctanoate and perfluorooctane sulfonate exposure on hepatoma Hep G2 cells*. Arch Toxicol, set. 2009. 83(9): 851-861.
- 1038 TILTON, S. C. et al. *Genomic profiling reveals an alternate mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow trout*. Environ Health Perspec, ago. 2008. 116(8): 1.047-1.055.
- 1039 WEBER LOZADA, K.; KERI, R. A. *Bisphenol A increases mammary cancer risk in two distinct mouse models of breast cancer*. Biol Reprod, set. 2011. 85(3): 490-497.
- 1040 WELSHONS, W.; NAGEL, S. C.; VOM SAAL, F. S. *Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure*. Endocrinology, Jun. 2006, 147(6 Supl): S56-69.
- 1041 MEEKS, J. J.; SHEINFELD, J.; EGGENER, S. E. *Environmental toxicology of testicular cancer*. Urol Oncol, mar. 2012. 30(2): 212-215.
- 1042 PARK, M. A. et al. *Cell growth of BG-1 ovarian cancer cells is promoted by di-nbutyl phthalate and hexabromocyclododecane via upregulation of the cyclin D and cyclin-dependent kinase-4 genes*. Mol Med Report, mar. 2012. 5(3): 761-766.
- 1043 HSIEH, T. H. et al. *Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway*. FASEB J, fev. 2012. 26(2): 778-787.
- 1044 HEILBRONN, L. K.; RAVUSSIN, E. *Calorie restriction and aging: review of the literature and implications for studies in humans*. Am J Clin Nutr, set. 2003. 78(3): 361-369.
- 1045 SUZUKI, M.; WILCOX, B. J.; WILCOX, C. D. *Implications from and for food cultures for cardiovascular disease: longevity*. Asia Pac J Clin Nutr, 2001. 10(2): 165-171.
- 1046 WILLCOX, D. C. et al. *Caloric restriction and human longevity: what can we learn from the Okinawans?* Biogerontology, jun. 2006. 7(3): 173-177.
- 1047 BERNSTEIN, A. M. et al. *First autopsy study of an Okinawan centenarian: absence of many age-related diseases*. J Gerontol A Biol Sci Med Sci, nov. 2004. 59(11): 1.195-1.199.
- 1048 ROSS, P. D. et al. *A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians*. Am J Epidemiol, 15 abr. 1991. 133(8): 801-809.
- 1049 ALBERTAZZI, P. et al. *The effect of dietary soy supplementation on hot flushes*. Obstet Gynecol, 1998. 91: 6-11.
- 1050 ATKINSON, C. et al. *The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial*. Am J Clin Nutr, fev. 2004. 79(2): 326-333.
- 1051 La VECCHIA, C. *Mediterranean diet and cancer*. Public Health Nutr, out. 2004. 7(7): 965-968.
- 1052 MISIRLI, G.; BENETOU, V.; LAGIOU, P.; BAMIA, C.; TRICHOPOULOS, D.; TRICHOPOULOU, A. *Relation of the traditional Mediterranean diet to cerebrovascular disease in a Mediterranean population*. Am J Epidemiol, 15 dez. 2012. 176(12): 1.185-1.192.
- 1053 SOFI, F.; CESARI, F.; ABBATE, R.; GENSINI, G. F.; CASINI, A. *Adherence to Mediterranean diet and health status:meta-analysis*. BMJ, 11 set. 2008. 337: a1344.
- 1054 TRICHOPOULOU, A.; BAMIA, C.; LAGIOU, P.; TRICHOPOULOS, D. *Conformity to traditional Mediterranean diet and breast cancer risk in the Greek EPIC (European prospective investigation into cancer and nutrition) cohort*. Am J Clin Nutr, set. 2010. 92(3): 620-625.
- 1055 SÁNCHEZ VILLEGAS, A.; MARTÍNEZ GONZÁLEZ, M.; MARTÍNEZ, J. A. *Mediterranean diet and cancer: epidemiological evidences*. Alim Nutri Salud, 2003. 10(1):1-9.

- 1056 LANOU, A. J.; SVENSON, B. *Reduced cancer risk in vegetarians: an analysis of recent reports*. Cancer Manag Res, 20 dez. 2010. 3: 1-8.
- 1057 KEY, T. et al. *Diet, nutrition and the prevention of cancer*. Public Health Nutrition, 2004. 7(1A): 187-200.
- 1058 EISELE, J. W.; REAY, D. T. *Deaths related to coffee enemas*. JAMA, 1980. 244(14): 1.608-1.609.
- 1059 CASSILETH, B. *Gerson regimen*. Oncology (Williston Park), fev. 2010. 24(2): 201.
- 1060 LECHNER, P.; KRONEBERGER, L. *Experiences with the use of diet therapy in surgical oncology*. Aktuel Ernährungsmed, 1990. (15): 72-78.
- 1061 MOLASSIOTIS, A.; PEAT, P. *Surviving against all odds: analysis of 6 case studies of patients with cancer who followed the Gerson therapy*. Integr Cancer Ther, 2007. 6(1): 80-88.
- 1062 HILDENBRAND, G. L. et al. *Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review*. Altern Ther Health Med, 1997. 1(4): 29-37.
- 1063 KUSH, L. H. et al. *The macrobiotic diet in cancer*. J Nutr, nov. 2001. 131(Supl. 11): 3.056S-3.064S.
- 1064 Lerman, R. H. *The macrobiotic diet in chronic disease*. Nutr Clin Pract, dez. 2010. 25(6): 621-6.
- 1065 CARRERA-BASTOS, P. et al. *The western diet and lifestyle and diseases of civilization*. RRCC, 2011. 2: 15-35.
- 1066 BELL, S. J.; GROCHOSKI, G. T.; CLARKE, A. J. *Health implications of milks containing beta-casein with the A2 genetic variant*. Crit Rev Food Sci Nutr, 2006. 46(1): 93-100.
- 1067 CORDAIN, L. *Cereal grains: humanity's double-edged sword*. World Rev Nutr Diet, 1999. 84: 19-73.
- 1068 CORDAIN, L.; TOOHEY, L.; SMITH, M. J.; HICKEY, M. S. *Modulation of immune function by dietary lectins in rheumatoid arthritis*. Br J Nutr, 2000. 83(3): 207-217.
- 1069 LINDEBERG, S. *Food and Western Disease: Health and nutrition from an evolutionary perspective*. 1ª ed. West Sussex: Wiley-Blackwell, 2010.
- 1070 HADJIVASSILIOU, M.; SANDERS, D. S.; GRUNEWALD, R. A. *Multiple sclerosis and occult gluten sensitivity*. Neurology, 2005. 64(5): 933-934.
- 1071 ELKAN, A. C. et al. *Gluten-free vegandiet induces decreased LDL and oxidized LDL levels and raised athero protective natural antibodies against phosphoryl choline in patients with rheumatoid arthritis: a randomized study*. Arthritis Res Ther, 2008. 10(2): R34.
- 1072 CH'NG, C. L.; JONES, M. K.; KINGHAM, J. G. C. *Celiac disease and autoimmune thyroid disease*. Clin Med Res, 2007. 5(3): 184-192.
- 1073 RUUSKANEN, A. et al. *Positive serum antigliadin antibodies without celiac disease in the elderly population: does it matter?* Scand J Gastroenterol, 2010. 45(10): 1.197-1.202.
- 1074 BIESIEKIERSKI, J. R. et al. *Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial*. Am J Gastroenterol, 2011. 106(3): 508-514; quiz 515.
- 1075 FUKUDOME, S.; SHIMATSU, A.; SUGANUMA, H.; YOSHIKAWA, M. *Effect of gluten exorphins A5 and B5 on the postprandial plasma insulin level in conscious rats*. Life Sci, 1995. 57(7): 729-734.
- 1076 CORDAIN, L. et al. *Origins and evolution of the Western diet: health implications for the 21st century*. Am J Clin Nutr, 2005. 8(2): 341-354.

- 1077 LUXWOLDA, M. F.; KUIPERS, R. S.; KEMA, I. P.; DIJCK-BROUWER, D. A.; MUSKIET, F. A. *Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l.* Br J Nutr, 14 nov. 2012. 108 (9): 1.557-1.561.
- 1078 LINDEBERG, S. et al. *A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease.* Diabetologia, 2007. 50(9): 1.795-1.807.
- 1079 BARNES, P. M.; BLOOM, B.; NAHIN, R. L. *Complementary and alternative medicine use among adults and children: United States, 2007.* Natl Health Stat Report, 10 dez. 2008. (12): 1-23.
- 1080 GANSLER, T. et al. *A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society's studies of cancer survivors.* Cancer, 2008. 113(5): 1.048-1.057.
- 1081 CHANG, K. H.; BRODIE, R.; CHOONG, M. A.; SWEENEY, K. J.; KERIN, M. J. *Complementary and alternative medicine use in oncology: A questionnaire survey of patients and health care professionals.* BMC Canc, 24 mai. 2011. 11: 196.
- 1082 TAUTZ, E.; MOMM, F.; HASENBURG, A.; GUETHLIN, C. *Use of complementary and alternative medicine in breast cancer patients and their experiences: A cross-sectional study.* Eur J Cancer, nov. 2012. 48(17): 3.133-3.139.
- 1083 SHELLEY, B. M. et al. *They don't ask me so I don't tell them': patient-clinician communication about traditional, complementary, and alternative medicine.* Ann Fam Med, mar-abr. 2009. 7(2): 139-147.
- 1084 KARALI, Y.; DEMIRKAYA, M.; SEVINIR, B. *Use of complementary and alternative medicine in children with cancer: effect on survival.* Pediatr Hematol Oncol, mai. 2012. 29(4): 335-344.
- 1085 TASAKI, K. et al. *Communication between physicians and cancer patients about complementary and alternative medicine: exploring patients' perspectives.* Psychooncology, mai-jun. 2002. 11(3): 212-220.
- 1086 LIU, J.; YU, R. C.; RAO, X. Q. *Study on effect of moxibustion and Guben Yiliu ¥2 combined with chemotherapy in treating middle-late stage malignant tumor.* Chin J Integ Med, 2001. 21: 262-264.
- 1087 CHEN, K. et al. *Clinical study on treatment of nasopharyngeal carcinoma by radio and chemotherapy with supplementary moxibustion on Shenque point.* Chin J Integ Med, 2000. 20: 733-735.
- 1088 CHENG, Z.; JIANG.; CHEN, K. *Radiochemical and chemotherapy therapy with Shenque Point moxibustion treatment of 42 cases of advanced nasopharyngeal carcinoma.* New J Tradit Chin Med, 2005. 37: 58-5.
- 1089 KUAI, L.; CHEN, H.; YANG, H. Y. *Current status and prospect of acupuncture-moxibustion in treatment of cancer pain: a review.* Zhong Xi Yi Jie He Xue Bao, fev. 2008. 6(2): 197-202.
- 1090 ZHANG, J. L. et al. *Research of moxibustion therapy for cancer: a review.* Jiangxi J Tradit Chin Med, 2008. 39: 59-61.
- 1091 BIAN, D. et al. *Effects of acupoint-injection plus moxibustion on IL-2/IL-2R expression in peripheral blood in the patient with carcinous pain.* Chin Acupunct Moxibustion, 2004. 24: 641-644.
- 1092 HUI, K. K. et al. *Acupuncture modulates the limbic system and subcortical gray structures of the human brain: evidence from fMRI studies in normal subjects.* Hum Brain Mapp, 2000. 9: 13-925.

- 1093 YAMAGUCHI, N. et al. *Acupuncture regulates leukocyte subpopulations in human peripheral blood*. Evid Based Complement Alternat Med, dez. 2007. 4(4): 447-453.
- 1094 QIU, X. et al. *Effects of moxibustion at shenque (CV 8) on serum IL-12 level and NK cell activities in mice with transplanted tumor*. J Tradit Chin Med, 2004. 24: 56-58.
- 1095 ZHANG, S. Y.; DU, Y. Q. *Effects of warming needle moxibustion on improvement of gastrointestinal and immune function in patients with postoperation of colorectal cancer*. Zhongguo Zhen Jiu, jun. 2011. 31(6): 513-517.
- 1096 PEI, J. et al. *Effects of moxibustion on the expression of IL-1beta, IL-2, IL-6 mRNA and protein in the cerebral cortex in tumor-bearing mice*. Zhen Ci Yan Jiu, ago. 2010. 35(4): 243-249.
- 1097 PEI, J. *Effect of moxibustion of dazhui (GV-14) on cellular immune function in tumor-bearing mice*. Int J Orient Med, 1995. 20: 72-76.
- 1098 DE VALOIS, B.; JACKSON, L. *Acupuncture and moxibustion in improving well-being and quality of life in patients with breast cancer or head, neck, and throat cancer who are undergoing standard treatment for lymphedema*. Study ID: CDR0000632850. NHS.
- 1099 DE VALOIS, B. A.; YOUNG, T. E.; MELSOME, E. *Assessing the feasibility of using acupuncture and moxibustion to improve quality of life for cancer survivors with upper body lymphoedema*. Eur J Oncol Nurs, jul. 2012. 16(3): 301-309.
- 1100 CHOI, G. S. et al. *Effects of moxibustion to zusanli (ST36) on alteration of natural killer cell activity in rats*. Am J Chin Med, 2004. 32(2): 303-312.
- 1101 SHEN, Y.; GODDARD, G. *The short-term effects of acupuncture on myofascial pain patients after clenching*. Pain Pract, set. 2007. 7(3): 256-264.
- 1102 LINDE, K. et al. *Acupuncture for tension-type headache*. Cochrane Database of Systematic Reviews, 2009. 1, Article ID CD007587.
- 1103 LINDE K. et al. *Acupuncture for migraine prophylaxis*. Cochrane Database of Systematic Reviews, 2009. 1, Article ID CD001218.
- 1104 EZZO, J. M. et al. *Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting*. Cochrane Database of Systematic Reviews, 2006. 2. Article ID CD002285.
- 1105 ZHENG, L. et al. *Effect of preventive moxibustion on heat shock proteins and stress hormones in natural menopausal rats*. Zhongguo Zhen Jiu, fev. 2010. 30(2): 135-139.
- 1106 JOHNSTON, M. et al. *Acupuncture may stimulate anticancer immunity via activation of natural killer cells*. Evid Based Complement Alternat Med, 2011. 2011: 481-625.
- 1107 LIU, L. J.; GUO, C. J.; JIAO, X. M. *Effect of acupuncture on immunologic function and histopathology of transplanted mammary cancer in mice*. Zhongguo Zhong Xi Yi Jie He Za Zhi, out. 1995. 15(10): 615-617.
- 1108 ZHAO, C. L. et al. *Effect of acupuncture on the activity of the peripheral blood T lymphocyte subsets and NK cells in patients with colorectal cancer liver metastasis*. Zhongguo Zhen Jiu, jan. 2010. 30(1): 10-12.
- 1109 ARRANZ, L.; GUAYERBAS, N.; SIBONI, L.; DE LA FUENTE, M. *Effect of acupuncture treatment on the immune function impairment found in anxious women*. Am J Chin Med, 2007. 35(1): 35-51.
- 1110 DENG, G. et al. *Acupuncture: integration into cancer care*. J Soc Integr Oncol, primavera de 2006. 4(2): 86-92.
- 1111 ZHANG, Z. et al. *The effects of electroacupuncture at the ST36 (Zusanli) acupoint on cancer pain and transient receptor potential vanilloid subfamily 1 expression in walker 256 tumor-bearing rats*. Anesth Analg, abr. 2012. 114(4): 879-885.

- 1112 Xi-PING, Li. et al. *Effect of electroacupuncture on gastric mucosal intestinal trefoil factor gene expression of stress-induced gastric mucosal injury in rats*. World J Gastroenterol, 28 mar. 2006. 12(12): 1.962-1.965.
- 1113 BIROCCO, N. et al. *The effects of reiki therapy on pain and anxiety in patients attending a day oncology and infusion services unit*. Am J Hosp Palliat Care, jun. 2012. 29(4): 290-294.
- 1114 COAKLEY, A. B.; BARRON, A. M. *Energy therapies in oncology nursing*. Semin Oncol Nurs, fev. 2012. 28(1): 55-63.
- 1115 VITALE, A. T.; O'CONNOR, P. C. *The effect of reiki on pain and anxiety in women with abdominal hysterectomies: a quasi-experimental pilot study*. Holist Nurs Prac, 2006. 20: 263-272.
- 1116 OLSON, K.; HANSON, J.; MICHAUD, M. *Other complementary therapies, reiki effects on pain and quality of life in advanced cancer patients*. J Pain Symptom Manag, 2003. 26: 990-997.
- 1117 HART, L. K.; FREEL, M. I.; HAYLOCK, P. J.; LUTGENDORF, S. K. *The use of healing touch in integrative oncology*. Clin J Oncol Nurs, out. 2011. 15(5): 519-525.
- 1118 ROGERS, M. E. *An introduction to the theoretical basis of nursing*. Filadélfia: Davis, 1970.
- 1119 WINSTED-FRY, P.; KIJEK, J. *An integrative review and metaanalysis of therapeutic touch research*. Altern Ther Health Med, 1999. 5: 58-67.
- 1120 SAMAREL, N. et al. *Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an explorative study*. Oncol Nurs Forum, 1998. 25: 1.369-1.376.
- 1121 AGHABATI, N.; MOHAMMADI, E.; ESMAIEL, Z. P. *The effect of therapeutic touch on pain and fatigue of cancer patients undergoing chemotherapy*. Evid Based Complement Alternat Med, 2010. 7: 375-381.
- 1122 KRIEGER, D.; PEPPER, E.; ANCOLI, S. *Therapeutic touch: searching for evidence of physiological change*. Am J Nurs, 1979. 79: 660-662.
- 1123 FIELD, T. et al. *Cortisol decreases and serotonin and dopamine increase following massage therapy*. Int J Neurosci, out. 2005. 115(10): 1.397-1.413.
- 1124 HERNANDEZ-REIF, et al. *Breast cancer patients have improved immune and neuroendocrine functions following massage therapy*. J Psychosom Res, jul. 2004. 57(1): 45-52.
- 1125 KLEIN, J.; GRIFFITHS, P. *Acupressure for nausea and vomiting in cancer patients receiving chemotherapy*. Br J Community Nurs, set. 2004. 9(9): 383-388.
- 1126 ZICK, S. M. et al. *Relaxation acupressure reduces persistent cancer-related fatigue*. Evid Based Complement Alternat Med, 2011. Article ID 142913.
- 1127 SEGAL, M. *Reflexology*. Hollywood: Wilshire Book Company, 1979.
- 1128 KIM, J. I.; LEE, M. S.; KANG, J. W.; CHOI DO, Y.; ERNST, E. *Reflexology for the symptomatic treatment of breast cancer: a systematic review*. Integr Cancer Ther, dez. 2010. 9(4): 326-330.
- 1129 YANG, J. H. *The effects of foot reflexology on nausea, vomiting and fatigue of breast cancer patients undergoing chemotherapy*. Taehan Kanho Hakhoe Chi, fev. 2005. 35(1): 177-185.
- 1130 STEPHENSON, N. L.; WEINRICH, S. P.; TAVAKOLI, A. S. *The effects of foot reflexology on anxiety and pain in patients with breast and lung cancer*. Oncol Nurs Forum, jan-fev. 2000. 27(1): 67-72.
- 1131 STEPHENSON, N. L. et al. *Partner-delivered reflexology: effects on cancer pain and anxiety*. Oncol Nurs Forum, jan. 2007. 34(1): 127-132.

- 1132 RAMAKRISHNAN, G. et al. *Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells*. Cell Prolif, abr. 2009. 42(2): 229-240.
- 1133 FÉHER, J.; LENGYEL, G. *Silymarin in the prevention and treatment of liver diseases and primary liver cancer*. Curr Pharm Biotechnol, jan. 2012. 13(1): 210-217.
- 1134 LI, W. et al. *Molecular mechanism of silymarin-induced apoptosis in a highly metastatic lung cancer cell line anip973*. Cancer Biother Radiopharm, jun. 2011. 26(3): 317-324.
- 1135 ZENG, J. et al. *Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria*. Mol Cancer Ther, jan. 2011. 10(1): 104-116.
- 1136 VAID, M.; PRASAD, R.; SUN, Q.; KATTIYAR, S. K. *Silymarin targets β -catenin signaling in blocking migration/invasion of human melanoma cells*. PLoS One, 2011. 6(7): e23000.
- 1137 YU, H. C. et al. *Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog*. Phytother Res, mai. 2012. 26(5): 709-715.
- 1138 CHTOUROU, Y. et al. *Manganese induces oxidative stress, redox state unbalance and disrupts membrane bound ATPases on murine neuroblastoma cells in vitro: protective role of silymarin*. Neurochem Res, ago. 2011. 36(8): 1.546-1.557.
- 1139 TOYODA-HOKAIWADO, N. et al. *Chemopreventive effects of silymarin against 1,2-dimethylhydrazine plus dextran sodium sulfate-induced inflammation-associated carcinogenicity and genotoxicity in the colon of gpt delta rats*. Carcinogenesis, out. 2011. 32(10): 1.512-1.517.
- 1140 AGARWAL, R.; AGARWAL, C.; ICHIKAWA, H.; SINGH, R. P.; AGGARWAL, B. B. *Anticancer potential of silymarin: from bench to bed side*. Anticancer Res, 2006. 26: 4.457-4.498.
- 1141 CECEN, E. et al. *Protective effects of silymarin against doxorubicin-induced toxicity*. Asian Pac J Cancer Prev, 2011. 12(10): 2.697-2.704.
- 1142 TYAGI, A. K.; AGARWAL, C.; CHAN, D. C.; AGARWAL, R. *Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells*. Oncol Rep, fev. 2004. 11(2): 493-499.
- 1143 CHANG, H. R. et al. *Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel*. Mol Carcinog, out. 2011. 50(10): 811-823.
- 1144 NAG, S. A. et al. *Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action*. Front Pharmacol, 2012. 3: 25.
- 1145 SUH, S. O. et al. *Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer*. Am J Chin Med, 2002. 30(4): 483-494.
- 1146 YUN, T. K.; CHOI, S. Y. *A case-control study of ginseng intake and cancer*. Int J Epidemiol, dez. 1990. 19(4): 871-876.
- 1147 YUN, T. K.; CHOI, S. Y.; YUN, H. Y. *Epidemiological study on cancer prevention by ginseng: are all kinds of cancers preventable by ginseng?* J Korean Med Sci, dez. 2001. 16 Supl: S19-27.
- 1148 SUPRATMAN, U. et al. *Anti-tumor promoting activity of bufadienolides from Kalanchoe pinnata and K. daigremontiana x tubiflora*. Biosci Biotechnol Biochem, abr. 2001. 65(4): 947-949.
- 1149 WU, P. L. et al. *Kalanchosides A-C, new cytotoxic bufadienolides from the aerial parts of Kalanchoe gracilis*. Org Lett, 9 nov. 2006. 8(23): 5.207-5.210.

- 1150 LAI, Z. R. et al. *Antioxidant, anti-inflammatory and antiproliferative activities of Kalanchoe gracilis (L.) DC stem*. Am J Chin Med, 2011. 39(6): 1.275-1.290.
- 1151 GÁLVEZ, M. et al. *Cytotoxic effect of Plantago. spp. on cancer cell lines*. J Ethnopharmacol, out. 2003. 88(2-3): 125-130.
- 1152 CHIANG, L. C.; CHIANG, W.; CHANG, M. Y.; LIN, C. C. *In vitro cytotoxic, antiviral and immunomodulatory effects of Plantago major and Plantago asiatica*. Am J Chin Med, 2003. 31(2): 225-234.
- 1153 OSTERMANN, T.; RAAK, C.; BÜSSING, A. *Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review*. BMC Cancer, 18 dez. 2009. 9: 451.
- 1154 GROSSARTH-MATICEK, R.; KIENE, H.; BAUMGARTNER, S. M.; ZIEGLER, R. *Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study*. Altern Ther Health Med, mai-jun. 2001. 7(3): 57-66, 68-72, 74-76 passim.
- 1155 HORNEBER, M. A. et al. "Tratamiento con muérdago en oncología" (Revisão Cochrane traduzida). In: *La Biblioteca Cochrane Plus*, 2008. 3.
- 1156 CEBOVIĆ, T.; SPASIĆ, S.; POPOVIĆ, M. *Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo*. Phytother Res, ago. 2008. 22(8): 1.097-1.103.
- 1157 Yu, H. C. et al. *Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog*. Phytother Res, mai. 2012. 26(5): 709-715.
- 1158 BÜSSING, A. et al. *In vitro response of stimulated B-CLL lymphocytes of patients treated with Viscum album L. extracts*. Anticancer Res, nov-dez. 2007. 27(6B): 4.195-4.200.
- 1159 KUEHN, J. J. *Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non-Hodgkin lymphoma*. Dtsch Med Wochenschr, 26 nov. 1999. 124(47): 1.414-1.418.
- 1160 GONZALES, G. F.; VALERIO JR., L. G. *Medicinal plants from Peru: a review of plants as potential agents against cancer*. Anticancer Agents Med Chem, Set. 2006. 6(5): 429-444.
- 1161 PILARSKI, R. et al. *Anticancer activity of the Uncaria tomentosa (Willd.) DC. preparations with different oxindole alkaloid composition*. Phytomedicine, 1º dez. 2010. 17(14): 1.133-1.139.
- 1162 García PRADO, E. et al. *Antiproliferative effects of mitraphylline, a pentacyclic oxindole alkaloid of Uncaria tomentosa on human glioma and neuroblastoma cell lines*. Phytomedicine, abr. 2007. 14(4): 280-284.
- 1163 DREIFUSS, A. A. et al. *Antitumoral and antioxidant effects of a hydroalcoholic extract of cat's claw (Uncaria tomentosa) (Willd. Ex Roem. & Schult) in an in vivo carcinosarcoma model*. J Ethnopharmacol, 6 jul. 2010. 130(1): 127-133.
- 1164 ALLEN-HALL, L.; ARNASON, J. T.; CANO, P.; LAFRENIE, R. M. *Uncaria tomentosa acts as a potent TNF-alpha inhibitor through NF-kappa beta*. J Ethnopharmacol, 17 fev. 2010. 127(3): 685-693.
- 1165 FARIAS, I. L. et al. *Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial*. Evid Based Complement Alternat Med, 2012. 2012: 892.182.
- 1166 ULBRICHT, C. et al. *Essiac: systematic review by the natural standard research collaboration*. J Soc Integr Oncol, primavera de 2009. 7(2): 73-80.
- 1167 EBERDING, A. et al. *Evaluation of the antiproliferative effects of Essiac on in vitro and in vivo models of prostate cancer compared to paclitaxel*. Nutr Cancer, 2007. 58(2): 188-196.
- 1168 ZICK, S. M. et al. *Trial of Essiac to ascertain its effect in women with breast cancer (TEA-BC)*. J Altern Complement Med, dez. 2006. 12(10): 971-980.

- 1169 CHEN, C. H. et al. *Aristolochic acid-associated urothelial cancer in Taiwan*. Proc Natl Acad Sci EUA, 22 mai. 2012. 109(21): 8.241-8.246.
- 1170 ANTONI, M. H. et al. *The influence of bio-behavioural factors on tumour biology: pathways and mechanisms*. Nat Rev Cancer, mar. 2006. 6(3): 240-248.
- 1171 DHABHAR, F. S. et al. *High-anxious individuals show increased chronic stress burden, decreased protective immunity, and increased cancer progression in a mouse model of squamous cell carcinoma*. PLoS One, 2012. 7(4): e33069.
- 1172 HAMER, M.; CHIDA, Y.; MOLLOY, G. J. *Psychological distress and cancer mortality*. J Psychosom Res, mar. 2009. 66(3): 255-258.
- 1173 VISINTAINER, M. A.; Volpicelli, J. R.; Seligman, M. E. *Tumor rejection in rats after inescapable or escapable shock*. Science, 23 abr. 1982. 216(4.544): 437-439.
- 1174 THAYER, J. F.; STERNBERG, E. *Beyond heart rate variability: vagal regulation of allostatic systems*. Ann N Y Acad Sci, nov. 2006. 1.088: 361-372.
- 1175 FANG, CY. et al. *Enhanced psychosocial well-being following participation in a mindfulness-based stress reduction program is associated with increased natural killer cell activity*. J Altern Complement Med, mai. 2010. 16(5): 531-538.
- 1176 MASSION, A. et al. *Meditation, melatonin and breast/prostate cancer: Hypothesis and preliminary data*. Medical Hypotheses, 1995. 44(1): 39-46.
- 1177 VUJANOVIC, N. L.; BASSE, P.; HERBERMAN, R. B.; WHITESIDE, T. L. *Antitumor functions of natural killer cells and control of metastases*. Methods, abr. 1996. 9(2): 394-408.
- 1178 NARITA, M.; TSENG, L. *Evidence for the existence of the β -endorphin-sensitive "ε-opioid receptor" in the brain: the mechanisms of ε-mediated antinociception*. Jpn J Pharmacol, mar. 1998. 76(3): 233-253.
- 1179 WAKAO, K. et al. *Involvement of granzyme B expression in the enhancement of natural killer activity by β-endorphin*. Brain Behav Immun, mar. 2000. 14(1): 27-40.
- 1180 SARKAR, D. et al. *Cyclic adenosine monophosphate differentiated β-endorphin neurons promote immune function and prevent prostate cancer growth*. Proc Natl Acad Sci EUA, 1^o jul. 2008. 105(26): 9.105-9.110.
- 1181 SLAGTER, H. A.; DAVIDSON, R. J.; LUTZ, A. *Mental training as a tool in the neuroscientific study of brain and cognitive plasticity*. Front Hum Neurosci, 10 fev. 2011. 5: 17.
- 1182 SPIEGEL, D.; BLOOM, J. R.; KRAEMER, H. C.; GOTTHEIL, E. *Effect of psychosocial treatment on survival of patients with metastatic breast cancer*. Lancet, 14 out. 1989. 2(8.668): 888-891.
- 1183 BOURRE, J. M. et al. *Function of dietary polyunsaturated fatty acids in the nervous system*. Prostaglandins Leukot Essent Fatty Acids, Jan. 1993. 48(1):5-15.
- 1184 PEET, M.; MURPHY, B.; SHAY, J.; HORROBIN, D. *Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients*. Biol Psychiatry, 1^o mar. 1998. 43(5): 315-319.
- 1185 EDWARDS, R.; PEET, M.; SHAY, J.; HORROBIN, D. *Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients*. J Affect Disord, mar. 1998. 48(2-3): 149-155.
- 1186 WEISSMAN, M. M. et al. *Cross-national epidemiology of major depression and bipolar disorder*. JAMA, 24-31 jul. 1996. 276(4): 293-299.
- 1187 GINTER, E.; SIMKO, V. *Polyunsaturated fatty acids n-3: new data on heart disease, cancer, immune resistance and mental depression*. Bratisl Lek Listy, 2010. 111(12): 680-685.

- 1188 JONSDOTTIR, I. H.; HOFFMANN, P.; THORÉN, P. *Physical exercise, endogenous opioids and immune function*. Acta Physiol Scand Suppl, 1997. 640: 47-50.
- 1189 DISTASIO, S. A. *Integrating ioga into cancer care*. Clin J Oncol Nurs, fev. 2008. 12(1): 125-130.
- 1190 SPEED-ANDREWS, A. E. et al. *Pilot evaluation of an Iyengar ioga program for breast cancer survivors*. Cancer Nurs, set-out. 2010. 33(5): 369-381.
- 1191 MUSTIAN, K. M. et al. *Effect of YOCAS ioga on sleep, fatigue, and quality of life: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors*. J Clin Oncol, 2010. 28: 15s (supl.; resumo 9013).
- 1192 BRUDNOWSKA, J.; PEPLONSKA, B. *Night shift work and cancer risk: a literature review*. Med Pr, 2011. 62(3): 323-338.
- 1193 THOMPSON, C. L. et al. *Short duration of sleep increases risk of colorectal adenoma*. Cancer, 15 fev. 2011. 117(4): 841-847.
- 1194 KRIPKE, D. F.; LANGER, R. D.; KLINE, L. E. *Hypnotics' association with mortality or cancer: a matched cohort study*. BMJ Open, 27 fev. 2012. 2(1): e000850.
- 1195 CUTANDO, A. et al. *Role of melatonin in cancer treatment*. Anticancer Res, Jul. 2012. 32(7): 2.747-2.753.
- 1196 SÁNCHEZ-HIDALGO, M.; GUERRERO, J. M.; VILLEGAS, I.; PACKHAM, G.; DE LA LASTRA, C. A. *Melatonin, a natural programmed cell death inducer in cancer*. Curr Med Chem, 2012. 19(22): 3.805-3.821.
- 1197 DUMONT, M.; LANCTÔT, V.; CADIEUX-VIAU, R.; PAQUET, J. *Melatonin production and light exposure of rotating night workers*. Chronobiol Int, mar. 2012. 29(2): 203-210.
- 1198 BLASK, D. E. *Melatonin, sleep disturbance and cancer risk*. Sleep Med Rev, ago. 2009. 13(4): 257-264.
- 1199 SIGURDARDOTTIR, L. G. et al. *Circadian disruption, sleep loss and prostate cancer risk: A systematic review of epidemiological studies*. Cancer Epidemiol Biomarkers Prev, jul. 2012. 21(7): 1.002-1.011.
- 1200 MEYERHARDT, J. A. et al. *Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer*. JAMA, 15 ago. 2007. 298(7): 754-764.
- 1201 VRIELING, A. et al. *Dietary patterns and survival in German postmenopausal breast cancer survivors*. Br J Cancer, 15 jan. 2013. 108(1): 188-192.
- 1202 ROCK, C. L.; DEMARK-WAHNEFRIED, W. *Nutrition and survival after the diagnosis of breast cancer: a review of the evidence*. J Clin Oncol, 1º ago. 2002. 20(15): 3.302-3.316.
- 1203 MEYERHARDT, J. A. et al. *Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803*. J Clin Oncol, 1º ago. 2006. 24(22): 3.535-3.541.
- 1204 PATTERSON, R. E.; CADMUS, L. A.; EMOND, J. A.; PIERCE, J. P. *Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature*. Maturitas, mai. 2010. 66(1): 5-15.
- 1205 LETOURNEAU, J. M. et al. *Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer*. Cancer, 1º abr. 2012. 118(7): 1.933-1.939.